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Summary of Thesis
This Thesis ad d re sses  sev era l issues rela ted  to the  pathogenesis  of 
pep tic  u lcers  in p a tien ts  receiv ing  non-stero idal a n ti - in f lamm atory  
d ru g s  (NSAID).
Section I d iscu sses  the  background  of Thesis w ith re sp ec t to the 
mechanisms of mucosal damage by  NSAID, the  in te rac tio n  betw een 
NSAID and H p y lo ri, and  the  in teraction  betw een NSAID and 
an ti-rheum ato id  second-line d ru g s .
S uppression  of mucosal p rostag land in  sy n th esis  is centred to the 
mode of action of the  v as t m ajority of NSAID, and  y e t several 
s tu d ies  have failed to find  a correlation betw een th e  d eg ree  of 
p ro stag lan d in  inh ibition and th a t of mucosal dam age. This 
em phasizes th e  im portance of o th e r mechanisms of tox ic ity  b y  NSAID 
su ch  as stim ulation of g as tr ic  acid secre tion , in te rfe ren ce  w ith the  
mucus lay e r, reduction  of mucosal blood flow, and  the  histological 
m anifestation of chronic NSAID in take . Details of such  mechanisms, 
in  th e  p resen ce  o r absence of H py lo ri, and  th e ir  th e rap eu tic  
implications a re  all d iscussed  in  C hapters 1 and 2. It becomes c lear, 
a s  shown in  C hap ter 2, th a t NSAID and H py lori sh a re  several 
pathogenetic  mechanisms which might ultim ately lead to an  in crease  in 
th e  p revalence of p ep tic  u lcers  in  NSAID p a tien ts  in fected  w ith H 
py lo ri.
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In  addition to tak ing  NSAID and the  possibility  of being in fected  
w ith H p y lo ri, the prevalence of u lcers  in rheum atoid a r th r i t is  
p a tien ts  might be influenced by  the  concu rren t treatm ent w ith 
an ti-rheum ato id  second-line d ru g s  such  as gold compounds and  
su lp h asa laz in e . This is described  in  C hap ter 3, which attem pts to  
explain  the  in te re s tin g  observation  th a t pa tien ts  on long term  gold 
in jections ap p ear to have a lower prevalence of bo th  H py lori and  
p ep tic  u lc e rs , su g g estin g  th a t gold may have a toxic effect on th is  
organism  and  th u s  p ro tec t aga inst NSAID - induced gastric  damage.
With the  increasing  evidence fo r an  in teraction  between NSAID and  H 
p y lo ri, which is damaging to the  g as tric  mucosa, the accu ra te  
diagnosis of H pylori in  chronic NSAID u se rs  becomes of crucia l 
im portance. Almost all d iagnostic te s ts  fo r H pylori were p rev iously  
evaluated  in  p a tien ts  not tak in g  NSAID. This subject is s tu d ied  in  
C hap ter 4, which assesses  th e  efficacy of histology, u rease  enzyme 
ac tiv ity  (C L O -test), latex  agg lu tination  (P y lo rise t), and  an  
enzym e-linked immunosorbent a ssay , ELISA (Helico-G) in d iagnosing  
H pylori in  the  p resence  or absence of NSAID, u sing  cu ltu re  as  
s ta n d a rd . The sen sitiv ity  and  specificity  of the  th re e  b iopsy  - 
re la ted  te s ts  (cu ltu re , histology and  CLO -test) were g re a te r  th an  
90% and not affected  by  NSAID in tak e . However, the sen sitiv ity  and  
specifity  of Pyloriset and  Helico-G were lower than  those of th e  
b io p sy -re la ted  te s ts ,  and  th e  specifity  was even lower in  th e  
p resen ce  of NSAID. These re su lts  should not lead to abandoning  
th e  search  fo r more effective serological te s ts  because of th e  
p o ten tia l b enefits  of serod iagnosis , such  as convenience, low co s t, 
an d  early  diagnosis.
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Such charac teris tics  can be v ery  helpful especially in  screen in g  fo r 
H py lo ri and in m onitoring the response to th e rap eu tic  reg im es. 
T ak ing  such  benefits  into consideration, and hav ing  accep ted  the  
va lid ity  of cu ltu re , histology and CLO-test in d iagnosing  H py lori in  
NSAID p a tien ts , C hap ter 5 moves on to evaluate th e  efficacy of 
Biolab Malakit and Bio-Rad GAP te s ts ,  in comparison with P yloriset 
and  Helico-G, tak ing  all th e  biopsy - re lated  te s ts  as s tan d a rd . 
B io-Rad GAP te s t had the  h ighest sen sitiv ity  b u t the  lowest 
spec ific ity . The sen sitiv ity  and specificity  of the  o th er th ree  
serological te s ts  were low, and the  specificity  of all th e  serological 
te s ts  was also lower in  p a tien ts  tak ing  NSAID.
The perform ance of the  serological te s ts  s tudied  in  C hap ters  4 and 5 
would limit th e ir  value in p red ic tin g  peptic u lcers in p a tien ts  tre a ted  
w ith NSAID, unlike the situation  in dyspeptic  p a tien ts  not on 
NSAID. The Health A ssessm ent Q uestionnaire (HAQ) is an  
estab lish ed  method of assessin g  physical disability  in  p a tien ts  with 
chron ic  a r th r i t is .  The prevalence of peptic u lcers  might be h ig h er 
in  p a tien ts  with deb ilita ting  a r th r it is  because, it  could be a rg u e d , 
th e ir  advanced disease req u ires  more agg ressive  u se  of NSAID. 
T his hypothesis was te sted  in  C hapter 6, which used  HAQ to classify  
chronic a r th ritic  pa tien ts  according to th e ir  physical d isab ility . 
P a tien ts  with high HAQ scores (g re a te r  than  2 .0 , severe ly  disabled 
b y  a r th r i t is )  had the  h ighest prevalence of u lcers  desp ite  tak ing  
com parable types and  doses of NSAID. The explanation fo r th is  is  
no t fu lly  clear, b u t the re su lts  might help in  th e  p rocess of 
se lec tin g  pa tien ts  fo r prophylactic  th e rap y  against NSAID - re la ted  
p ep tic  u lce rs .
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Active chronic inflammation of the  u p p er g astro in testin a l tra c t h as , 
fo r a long time, been though t to play an im portant role in the 
pathogenesis of pep tic  u lceration . The situation  is not c lear in 
chronic NSAID u s e rs , who a re  known to have a h ig h er r is k  of 
developing u lce rs . This issue is ad d ressed  in Section IV, which 
aims a t iden tify ing  any  specific histological fea tu re s  in  the  stom ach, 
duodenum , o r oesophagus of p a tien ts  receiv ing  NSAID.
C hap ter 7 shows th a t the  commonest histological abnorm ality in  the 
g as tr ic  mucosa, is th a t of chronic superficial g a s tr i t is ,  followed by  
chemical g a s tr it is . The la tte r  is mostly found in  chronic NSAID 
u se rs  who do not have a previous h is to ry  of gas tro -duodenal 
su rg e ry . I ts  im portance stems from its  close association with NSAID 
re la ted  gastric  u lce rs .
In  the  duodenum, C hapter 8, a s tro n g  association is shown to ex ist 
betw een active chronic duodenitis, g as tric  m etaplasia, H py lo ri - 
positive g a s tr it is , and duodenal u lceration , reg a rd le ss  of NSAID 
in tak e . These re su lts  h ighlight the potential benefits  of e rad ica ting  
H pylori in  the  management of NSAID - re la ted  duodenal u lcera tion .
T here  are  v e ry  few stud ies on the possible effects  of NSAID on the 
oesophageal mucosa. Individual case rep o rts  and  experim ental animal 
s tu d ies  have given conflicting re s u l ts . The endoscopic p a r t  of 
C hap ter 9 shows th a t oesophagitis, with o r w ithout u lcers and 
erosions, is commoner in NSAID p atien ts  w ith u p p e r abdominal 
complaints th an  in  th e ir  symptomatic co u n te rp a rts  not tak ing  NSAID.
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On the  o ther hand , th e  histological assessm ents su g g es t th a t 
pap illary  elongation and  basal cell h y p erp lasia , the  major fe a tu re s  of 
histological oesophagitis, a re  less common in th e  p resen ce  of NSAID. 
T his implies th a t th e  NSAID - re la ted  oesophageal endoscopic 
abnorm alities a re  more likely to reflec t a localised form of damage 
which is comparable to o th e r cases of p ill-induced  o eso p h ag itis . The 
significance of such observation  is th a t the  ad v e rse  effects  of NSAID 
on the  oesophageal mucosa could be minimized b y  tak in g  simple 
m easures to p rev en t the  re ten tion  of th ese  tab le ts  w ithin th e  
oesophagus, such  as swallowing them with food and  liqu ids.
Several s tu d ie s , mostly conducted in experim ental anim als, have 
su g g ested  th a t NSAID - re la ted  damage is m ediated, a t least in  p a r t ,  
b y  mucosal ischaemia. The situation  is not c lear in  chronic NSAID 
u s e rs ,  who have o th er fac to rs  th a t might a ffect mucosal blood flow, 
such  as old ag e , smoking, and  H py lori. The influence of th ese  
fac to rs  is s tud ied  in C hap ter 10. Duodenal mucosal blood flow, 
m easured by  laser Doppler flow m etry, is lowest in  chronic NSAID 
u se rs  who smoke, and  in  those with H pylori infection o r duodenal 
u lceration . The combination of smoking and  H py lori has an  
independent effect in  low ering duodenal mucosal blood flow. G astric  
blood flow does not seem to be affected  by  any  of th e  above fa c to rs , 
However, g as tr ic  blood flow is m arkedly lower th an  th a t of th e  
duodenum , and  th is  might make it d ifficult to observe s ign ifican t 
d ifferences in  g astric  blood flow in  response to sm oking, H p y lo ri, 
o r  g astric  u lceration . In  add ition , the  find ing  of lower blood flow in  
th e  stomach th an  th e  duodenum , like the re la tive  r a r i ty  of ac tive  
duodenitis and  g as tric  m etaplasia observed  in  C hap ter 8 , might
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explain why g as tr ic  u lcers occur more commonly than  duodenal u lcers  
in chronic NSAID u se rs .
As d iscussed  in  C hapter 3, a s ign ifican t num ber of p a tien ts  w ith 
rheum atoid a r th r i t is ,  receiv ing  NSAID, also re q u ire  rheum atoid 
d isease modifying ag en ts , known as  second-line d ru g s .  The 
po ten tial benefits  of such  ag en ts  a re  freq u en tly  lim ited b y  th e  
development of g as tro -in te stin a l side e ffe c ts , which in  tu r n  leads to 
the  in te rru p tio n  o r even the  term ination of second-line th e rap y . 
These side effects  have, un til re c en tly , been  s tud ied  on basis  of 
p a tie n ts ' complaints only, and th ese  a re  known to co rre la te  poorly  
with gastro -duodenal damage in  the  p resen ce  of NSAID. U sing 
endoscopy, C hap ter 11 in v estig a tes  th e  p revalence of p ep tic  u lcers  
in rheum atoid a r th r it is  p a tien ts  tak in g  NSAID w ith o r  w ithout 
second-line d ru g s . Patien ts receiv ing  NSAID only , o r to g e th e r  w ith 
su lphasalazine, penicillamine or hydroxych lo roqu ine , a p p ea r  to have 
a similar p revalence of pep tic  u lce rs . However, the  chron ic  in take 
of gold injections p lus NSAID is associated  w ith a sm aller num ber of 
u lce rs  than  th a t of NSAID only. This find ing  is likely to  influence 
the choice of second-line agen ts  in  rheum atoid a r th r i t is .  A lso, the  
absence of a r ise  in the p revalence of u lce rs  in the su lphasalazine 
g roup  is re a ssu rin g : u p p e r abdominal symptom s, freq u e n tly  seen  in  
such  p a tien ts , should not necessarily  lead to s topp ing  su lphasalazine 
th e ra p y . Indeed , these  symptoms d isap p ear in  the  m ajority of cases 
w ith minor adjustm ent of th e  dose of su lphasalazine, and  w ith th e  
tem porary use  of anti-em etics ea rly  in  th e  course of su lphasalazine 
th e ra p y .
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C h ap te r 12 attem pts to explain  some of the endoscopic findings of 
C h ap te r 11, with re sp e c t to th e  ap p aren tly  favourab le  e ffects  of gold 
on the  g as tr ic  mucosa. Compared with p a tien ts  tre a te d  w ith NSAID 
only  o r w ith su lphasalazine, th e  p revalence of bo th  p ep tic  u lcers and 
H py lo ri is lower in  p a tien ts  receiv ing  long term  gold in jections. 
T h is confirms the  find ings of C hap ter 11, and  su g g e s ts  th a t the 
a p p a ren tly  p ro tec tiv e  effect of gold against NSAID - re la ted  u lcers is 
p ro b ab ly  m ediated, a t least in  p a r t ,  b y  the  effect of gold on g as tric  
H p y lo ri.
In  conclusion, th is  T hesis consists  of a g roup of s tu d ies  aimed a t 
c la rify in g  severa l a sp ec ts  of the pathogenesis of NSAID - re la ted  
p ep tic  u lc e rs , and  it is hoped th a t the  find ings w ill a s s is t in  the 
management of such  lesions in  chronic NSAID u s e rs .
SECTION 1 
BACKGROUND OF THESIS
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INTRODUCTION
NSAID a re  known to inhib it mucosal p rostag landin  sy n th e s is , 
stim ulate g astric  acid secre tion , in te rfe re  with mucosal blood flow 
and  th e  mucus la y e r , and  increase  th e  mucosal perm eability. These 
activ ities  a re  review ed in C hap ter 1, which also considers the 
th e rap eu tic  approaches to NSAID - rela ted  damage. The recen t 
e n try  of H pylori in to  the  debate of peptic u lcer aetiology makes it 
essen tia l to consider the  possible role of th is organism  in  the  
pathogenesis  of u lce rs  in  p a tien ts  tak in g  NSAID. C hapter 2 review s 
th e  pathogenetic mechanisms common to both  NSAID and H py lo ri. 
The impact of the  co n cu rren t in take of anti-rheum atoid second-line 
d ru g s  on both  H py lo ri and  NSAID - re lated  u lcers is also d iscussed  
in  C hap ter 3.
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CHAPTER 1
1. MECHANISMS OF NSAID - RELATED PEPTIC DAMAGE AND 
THEIR IMPLICATIONS FOR MANAGEMENT.
1.1 INTRODUCTION
D espite the  wide acceptance of the s tro n g  association between 
n o n -ste ro id a l anti-inflam m atory d ru g s  (NSAID) and  peptic u lcer 
d isease , th e re  a re  several issues related  to the  pathogenesis and 
management of th is  disease th a t are  a t r isk  of being  over-looked or 
accep ted  unchallenged . This chapter d iscusses such  issues and 
considers  th e ir  implications for the  management of NSAID related  
p ep tic  u lcera tion .
1 .2 INTERFERENCE WITH PROSTAGLANDIN SYNTHESIS BY NSAID
Inhib ition  of p rostag land in  (PG) biosynthesis is the  most famous 
a c tiv ity  of NSAID, and it  is thought to account fo r th e ir  
anti-inflam m atory and  analgesic p ro p ertie s . It w as, and still 
rem ains, v e ry  desirab le  if not vital in the  treatm ent of a r th ritic  
d is o rd e rs . I t has subsequen tly  been considered a significant 
d isadvan tage  a f te r  associations have been made betw een NSAID - 
re la ted  pep tic  damage and  gastro -duodenal mucosal PG inhibition. 
Before th ese  po in ts a re  d iscussed  in fu r th e r  de ta ils , th e re  a re  
ce rta in  fea tu re s  re la ted  to the  effect of NSAID on PG production 
th a t should be noted .
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NSAID, such  as indom ethacin, su p p ress  PG b iosyn thesis  by  
in h ib itin g  cyclo-oxygenase ac tiv ity , the enzyme which is responsib le  
fo r  converting  arachidonic acid su b s tra te  to PG in te rm ed ia tes . 
NSAID are  considered  not to have any major effects on the  enzymes 
involved  in the  lipoxygenase system , and therefo re  th e  p roduction  of 
th e  leukotrienes would only be affected  by  these  d ru g s  to th e  ex ten t 
th a t  fu r th e r  arachidonic acid su b s tra te  would be available fo r 
leuko triene  b iosyn thesis  on account of the decreased  PG production .
NSAID appear to  v ary  in  th e ir  potencies to inh ib it PG sy n th es is  
(1 ) . Indomethacin and naproxen a re  pow erful in h ib ito rs , 
phenylbutazone is m oderate, while salicylic acid , a sp ir in , is only a 
weak inh ib ito r. O ther d ru g s  act as pro d ru g s  th a t show ac tiv ity  
th ro u g h  th e ir  m etabolites: one of these agen ts  is sulindac whose 
su lph ide  metabolite is able to ex e rt a potent inh ib iting  effect on PG 
sy n th es is  (2).
I t  is also in te re s tin g  to note th a t NSAID may show se lectiv ity  in 
term s of which PGs are  mainly affected . Previous observations w ith 
sheep  vesicular tissu e  incubated  in  Cu^2 containing medium ind icated  
th a t salicylic acid caused a p re fe ren tia l reduction  in  PGE2 sy n th es is  
re la tiv e  to th a t of PGF2 (3 ). In co n tras t, indom ethacin su p p ressed  
th e  production of PGE2, PGEa , and PGF2 to the  same ex te n t. More 
re ce n tly , it has been shown th a t etodolac, a d eriva tive  of 
pyranocarboxylic ac id , might selectively spare  g as tr ic  and  duodenal 
mucosal PGs desp ite  its  capacity  to su p p ress  synovial PG sy n th es is  
(4 ,5 ) .
While it is generally  ag reed  th a t NSAID su p p ress  g as tr ic  mucosal
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PGs, knowledge in  th is  field has largely  relied  on s tu d ie s  conducted  
in  animals or healthy  humans given sh o rt courses of a sp ir in  o r 
indom ethacin (1-3 , 6 -8 ). As shown above, what applies to th ese  two 
a g e n ts , asp irin  and  indom ethacin, might not necessarily  ap p ly  to th e  
r e s t  of NSAID, and species-specific  responses should  no t be 
igno red . Also, v e ry  little  is known about the  behav iou r of duodenal 
mucosal PGs in p a tien ts  tre a ted  with NSAID as the  v a s t m ajority of 
s tu d ies  have investiga ted  g as tric  PGs only. More im p o rtan tly , no 
correlation has been  found betw een the  degree  of PG inh ib ition  and  
th a t of NSAID-induced pep tic  damage (5 ,8 ) . These re se rv a tio n s  do 
not necessarily  minimize the  acknowledged im portance of PGs in  
m aintaining the in te g rity  of the  gastro -duodenal mucosa (9 ): th ey  
ra th e r  emphasize th e  im portance of considering  o th e r mechanisms of 
in ju ry  by  NSAID in  addition to th e ir  effect on PG p ro d u c tio n , as 
d iscussed  below.
1.3 OTHER MECHANISMS OF MUCOSAL TOXICITY BY NSAID
A spirin (10), indom ethacin (11), and fenoprofen  (12) w ere found 
to cause d isrup tion  of the  g astric  mucosal b a r r ie r  in  a  m anner th a t 
allows back diffusion of hydrogen  ion with i ts  dam aging 
consequences. A spirin  and  indom ethacin also increase  b asa l (13) and 
maximally stim ulated g as tric  acid secretion  (14,15) w hich may 
con tribu te  to th e ir  unw anted effects on the  g a s tr ic  and  duodenal 
mucosa.
Several s tud ies  have suggested  th a t NSAID can a f fe c t  th e  ra te  
of secretion a n d /o r  the  ch arac te ris tics  of the  mucus lay e r in  the  
stom ach. A spirin  (16) and indomethacin (17) were found  to inh ib it
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mucus secre tio n . It was also su g g ested  th a t a sp irin  could in crease  
pepsin-m ediated proteolysis of m ucus, decrease  mucus v iscosity , and  
increase the  perm eability of mucus to h y d rogen  ion (18). 
Indomethacin was also found to inh ib it active b icarbonate  secre tion  
by  th e  g as tr ic  mucosa (19). In add ition , indom ethacin was found to 
decrease g as tr ic  mucosal blood flow (14).
A nother mechanism th a t received  insu ffic ien t a tten tio n  in  th e  
p as t re la tes  to the possib ility  th a t b ac te ria  could mediate NSAID 
tox icity . In th e  in testine  it was o b serv ed  th a t th e  ulcerogenic effect 
of NSAID could be reduced  b y  antib io tic  treatm ent (20). G erm -free 
animals w ere also found to be re s is ta n t to indom ethacin-induced 
in testina l lesions (21). I t was p o stu la ted  th a t en te ric  bac te ria l 
B -glucuronidase hydrolyses the acy lg lucuron ides of NSAID re leased  
into the  in testina l tra c t from bile, and  the  free  acids th en  ir r i ta te  
the mucosal su rface  (20). In te re s t in  th ese  im portant observations 
has been rev ived  by  the recen t e n try  into the  argum ent of an o th e r 
organism : Helicobacter (H) py lo ri. I t is not c lear w hether NSAID 
in te rac t w ith H pylori in the  g a s tr ic  mucosa. However, s tu d ies  
conducted by  th e  au th o r have shown th a t human g a s tr ic  a n tra l 
mucosal specimens exposed to a m ixture of indom ethacin p lus H 
pylori cu ltu re  f iltra te  have lower PGE2 values and  histological 
viability  g rades than  biopsies incubated  with indom ethacin o r th e  
cu ltu re  f iltra te  alone (22). More re c en tly , it has been  found th a t 
the prevalence of NSAID-related u lcers  is h ig h er in  p a tien ts  w ith 
chemical g a s tr itis  or H p y lo ri-re la ted  g a s tr itis  (23, C hap ter 7 ). An 
in teraction  may, th e re fo re , ex ist betw een NSAID and H p y lo ri, and  
th is seems to be  damaging to the  g as tr ic  mucosa. The in te rac tio n  
betw een NSAID and  H py lori is  d iscussed  in  more detail in  C h ap te r 2
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of th is  T hesis.
It is w orth no ting  th a t a degree  of overlapp ing  might ex ist 
betw een two or more of th e  above mechanisms of NSAID tox ic ity . 
For exam ple, the  effect of indom ethacin on mucosal blood flow might 
not be to tally  in d ep en d en t of th a t on PG form ation. However,
desp ite  the  capacity  of PGs to inh ib it g as tr ic  acid (2 4 ,2 5 ), the  
effects  of NSAID on acid secre tion  is not necessarily  m ediated
th ro u g h  th e ir  su p p ressio n  of mucosal PG s: recen t s tu d ie s  have
su g g ested  th a t NSAID b y p ass  th e  H2 and m uscarinic re ce p to rs  and 
in te ra c t with secre tagogues a t a locus betw een th e  cataly tic  su b u n it 
of adenylate  cyclase activation  and  the p ro to n  pump (26). the
potentiation  of secre tagogue-stim ulated  acid secre tion  b y  
non-salicy late  NSAID has been  found to be dependen t on calcium
(26).
It is c lear, th e re fo re , th a t in  addition to th e ir  e ffec ts  on PG 
sy n th e s is , NSAID have sev era l o th er ac tiv ities which have to be 
ad d ressed  when management of N SA ID -related damage is considered .
1.4 IMPLICATIONS FOR MANAGEMENT
The above d iscussion  would su g g est th a t th e re  m ight be 
ju stifica tion , which is a t least th eo re tica l, fo r  the  u se  of any  class of 
an ti u lcer d ru g s  in  the  management of u lcers  induced b y  NSAID.
A ntacids th a t contain  aluminium hydrox ide o r  aluminium 
phosphate  have been  shown to p ro tec t th e  r a t ’s g a s tr ic  mucosa 
ag a in st necro tizing  conditions (27 ,28). Aluminium hydrox ide  was 
found to
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in c rea se  PGE2 release  by  the  g as tr ic  mucosa in  ra ts  (29 ). A local 
m echanism m ust be responsib le  fo r these  ac tiv ities of aluminium 
h y d ro x id e  since it  is poorly  ab so rb ed . A lso, p ro tec tio n  th ro u g h  
o th e r  mechanisms cannot be en tire ly  excluded: th ese  might include
ad so rp tio n  of bile ac id s, inactivation  of pepsin  o r stim ulation of 
m ucus p ro d u c tio n  (29). The value of an tacids in  tre a tin g  or 
p re v e n tin g  N SA ID -related damage in  man has not been  estab lished  
y e t .
Carbenoxolone sodium was p rev iously  rep o rted  to increase  the 
form ation of g as tr ic  mucosal PGE2 (30) and  to inh ib it throm boxane 
B2 , th e  stab le  metabolite of throm boxane A2 (31). D espite these 
h ig h ly  desirab le  p ro p ertie s  in  the  context of tre a tin g  u lcers  caused 
b y  NSAID, carbenoxolone is not widely u sed  in  clinical p ractice 
b ecause  of its  card iovascu lar side e ffec ts .
T rip o tass iu m -d ic itra te  b ism uthate (colloidal b ism uth ) was shown 
to stim ulate mucosal PGI2-like ac tiv ity  and  to p ro te c t the  r a t ’s 
g a s tr ic  mucosa aga inst 85% ethanol, 0.2N sodium hyd ro x id e , or 
ac id ified  indom ethacin (32). Colloidal b ism uth su b c itra te  was also 
found  to reduce  asp irin -in d u ced  m icrobleeding in  man desp ite  marked 
su p p re ss io n  of g as tr ic  mucosal PGs by  a sp ir in  (33 ). R ecently, 
in te re s t  has been  renew ed in  colloidal bism uth in ligh t of its  effect 
on H p y lo ri, and  might increase  fu r th e r  because of th e  apparen t 
in te ra c tio n  betw een NSAID and  H py lo ri (22 ,23).
D espite th e  conflicting re p o rts  on the  capacity  of sucra lfa te  to 
stim ulate mucosal PGE2 release  (34 ,35 ), it  is generally  accepted  th a t 
th is  complex molecule behaves as a mild ir r i ta n t  by  form ing a
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gelatinous mucoepithelium coat consisting  of necrotic epithelial cells 
and  mucus which in  tu rn  ac ts  as a shield  against acid and pepsin  
(36 ). The application of th ese  observations to NSAID-related damage 
in  man rem ains to be confirm ed.
In recen t y e a r s , severa l im portant clinical tr ia ls  have been 
rep o rted  on th e  value of Hg-an tagon ists  and  p rostag land in  analogues 
in  th e  trea tm en t o r p reven tion  of peptic u lce rs  in p a tien ts  receiv ing  
NSAID. C onflicting re su lts  were rep o rted  with cimetidine (37 ,38). 
R antidine was found to p rev en t N SA ID -related duodenal b u t not 
g a s tr ic  u lcera tion  (39). More recen tly , ran itid ine  was shown to heal 
63% of g as tr ic  and  84% of duodenal u lcers sifter 8 weeks of treatm en t, 
com pared with 79% and 92% a t 12 w eeks, re sp ec tiv e ly , in p a te in ts  
who continued to take  NSAID (40).
In  a doub le-b lind , p lacebo-controlled tr ia l Graham e t al have 
shown th a t m isoprostol, PGEi analogue, sign ifican tly  reduced  the 
freq u en cy  of g a s tr ic  u lce r development in  p a te in ts  tre a te d  with 
NSAID (41). The im portance of th ese  find ings and those of 
Ehsanullah e t al would ju s tify  a comparison betw een th e  two stud ies
(39 .41): In  add ition  to the  differences outlined  in  Table 1, it  is not 
c lear why NSAID p a tien ts  in the  E hsanullah 's s tu d y  (39) developed 
almost equal num bers of u lcers  in the stom ach and duodenum given 
th e  fac t th a t g a s tr ic  u lcers  tend  to be commoner than  duodenal 
u lce rs  in  p a tien ts  receiv ing  NSAID (42). Since th e  two stud ies
(39.41) w ere d iffe ren t in  th e ir  design and  in  the  dem ographic details 
of th e ir  p a tie n ts , it  is d ifficult to perform  a d ire c t comparison 
betw een ran itid in e  and  m isoprostol on basis  of th e ir  f ind ings. This 
makes it  essen tia l fo r  th e  two agen ts to be com pared in  one single
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tr ia l . When such  comparison was made betw een misoprostol and  
cim etidine, bo th  ag en ts  were highly p ro tec tiv e  in the  duodenum b u t 
m isoprostol was more effective in p ro tec tin g  against tolm etin-induced 
g a s tr ic  in ju ry  in healthy  vo lun teers (43). It might be tem pting to 
consider g iv ing th e  individual p a tien t tre a ted  with NSAID a 
combination of an  H2 an tag o n ist, to relieve dyspeptic  symptoms and  
p rev en t duodenal u lc e rs , and m isoprostol to p rev en t g a s tr ic  
u lcera tion . As a m atter of fac t, the  au th o r has seen p a tien ts  
who have a lready  been  tre a te d  with such  combination. To do so is 
d ifficu lt to ju s tify  not only on basis of cost b u t also because 
m isoprostol has been  shown to p ro tec t aga inst duodenal as well as 
g a s tr ic  u lcers  (41 ,43 ,44).
However, it is  v e ry  im portant to realise  th a t the  value of H2 
an tagon ists  has not been adequately  te s ted  as shown in  Table 1, and  
th e ir  use should not th ere fo re  be ru led  o u t, a t least in tre a tin g  
NSAID-induced pep tic  u lceration  (40). A d irect comparison is 
ind icated  betw een ran itid ine  and m isoprostol and more inform ation is 
needed about th e  value of o th er ag en ts  such as famotidine and  
omeprazole in  tre a tin g  o r p rev en tin g  u lcers  re lated  to NSAID. Also, 
th e  impact of th ese  treatm ent s tra teg ie s  on the complications of 
N SA ID -related lesions rem ains to be inv estig a ted .
In conclusion, NSAID have multiple effects on th e  
g a s tro -in te s tin a l mucosa in  addition to inhibition of mucosal PG 
s y n th e s is . The u n d e rs tan d in g  of such  effects is essen tia l fo r 
design ing  th e  ap p ro p ria te  lines of management of u lcers re la ted  to 
NSAID.
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Table Is Prevention of NSAID-Related Peptic Ulcers By Ranitidine 
(Ehsanullah et al, 39) Or Misoprostol (Graham et al, 41): Comparison 
Of The Design And Findings Of The Two Studies. No (%)
Rantidine Misoprostol 
Study Study
No of patients 
Osteoarthritis 
Rheumatoid arthritis 
Smokers 
NSAID used
Duration of NSAID treatment 
Duration of study 
Lesions studied
Prevention of ulcers: 
Gastric 
Duodenal 
Symptomatic relief 
Significant side effects 
of study drug
263
197 (75%)
66 (25%)
94 (36%) 
Naproxen 
Piroxicam 
Diclofenac 
Indomethacin 
8 weeks 
8 weeks 
erosions 
ulcers >5mm
No
Yes
Yes
Nil
420
420 (100%)
63 (15%)
Naproxen
Piroxicam
Ibuprofen
1 year 
12 weeks 
ulcers >3mm 
ulcers >5mm
Yes
Not studied 
No
Diarrhoea (25-39%)
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CHAPTER 2
2 THE INTERACTION BETWEEN NSAID AND H PYLORI
2.1 SUMMARY
Recent s tu d ies  have suggested  th a t H elicobacter pylori and 
non-ste ro ida l anti-inflam m atory d ru g s  a re  capable of in te rfe r in g  with 
various p ro tec tive  mechanisms in the  gastro -duodenal mucosa. While 
NSAID are  recognised  fo r th e ir  acid stim ulating a c tiv ity , the effect 
of H pylori on g as tr ic  acid secretion  rem ains h igh ly  speculative 
desp ite  its  association with hypergastrinaem ia . Both H pylori and  
NSAID have , how ever, been shown to influence the  p roduction  ra te  
a n d /o r  the  quality  of the mucus lay er, g as tric  cyclic AMP, mucosal 
p ro stag lan d in s, blood flow, and p la te le t-a c tiv a tin g  fac to r. 
C h arac teristic  histological abnorm alities have also been  iden tified . In 
add ition , NSA ID -related peptic u lcers seem to develop more commonly 
in  pa tien ts  in fected  with H pylori despite  th e  a p p a ren t reduction  in 
th e  prevalence of these organism s in chronic NSAID u se rs . It 
rem ains to be seen  w hether the  eradication of H py lo ri would reduce 
th e  freq u en cy  of NSAID induced peptic  u lce rs  o r p rev en t th e ir  
re c u rre n c e .
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2.2 INTRODUCTION
Helicobacter (H) py lo ri and non-stero idal anti-inflam m atory d ru g s  
(NSAID) are  p robably  th e  commonest known exogenous fac to rs  in  th e  
aetiology of pep tic  u lce r d isease. This C hap ter d escrib es  th e  
pathogenetic mechanisms common to H py lori and  NSAID and  
d iscusses the possib ility  of a sy n erg is tic  re la tionsh ip  betw een them . 
The im portance of such  a re la tionsh ip , if  p re se n t,  re la tes  to i ts  
potential to provide a new therap eu tic  approach  to th e  common, b u t 
y e t unreso lved , problem  of u lcers  induced by  NSAID.
2.3 EFFECT OF NSAID AND H PYLORI ON GASTRIC ACID 
SECRETION:
Because of the  widely accepted  im portance of g a s tr ic  acid in  th e  
pathogenesis of u lcers  in  g eneral, it was only n a tu ra l fo r many 
w orkers to inv estig a te  th e  possible effects of NSAID an d , more 
recen tly , H pylori on acid secre tion . NSAID (indom ethacin and  
asp irin  in p a rticu la r) were found to increase  basal and  maximally 
stim ulated gastric  acid secre tion  (13-15). NSAID seem to b y p ass  th e  
H2 and m uscarinic recep to rs  and in te ra c t w ith secre tagogues a t  a 
locus between th e  cataly tic  su b u n it of adenylate  cyclase ac tivation  
and  the  pro ton  pump (26). The potentiation  of secre tag o g u e  - 
stim ulated acid secre tion  by  non-salicy late NSAID has also b een  
found to be dependent on calcium (26).
The situation  is not so well defined in  th e  case of H p y lo ri. 
Because of its  association w ith hypergastrinaem ia, it  was specu la ted
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th a t H pylori could increase th e  p arie ta l cell mass th a t is 
ch arac te ris tic  of duodenal u lcer p a tien ts  (45). To d a te , th e  
evidence fo r an  increase  in  g a s tr ic  acid secre tion  b y  H py lo ri, has 
how ever, been lacking . On the  c o n tra ry , th e re  is a consensus th a t 
acu te  exposure to H pylori causes hypoch lo rhydria  (46-50).
Recent evidence indicates th a t H py lo ri associated  
hypergastrinaem ia might not be d ire c tly  re la ted  to th e  function  of 
th e  parie ta l cells (51), the num ber of an tra l G cells (52) o r to the  
bacterium ’s u rease  ac tiv ity  (53). I t  is more likely to be re la ted  to 
local inflammation (52-54) a n d /o r  p ro d u c ts  of the T lym phocyte such  
as in terleuk in -2  and  gam m a-interferon (55). G astric  acid secre tion  
in  chronic NSAID u se rs  who a re  in fec ted  with H py lo ri has not been  
s tu d ied , b u t indom ethacin has been  shown to po ten tia te  th e  
inh ib ito ry  effect of H pylori p ro te in  on g as tric  fund ic  cyclic AMP, 
which in tu rn  mediates acid sec re tio n , in  v itro  (56). This might 
exp lain , a t least in  p a r t ,  the ten d en cy  of many a r th r it ic s  to develop 
a degree of hypochlorhydria  (5 7 ), and  the lim itations of acid 
inhibition  in th e  management of NSAID re la ted  u lcers  (39 ,43).
2.4 THE MUCUS LAYER
The ability  to change the  ch a rac te r is tic s  of th e  g as tr ic  mucus 
lay er is common to both  NSAID an d  H py lori. A sp irin  (16) and  
indom ethacin (17) were found to in h ib it mucus secre tio n . A spirin  
can also increase  pepsin-m ediated  p ro teo lysis of m ucus, decrease  
mucus v iscosity , and  increase the  perm eability  of mucus to hyd rogen  
ion (18). Indom ethacin was show n to inhib it ac tive  b icarbonate  
secre tion  by  th e  g as tr ic  mucosa (19 ). I t was also su g g ested  th a t 
NSAID could cause d isrup tion  of th e  g as tr ic  mucosal b a r r ie r  which in
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tu rn  allows back  d iffusion of hydrogen  ion with its  damaging re su lts  
( 10- 12).
Sim ilarly, i t  has recen tly  been shown th a t incubation  of H py lori 
c u ltu re  f iltra te  w ith g as tr ic  mucus could lead to a g radual loss of 
m ucus v iscosity  (58), which might impair i ts  ab ility  to re ta rd  the  
d iffu sio n  of hy d ro g en  ions. It was concluded th a t the  degenerative  
ch an g es p roduced  in  the  g a s tr ic  mucus gel b y  H py lori might be a 
c o n tr ib u tin g  fac to r in  th e  pathogenesis of g a s tr itis  and  pep tic  u lcers  
(58)
2.5 MUCOSAL PROSTAGLANDINS:
I t is  generally  accepted  th a t NSAID, w ith few exceptions (5 ), 
a re  capable of su p p re ss in g  g as tr ic  and  duodenal mucosal 
p ro s tag lan d in  (PG) sy n th e s is , a lthough no correlation  has been 
found  betw een the  d eg ree  of PG inhibition and  the  endoscopic 
abnorm alities (5 ,8 ) .
B ecause of its  s tro n g  association with g a s tr itis  and neutrophilic  
in filtra tio n , H pylori is ex p ec ted , a t least in  th eo ry , to stim ulate PG 
p ro d u c tio n , as human n eu tro p h ils  and  m acrophages a re  capable of 
sy n th e s is in g  PGs (59). A lso, g a s tr itis  like any  o th er inflammation 
ir re sp e c tiv e  of H pylori s ta tu s  is associated  with elevated PG values 
(6 0 ,6 1 ). It was s u rp r is in g , th e re fo re , to find  th a t p a tien ts  w ith H 
p y lo ri re la ted  g a s tr itis  had  PG values similar to those w ithout H 
p y lo ri (61-63). This led to speculation  th a t H pylori infection might 
re s u l t  in  a t least a p a rtia l block in  PG sy n th esis  a t the level of the  
n eu tro p h ils , mucosal cells, o r bo th  (61). Indeed , some w orkers
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re p o rte d  reduced  levels of PGI2 stab le  m etabolites in  p a tien ts  
in fec ted  with H py lori (64), b u t th is  was not confirmed b y  o th e rs  
(61-63). It was also in te re s tin g  to find th a t the  combination of 
indom ethacin and H py lori cu ltu re  f iltra te  reduced  g a s tr ic  a n tra l 
mucosal PGE2 and epithelial v iab ility  to a g re a te r  deg ree  th an  
indom ethacin alone, in  v itro  (22). This in  tu rn  might su g g e s t a 
sy n e rg is tic  re lationsh ip  betw een H py lo ri and  NSAID in  causing  
mucosal damage.
2.6 MUCOSAL BLOOD FLOW:
S everal s tud ies  have dem onstrated  th a t sh o rt courses of NSAID 
could reduce g as tr ic  mucosal blood flow in  th e  lab o ra to ry  animals 
(1 4 ,6 5 ,6 6 ). The s ituation  is not c lear in  p a tien ts  on long term  
NSAID, who could have o th e r fac to rs  th a t might a lte r  blood flow. 
A lso, v e ry  little  is known about th e  duodenal m icrocirculation in 
su ch  p a tie n ts . However, it  has been  shown th a t duodenal, b u t  not 
g a s tr ic , mucosal blood flow is lowest in NSAID p a tien ts  who smoke, 
o r those  with duodenal u lce rs  or H py lo ri (67, C hap ter 10); no
co rre la tion  could be found w ith age o r sex . The data  in  C h ap te r 10
also show th a t the  su p p ress iv e  effect of smoking and H p y lo ri on
duodenal blood flow, in  NSAID p a tie n ts , was in d ep en d en t of
u lcera tion  and  o th e r dem ographic v ariab les . A lthough su ch  find ings 
do not d ispu te  th e  capacity  of NSAID to lower mucosal blood flow in 
g en era l, th ey  might re p re se n t an o th er aspect of th e  sy n e rg is tic  
re la tionsh ip  though t to ex is t betw een NSAID and H p y lo ri, a t least 
w ith re sp ec t to duodenal blood flow.
2.7 HISTOLOGICAL AND ENDOSCOPIC ABNORMALITIES:
A ctive chronic g a s tr itis  is the  classical histological p ic tu re  found 
in  association with H pylori in the majority of infected su b jec ts . It 
is  b e s t remembered as the  main abnorm ality seen a f te r  the delibera te  
ingestion  of the  organism s in o rd e r to fulfil Koch’s postu lates fo r th e  
pathogen ic ity  of H pylori (46 ,47), and in epidemic g as tr itis  (48). It 
is  also the  commonest histological find ing  in patien ts  tre a ted  with 
NSAID (23, C hap ter 7 ). N eutrophilic in filtra tio n , common to most 
cases of NSAID and H pylori g a s tr it is , could be related  to th e  
capacity  of NSAID and H pylori to stim ulate the  production of th e  
p la te le t-ac tiv a tin g  fac to r (PAF) (68 ,69). In addition to its  
u lcerogenic actions (68), PAF might be involved in the aggregation  
and  activation  of neu trophils  (70), which might su b sequen tly  
co n trib u te  to u lcer form ation: neutropenic ra ts  a re  less likely to
develop g as tr ic  mucosal in ju ry  by  indomethacin o r naproxen (70). 
However, these  in te re s tin g  observations might not apply  to p a tien ts  
w ith chemical g a s tr it is , ano ther histological abnorm ality ch arac te ris tic  
of chronic NSAID in take (23,71 C hapter 7 ). Not unlike bile re flux  
g a s tr it is  in p a tien ts  w ith a h is to ry  of gastroduodenal su rg e ry  (72), 
i t  is ch arac te rised  by  foveolar h yperp lasia , vasodilatation, oedema, 
lack of inflammatory cells, and the p resence of muscle fibers  in  th e  
lamina p ro p ria  (23,71-74, C hapter 7 ). H pylori is v ery  ra re  in  
cases of chemical g a s tr itis  (23, 71-74, C hapter 7 ), and  the
histological p ic tu re  can be found in about 25% of chronic NSAID 
u se rs  (23,71 C hapter 7 ). The im portance of such  en tity  stems from 
th e  positive correlation betw een the  histological chemical scores and 
th e  degree  of endoscopic damage: NSAID re la ted  peptic u lce rs ,
m easuring 5mm in  diam eter, were found more commonly in  pa tien ts
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with chemical g as tr itis  o r H pylori positive g a s tr itis  than  in those 
w ithout e ith e r of these conditions (23, C hapter 7 ). This is  in 
agreem ent w ith ano ther s tu d y  (75) which found a g re a te r  num ber of 
g a s tr ic  u lcers in NSAID p atien ts  infected with H py lo ri compared 
w ith p a tien ts  e ith er tak ing  NSAID or infected  with H py lo ri. The 
p revalence of NSAID re la ted  u lcers in H pylori positive p a tien ts  has 
also been found to be twice th a t in H pylori negative ind iv iduals, 
b u t th e  d ifferences were not significant due to the  small num bers of 
p a tien ts  and u lcers stud ied  (76). The same s tu d y  (76) found a 
g re a te r  num ber of submucosal haem orrhages and erosions in H pylori 
negative  NSAID u s e rs , unlike the re su lts  of ano ther re p o rt which 
su g g ested  th a t the p resence of H pylori had no influence on the 
p revalence of such  lesions following the acute adm inistration  of 
n ap roxen  or asp irin  in healthy  volunteers (77).
The in te rp re ta tio n  of the  findings re la ted  to submucosal 
haem orrhages or erosions is made difficult by  the  chronic n a tu re  of 
H py lo ri in fection , its  association with u lce rs , and the  lack of 
evidence th a t such minor lesions can really  p ro g ress  to u lc e r s . 
A nother possible explanation fo r the differences in  the  find ings of 
th e  above s tu d ies  (23,75-77, C hapter 7) is the  failu re  to co rrec t fo r 
th e  p resen ce  of chemical g a s tr itis , which appears  to ac t as  an 
independen t fac to r, and  th e  use  of serological te s ts  of unproven  
value in  p a tien ts  tre a ted  with NSAID. Diagnostic t i tre s  of H pylori 
IgG antibodies could still be detected  in pa tien ts  w ith chemical 
g a s tr i t is ,  w ith its  h igh  prevalence of NSAID u lc e rs , desp ite  the 
fa ilu re  to confirm the  p resence of the organism s b y  c u ltu re , 
h isto logy , o r u rease  ac tiv ity  (78, C hapter 4 ) . Also, serology might 
not be reliable enough in p red ic iting  the  presence of H py lo ri o r
40
u lce rs  in NSAID p a tien ts , unlike o ther categories of p a tien ts  
(7 9 ,8 0 ), because of the following: F irs tly , NSAID u lcers  can be
completely asymptomatic (81,82, C hapter 11); Secondly, the  
specific ity  of some IgG te s ts  might be low in p a tien ts  rece iv ing  
NSAID (78, C hapter 4 ); T h ird ly , despite  the ap p a ren t sy n e rg is tic  
re la tionsh ip  between H pylori and  NSAID, the  in take of such  d ru g s  
m ight be associated with a reduced  prevalence of H py lori infection 
(23,78,83-85, C hapters 4 ,7 ) : th is  could be due to a d irec t toxic
ac tio n , or ind irec tly  re la ted  to the increase in  acid secre tion  
(13-15,26) and the in te rfe ren ce  with the mucus lay er (10-12,16-19) 
re n d e rin g  the  na tu ra l hab ita t of H pylori organism s u n su itab le  fo r 
th e ir  su rv ival.
The virulence of H pylori s tra in s  might also explain some of the  
d ifferences in the rep o rted  ra te s  of u lcer form ation. W estern 
b lo ttin g  analysis of system ic IgG or IgA responses to H py lo ri has 
shown the an tigenicity  of 110-120 kDa, 89 kDa, 61 kD a, 54 kDa and  
31 kDa p ro te in s, although th e re  is substan tia l variab ility  am ongst 
su b jec ts  (86,90). The 120 kDa p ro te in , which is recognized  
system ically in 83% of H pylori positive su b jec ts , is a su rface  p ro te in  
not ex p ressed  in some H pylori s tra in s  (88).
I t  has been suggested  th a t 120 kDa positive s tra in s  have 
pathogenetic  fea tu res  associated with active g as tr itis  and  pep tic  
u lcera tion  (90). Infection with 120 kDa negative s tra in s  might 
explain  why peptic u lceration  develops in only a p roportion  of 
su b jec ts  infected with H pylori (90). A vaculating cytopath ic ag en t 
has also been described  in  some s tra in s  of H pylori (91). It is n o t,
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how ever, known w hether these im portant find ings would app ly  to 
p a tien ts  receiv ing  long term  NSAID.
2.8 THERAPEUTIC CONSIDERATIONS:
The role of e rad icating  H pylori in  the  healing o r th e  p rev en tio n  
of NSAID re la ted  pep tic  u lcers  has not been  s tu d ied . However, in  
addition  to th e ir  an tibacteria l ac tiv ity , agen ts  c u rre n tly  u sed  in the  
trea tm en t of H pylori infection were p rev iously  found to possess  
p ro p ertie s  re levan t to th e  mechanisms of NSAID induced mucosal 
damage. Colloidal bism uth su b c itra te  was shown to stim ulate g as tr ic  
and  duodenal alkaline secretion  th rough  a p ro stag lan d in  dependen t 
mechanism (92). The same agen t was also found to have a 
p ro tec tive  action against asp irin -induced  m icrobleeding, and  th is  
p ro tection  occurred  desp ite  a marked su p p ressio n  of mucosal 
p rostag land in  production  (33). Also, it was dem onstrated  th a t th e  
ulcerogenic effect of NSAID could be reduced  in  animals and  hum ans 
by  antib iotic treatm ent (20 ,93), and th a t germ -free  animals were 
re s is ta n t to indom ethacin-induced in testina l lesions (21).
The common n a tu re  of NSAID rela ted  u lcers in association w ith H 
pylori colonization, especially in the  e ld e rly , should act as an  
incentive to devise an effective th erap eu tic  ap p roach . In  1983, 
enough NSAID were made available to tre a t  almost 3 million people 
daily in  the USA (94), and  22 million p resc rip tio n s  were issu ed  fo r 
such  ag en ts  in  the  UK (95). About half of th e  NSAID p resc rib ed  
were fo r the  over 60's (95). H pylori infection can be identified  in  
about 80% of people of th is  age group (96) although  in th e  p resen ce  
of NSAID the  prevalence of H pylori might fall to 30-50%, according
42
to data  collected by the  au th o r betw een 1987-1992 (23,67,78)
It is estim ated, th e re fo re , th a t betw een 25-40% of all NSAID 
u se rs  and 30-50% of e lderly  p a tien ts  tak in g  NSAID could be in fected  
with H py lo ri, and as a re su lt ,  a re  a t  special r isk  of developing 
pep tic  u lc e rs . The managment of u lcers  in th is  large  num ber of 
p a tien ts  is not only essen tia l b u t might also need to be d iffe ren t 
from th a t of o ther ty p es  of u lc e rs . I t ’s effect on u lce r 
com plications, especially in the  e lderly , also needs to be clarified .
Despite th e  evidence fo r a low prevalence of H py lori in  chronic 
NSAID u s e rs , it  has to be em phasised th a t the  possible use  of 
NSAID to erad icate  H py lori should not be considered , know ing th a t 
such  eradication  might involve the im pairment of the  mucus lay er 
with its  damaging consequences.
In conclusion, the  evidence fo r a sy n erg is tic  re la tionsh ip  
betw een NSAID and H py lo ri, desp ite  be ing  con tested  should not be 
ignored  because of its  po tential th e rap eu tic  im plications. A lso, th e  
suggestion  th a t  NSAID might influence th e  p revalence of H py lo ri 
would indicate th a t the two facto rs a re  uncom fortable p a r tn e rs  in  
pep tic  u lcer d isease.
43
CHAPTER 3
3. NSAID-RELATED ULCERS AND ANTI-RHEUMATOID 
SECOND-LINE DRUGS
3.1 INTRODUCTION
Many p atien ts  with rheum atoid a r th r i t is  need bo th  NSAID and 
second-line d ru g s  fo r  th e  trea tm en t of th e ir  a r th r i t is .  
G astro -in testina l side e ffec ts , p rev iously  stud ied  on basis  of p a tien ts  
symptoms only, a re  the  commonest cause of in te r ru p tin g  o r even 
d iscontinu ing  second-line th e ra p y . The issue  is also complicated by  
th e  concurren t in take of NSAID. The s tu d ies  included in Section VI 
su g g est th a t p a tien ts  rece iv ing  NSAID and in tram usclar gold 
injections have a lower p revalence  of pep tic  u lcers th an  those tre a te d  
w ith NSAID only or w ith o th e r second-line d ru g s  includ ing  
su lphasalazine, penicillam ine, and  hydroxychloroquine. The 
p revalence of H pylori was also lower in  p a tien ts  tre a te d  w ith gold. 
In  ligh t of these  f in d in g s , C hap ter 3 review s the  mechanisms of 
in te rac tio n  betw een gold and  th e  g a s tr ic  mucosa, and  d iscu sses  th e ir  
im plications fo r the management of N SA ID-related u lcers  in  p a tien ts  
w ith rheum atoid a r th r i t is .
44
3.2  HISTORICAL BACKGROUND
As some rheum atologists a re  re th in k in g  the  value of gold 
th e ra p y  in  rheum atoid a r th r i t is  (RA) (97-100) an  in creased  in te re s t 
in  th is  precious metal has occu rred  amongst g astro en tero lo g ists  
(82,101-105, C hap ter 11) because of its  po tential b enefits  in pep tic  
u lce r d isease .
The v a ry in g  degrees of in te re s t in gold th e ra p y , noted over the  
y e a rs , has each time been linked to its  an tibacteria l ac tiv ity . N early 
a  c e n tru ry  a f te r  gold was u sed  in  the  treatm ent of tubercu losis  (106) 
and  60 y ea rs  a f te r  its  f i r s t  u se  in  the th e rap y  of rheum atoid 
a r th r i t is  (107), then  th o u g h t to be tubercu lous in o rig in , th e  d ru g  
is now being  reconsidered  in  th e  trea tm en t of ano ther infection: 
H elicobacter (H) pylori (101-105), which has been linked to pep tic  
u lce r d isease .
3 .3  MECHANISMS OF INTERACTION BETWEEN GOLD AND THE 
GASTRIC MUCOSA, AND THEIR THERAPEUTIC IMPLICATIONS
Not unlike its  an ti-rheum ato id  a c tiv ity , the  effect of gold on the  
g a s tr ic  mucosa is still poorly  u n d ersto o d . Its  ap p aren t p ro tec tive  
effec ts  on th e  stomach a re  in  co n tra s t to those on the  colonic mucosa 
w here it may cause colitis (108). Gold may affect fac to rs  involved in  
th e  pathogenesis  of pep tic  u lce r d isease including  g astric  ac id , H 
p y lo ri, and  NSAID; and  th e  p ro tec tiv e  fac to rs , including mucosal 
p ro stag lan d in s , b icarbonate  sec re tio n , and the  mucus lay er. These 
fac to rs  cannot always be considered  sep a ra te ly , as the  individual
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p a tien t might be in fected  with H py lori, receiv ing  an  NSAID with 
decreased  g as tr ic  p rostag land in  sy n th es is , all of which increase the  
r is k  of u lcer form ation.
The effect of gold on g as tric  acid secre tion  has not been 
s tu d ie d . D espite its  im portance, the  role of acid in th e  pathogenesis 
of p ep tic  u lcers  in  rheum atoid p a tien ts  might not be critica l, as many 
RA p a tien ts  tend  to have hypochlorhydria (57). Also, the effect of 
gold on g as tr ic  p ro stag lan d in s, m ucus, and  b icarbonate  secretion  
rem ains specu la tive . Since gold and bism uth a re  classified close to 
one an o th e r in  the  periodic table of elem ents, it might be justifiable 
to  suppose th a t th e ir  mode of action might be similar (82,101, 
C h ap te r 11). Colloidal bism uth su b c itra te  was found to have a 
p ro tec tiv e  effect against asp irin -induced  g as tr ic  m icrobleeding, and 
th is  p ro tec tion  occurred  desp ite  suppression  of mucosal p rostaglandin  
p roduction  b y  a sp irin  (33). In  addition , colloidal bism uth su b c itra te  
was shown to stim ulate g as tric  and duodenal alkaline secretion 
th ro u g h  a p rostag land in  dependent mechanism (92). Whether gold 
possesses  similar favourable p ro p erties  to bism uth needs to be 
in v e s tig a te d .
More is known about the  in teraction  betw een gold, H pylori, and  
NSAID th an  th a t betw een gold and o th er fac to rs  such  as acid , 
p ro stag lan d in s , and  bicarbonate secre tion . The low prevalence of H 
p y lo ri in  rheum atoid p a tien ts  tre a ted  with gold compounds might be 
due to e ith e r a d irec t bacteric idal e ffec t, as  shown by  in v itro  
s tu d ies  (101), o r inhibition of H pylori u rease  ac tiv ity  (102), o r 
b o th . The fa ilu re  of some stud ies to dem onstrate any  significant 
effec t of gold on H pylori colonization (103) could be explained by
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th e  difference in th e  methodology of detecting  H pylori organism s: 
unlike c u ltu re , h isto logy, and the  C LO -test, which involve g as tr ic  
b iopsies , the  specificity  of some serological te s ts  fo r H pylori might 
be less reliable in  RA (78, C hap ter 4 ) . The immunomodulatory 
a c tiv ity  of gold is  ano ther mechanism by which th is  agen t might 
influence the  su rv iv a l of H py lo ri, and  th is  is of p a rtic u la r  relevance 
to p a tien ts  with RA. It has been  observed  th a t immuno-deficient 
p a tien ts  a re  less likely to be in fected  with H pylori possib ly  due to 
im paired host cellu lar immune responses (109,110). Sulphaslazine, 
known to have a n ti-a r th r itic  ac tiv ity  comparable to th a t of gold, does 
not seem to affect th e  prevalence of H pylori (105, C hapter 12).
Chronic su p p ress io n , ra th e r  th an  eradication of H pylori by  gold 
com pounds, could also explain th e  small num ber of cases of 
detectab le  organism s in biopsies taken  from chronic gold u se rs  (105). 
This implies th a t H pylori might re c u r  or become more easily  
detectab le  upon th e  w ithdrawal of gold th e rap y . The presum ed 
effect of in tram uscu lar gold on H py lo ri (105) is though t to be due 
to the  d is trib u tio n  of gold into the  gastric  mucosa, g as tr ic  
secre tio n s , o r b o th . T here have been  no stud ies on g as tric  tissu e
o r juice levels of gold, b u t it  could be speculated th a t such  levels
might be h ig h er if  oral gold p repara tions are  u sed , which in  tu rn  
might be more effective agains H py lo ri.
It has to be  emphasized th a t the use of c u rre n t gold 
p rep ara tio n s  to erad icate  o r su p p re ss  H pylori in n o n -a rth ritic  
p a tien ts  cannot be ju stified , a t th is  s tag e . This is because of th e ir
re la tive  ex p en se , potential tox ic ity , and the availability of sa fe r
anti-H  pylori d ru g s  such  as bism uth compounds, an tib io tics, and
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more recen tly , the  proton-pum p in h ib ito rs .
In  conclusion, gold continues to be an  in trig u in g  precious metal 
w hich has fascinating  and complicated activ ities in biological system s. 
An u n d ers tan d in g  of its  effects  on H pylori may yield usefu l 
inform ation germane to its  mode of action in RA. I ts
g astro p ro tec tiv e  p roperties  a re  a s u rp r is in g  and a welcome bonus to 
RA pa tien ts  whose stomachs a re  otherw ise exposed to the  in su lts  of 
th e ir  antirheum atic th erap y .
SECTION II 
AIMS OF THESIS
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SECTION II 
AIMS OF THESIS
It is obvious, as d iscussed  in  C hap ters  1-3, th a t  the  
pathogenesis of NS A ID -related pep tic  damage is still no t fu lly  
understood . T here  a re  several a reas th a t need fu r th e r  c larification ; 
th ese  include the  possib le in teraction  betw een NSAID and  H p y lo ri, 
the  effect of NSAID on the  detection of H p y lo ri, th e  histological 
fea tu res  of N SA ID -related damage, th e  effect of NSAID on mucosal 
blood flow, and  th e  possible in terac tion  betw een NSAID and  
anti-rheum atoid  second-line d ru g s .
The suggestion  th a t NSAID-related u lcers  occur more commonly 
in patien ts  in fected  with H pylori (Section I ) ,  makes it e ssen tia l to 
be able to de tect th ese  organism s accu ra te ly  in  p a tien ts  tak in g  
NSAID. The aim of C hap ter 4 is , th e re fo re , to a ssess  the  efficacy  
of cu ltu re , h isto logy, C LO -test, Helico-G, and  P yloriset te s ts  in 
iden tify ing  H pylori in fection , in th e  p resen ce  o r absence of NSAID, 
u s in g  cu ltu re  as s ta n d a rd .
Given the  po ten tia l advantages of d iagnosing  H py lo ri b y  
sero logy, including sp eed , convenience, low co st, and  labour sav in g , 
C hap ter 5 aims a t  evaluating  a to tal of fo u r serological te s ts  in  
p a tien ts  tak ing  NSAID. These include Biolab M alakit, B io-Rad GAP 
IgG , Helico-G, and  P yloriset te s ts .  All th re e  b io p sy -re la ted  te s ts  
a re  used  as s ta n d a rd .
C hapter 6 a sse sse s  the  ab ility  of th e  Health A ssessm ent 
Q uestionnaire to p red ic t NSAID-related u lcers  in  p a tien ts  with
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a r th r i t is .  This is based  on th e  hypo thesis  th a t p a tien ts  w ith 
deb ilita ting  joint d isease might be a t a g re a te r  r isk  of developing 
N SAID-related u lce rs .
Active chronic inflammation of the  u p p e r g as tro -in te s tin a l t ra c t  
has always been though t to p lay  an  im portant role in  th e  
pathogenesis of pep tic  u lce r d isease . The s ituation  is not c lear in  
chronic NSAID u s e rs . Section IV aims a t iden tify ing  th e  histological 
abnorm alities associated  w ith NSAID in take in  th e  stomach (C h ap te r 
7 ) , duodenum (C hap ter 8 ) , and th e  oesophagus (C h ap te r 9 ).
The in te rfe ren ce  w ith g as tr ic  mucosal blood flow is an o th e r 
im portant side-effec t of NSAID. L ittle is known abou t th e  duodenal 
m icrocirculation in NSAID p a tien ts  and it is not c lear w hether th e  
mucosal blood flow is affected  by  fac to rs  such  as a g e , sm oking, H 
p y lo ri, and active u lcera tion . C hap ter 10 aims a t in v estig a tin g  th e  
influence of these  fac to rs  on g as tr ic  and  duodenal blood flow in  
p a tien ts  receiv ing  long term  NSAID.
Since many p a tien ts  w ith rheum atoid a r th r i t is  a re  tre a te d  w ith 
bo th  NSAID and second-line d ru g s , it might not be easy  to explain  
th e  source of g a s tro -in te s tin a l complaints in  such  p a tie n ts . The aim 
of C hapter 11 is to iden tify  the  endoscopic abnorm alities in p a tien ts  
receiv ing  NSAID only , o r w ith gold, su lphasalazine, penicillam ine, 
and  hydroxychloroquine. In  add ition , C hap ter 12 in v estig a tes  th e  
prevalence of bo th  u lcers  and H pylori in  p a tien ts  tre a ted  w ith 
NSAID only o r w ith gold and  sulphasalazine: th e  la t te r  two ag en ts
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a re  known to have comparable an ti-rheum ato id  e ffec t, and  were 
o rig inally  used  fo r th e ir  presum ed a n ti—microbial ac tiv ity , in  the 
d ay s  when rheum atoid a r th r i t is  was th o u g h t to be of bac teria l o rig in .
SECTION III 
DIAGNOSTIC STUDIES
INTRODUCTION
This section investiga tes  the efficacy of a to tal of seven te s ts  
u sed  in the  diagnosis of H pylori in  the p resence  or absence of 
NSAID: 3 b io p sy -re la ted  te s ts  (c u ltu re , h isto logy, C L O -test), and  4
serological te s ts  (P y lo rise t, Helico-G, Biolab Malakit, and Bio-Rad 
GAP IgG ). It also te s ts  the capacity  of th e  Health A ssessm ent 
Q uestionnaire to p red ic t NSAID-related u lcers  in a r th ritic  p a tien ts  
tak in g  NSAID.
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CHAPTER 4
4 INFLUENCE OF NSAID ON THE EFFICACY OF DIAGNOSTIC 
TESTS FOR H PYLORI
4 .1  SUMMARY
B ackground: The efficacy of various te s ts  used  in th e  diagnosis
of H elicobacter py lo ri has not been fully  estab lished . A lso, it  is not 
know n w hether th e  yield of such  te s ts  can be influenced b y  
n o n -s te ro id a l anti-inflam m atory d ru g s .
Aims: To evaluate  the efficacy of cu ltu re , histo logy, C L O -test,
Helico-G and P ylo rise t te s ts  in diagnosing H pylori in th e  p resen ce  
o r  absence  of NSAID.
P atien ts  and Methods: Of 134 pa tien ts  s tu d ied , 75 took NSAID
a n d  59 did n o t. At endoscopy, biopsies were taken  fo r  c u ltu re , 
h isto logy  and  C L O -test. Blood was also taken fo r ELISA (Helico-G) 
a n d  la tex  agg lu tination  (Pyloriset) te s ts .
R esu lts: The sen sitiv ity , specific ity , and p red ic tive  values of
h isto logy  and C L O -test, compared with cu ltu re , ranged  betw een 
90-97% reg ard less  of NSAID in tak e . In  patien ts  not tak in g  NSAID, 
Helico-G had a sen sitiv ity  of 75% (p<0.05) and a specificity  of 61%; 
P y lo rise t’s sen sitiv ity  and specificity  w ere, resp ec tiv e ly , 63% 
(p<0.05) and 67%. In p a tien ts  tak ing  NSAID the  sen sitiv ity  of 
Helico-G was 81% and  its  specificity  was 45% (p<0.05); Pyloriset had
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a sen sitiv ity  of 61% (p<0.05) and specificity  of 50% (p<0.05).
Conclusion: These findings su g g est th a t H py lo ri is more
re liab ly  diagnosed b y  cu ltu re , histology and CLO -test than  b y  the  
serological te s ts  u sed  in  th is  s tu d y , especially in  p a tien ts  tre a te d  
w ith  NSAID.
4 .2  INTRODUCTION
The increasing  realization of the  im portance of H elicobacter (H) 
p y lo ri in the developm ent, trea tm en t, and re cu rre n ce  of pep tic  
u lcera tion  (111-115) has made the identification of th ese  organism s an 
essen tia l p a r t  of the  investigation  and management of pep tic  u lcer 
d isease . Several te s ts  have been proposed includ ing  c u ltu re , 
h isto logy , u rease  enzyme ac tiv ity , and serological te s ts  (79, 
116-121). The value of such methods in general and  th e  serological 
te s ts  in p a rtic u la r  has not been fully  estab lish ed . Also, th e ir  
application to p a tien ts  tre a ted  with non-stero idal anti-inflam m atory 
d ru g s  (NSAID), who a re  a t a p a rtic u la r  r isk  of developing pep tic  
dam age, has not been adequately  investiga ted .
The aim of th is  s tu d y  was to evaluate the  efficacy of cu ltu re , 
h isto logy , u rease  ac tiv ity  (C L O -test), enzyme linked immunosorbent 
a ssa y  (ELISA, Helico-G), latex agglutination te s t  (P y lo rise t) in  
d iagnosing  H py lori in  the  p resence o r absence of NSAID
4 .3  PATIENTS AND METHODS
P atien ts , over the  age of 18 y e a rs , were rec ru ited  from the
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G astroenterology and  Rheumatology clinics. NSAID had to be tak en  
fo r a minimum of 4 weeks p rio r  to endoscopy. P atien ts w ere 
excluded if th ey  had a h is to ry  of g as tric  s u rg e ry  o r if th ey  had  
received  antib iotics or u lcer healing d ru g s  w ithin 2 weeks of 
endoscopy.
Informed consent was obtained and endoscopy carried  o u t, u s in g  
3-6mg midazolam in travenously  fo r sedation , w ithin 3 hours of tak in g  
10ml of venous blood for serology te s ts .  Biopsies were taken  from 
healthy  looking mucosa in the  g as tr ic  an trum  and  a t least 2cm away 
from the  u lcer edge, in pa tien ts  w ith u lc e rs , fo r  cu ltu re  ( lb io p s y ) , 
h istology (2 b io p sies), and CLO -test (1 b io p sy ). In  p a tien ts  w ith 
u lc e rs , biopsies were also taken  from the  u lce r edge and base to 
exclude malignancy which, if found , excluded p a tien ts  from the  final 
an a ly s is .
H pylori was detected by  cu ltu re  and  histology as p rev iously  
described  (61). G astritis  was classified accord ing  to the  Whitehead 
system  modified to cover chemical and  lymphocytic g a s tr i t is  
(23,72,122,123, C hapter 7).
U rease ac tiv ity  was te sted  fo r by  in se rtin g  one a n tra l b io p sy , 
immediately a f te r  it  was obtained, into the  gel pellet of th e  C LO -test 
slide (Delta-W est L td , B entley, W estern A u stra lia ). The slides w ere 
review ed for the  positive red  colouration a t 3 and 24hours.
Serum IgG H pylori antibodies were m easured usin g  a q u an titiv e  
commercial IgG ELISA (Helico-G) according  to the  m an u fac tu rer 's  
in stru c tio n s  (Porton Cam bridge, M aidenhead, UK). In  summ ary, a
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s ta n d a rd  curve was p rep a red  and lOOul serum  a liquo tes, d ispensed  
into microwell s tr ip s  p recoated  with H pylori cell m em brane-derived 
an tig en . The microwells were incubated  a t 37°C fo r one h o u r, 
w ashed in b u ffe r , and  lOOul antibody conjugate ad d ed , to be 
incubated  again fo r  30 m inutes and washed as above. S u b stra te  
chromogen (lOOul of tetram ethylbenzid ine was ad d ed , shaken  fo r 10 
m inutes, and the reaction  was th en  s topped  u s in g  50ul of 2M 
su lp h u ric  acid. Each microwell was th en  read  a t absorbance of 
450nm in  an ELISA re a d e r  (Labsystem s, U xbridge, UK). An 
an tibody  level of 10 u n its  o r more was considered  as indicative of 
infection with H py lo ri.
To te s t for IgG H pylori antibodies by  latex  agg lu tina tion , 
P y loriset (Orion D iagnostics, Finland) was u sed . The te s t  u ses 
latex  partic les coated w ith ac id -ex trac ted  an tigen  of H p y lo ri. A 
drop (40ul) of p a tie n t’s serum , a lready  d ilu ted  1:2 in  
phosphate-saline b u ffe r , was placed in  the cen tre  of th e  te s t s lide , 
and  one drop of latex  reag en t was added to be mixed w ith the  
serum . The te s t slide was then  gen tly  ro ta ted  fo r 3 m inutes and  
observed  fo r evidence of agg lu tination . A positive re su lt was taken  
as  white g ranules on a b lack background . In each series  of te s ts  
positive and negative se ra  were used  as con tro ls.
S tatistical analyses included C h i-square  (X2) te s t w ith correction  
fo r multiple com parisons, analysis of variance , and  McNemar's te s t  
(124) w here ap p ro p ria te . P atien ts were endoscoped a t random , and  
all specimens ca rried  code num bers to facilitate  random ization.
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4 .3  RESULTS
A total of 134 p a tien ts  en te red  th e  final ana lysis : 75 took NSAID 
an d  59 did n o t. T heir c h a rac te ris tic s  a re  shown in  Table 2.
P atien ts  in  bo th  g roups w ere comparable in  th e ir  ag es , smoking 
a n d  d rin k in g  h a b its , and  th e  occurance of abdominal com plaints. 
T he details of NSAID and second-line d ru g s  u sed  b y  p a tien ts  w ith 
rheum atoid a r th r i t is  (NSAID group) a re  p re se n te d  in  Table 3. 
NSAID taken  b y  the  m ajority of p a tien ts  in th is  g roup  a re  known fo r 
th e ir  p o ten t anti-inflam m atory ac tiv itiy  and  re la tive ly  marked 
u lcerogen ic  po ten tia l. The median d u ra tion  of th e ir  in take was two 
y e a r s .
P atien ts  not tre a ted  w ith NSAID, who a re  positive fo r H pylori 
acco rd in g  to various te s ts ,  a re  shown in  Table 4. They a re  
su b g ro u p ed  accord ing  to th e  p resen ce  or absence of symptoms, and  
to  th e ir  endoscopic and  histological f in d in g s . Similar num bers of H 
p y lo ri positive p a tien ts  w ere iden tified  b y  c u ltu re , h isto logy, and  
C L O -test in  various su b g ro u p s . A lthough such  num bers were 
g re a te r  b u t not s ign ifican tly  d iffe ren t from those identified  by  the  
serological te s ts ,  the  la tte r  included more false  positive cases which 
in  tu r n  re su lted  in  lower sp ecific ity , a s  will be seen  in  Table 7.
H py lori positive p a tien ts  in  th e  NSAID g ro u p , classified 
acco rd in g  to th e ir  symptoms and  endoscopic fin d in g s , a re  shown in 
T able  5. The serological te s ts ,  Helico-G in  p a r tic u la r , diagnosed 
g re a te r  num bers of H py lo ri positive p a tien ts  rece iv ing  NSAID b u t 
th e  significance of th is  find ing  is limited b y  the  low specificity  of
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such  te s ts  (see below ). I t is also w orth noting th a t p a tien ts  tre a te d  
w ith NSAID had a to tal of 30 cases of u lcers or erosions (30/75,40%), 
and  only 18 of th ese  (18/30 , 60%) were associated w ith abdominal 
com plain ts.
The histological abnorm alities in pa tien ts  receiv ing  NSAID and 
th e  co rresp o n d in g  num bers of H pylori positive cases a re  p resen ted  
in  Table 6. The major abnorm ality was th a t of chronic superficial 
g a s tr i t is ,  followed by  chemical g a s tr itis . H pylori was iden tifed  in 
more th an  60% of cases of chronic superficial g a s tr itis  by  all te s ts  
u se d , w ith th e  g re a te s t p roportion  (83%) diagnosed b y  Helico-G te s t .  
Six of 11 cases (54%) of chemical g as tr itis  w ere associated  with 
p ep tic  dam age, compared w ith 18 of 36 (50%) with H py lo ri, and 6 of 
29 (21%, p<0.05) in  p a tien ts  w ithout chemical g a s tr itis  o r H py lo ri.
The sen s itiv ity , spec ific ity , and the p red ic tive  values of various 
te s ts ,  compared w ith c u ltu re , are  summarized in Table 7. Histology 
and  C L O -test had the  h ig h est sen sitiv ity , sp ecific ity , and  p red ic tive  
v a lu es , reg a rd le ss  of NSAID in take. Helico-G and  Pyloriset te s ts  
had th e ir  lowest specific ity  and  negative p red ic tive  values in p a tien ts  
tre a te d  w ith NSAID. Compared with P y lo rise t, Helico-G had h igher 
sen s itiv ity  and  positive p red ic tiv e  values b u t lower specific ity  and 
negative  p red ic tiv e  v a lues, in  the p resence o r absence of NSAID.
U sing c u ltu re , h isto logy and C LO -test, the  prevalence of H 
py lo ri in  th e  NSAID g ro u p  was 43-48% compared with 64-69% in 
p a tie n ts  not tre a te d  with NSAID (p<0.01). No sign ifican t d ifferences 
w ere d e tec ted  u s in g  Helico-G or Pyloriset te s ts .  A lso, H py lori IgG 
ti t re s  m easured b y  Helico-G in  patien ts  tak ing  NSAID were comparable
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to those in p a tie n ts  not receiv ing  such  d ru g s . Of 15 pa tien ts  
tre a te d  with gold and  NSAID 5 were positive fo r H pylori by  
c u ltu re , and  th is  did not a lte r  the  in te rp re ta tio n  of the  above 
m entioned fin d in g s . The p resence  o r absence of rheum atoid fac to r 
d id  not seem to influence the sen sitiv ity  o r specificity  of the 
serological te s ts  u sed  in  th is  s tu d y .
TABLE 2 PATIENTS’ DEMOGRAPHIC DETAILS
Patien ts Patien ts
On NSAID Not on NSAID Total
Num ber 75 59 134
Males 22 18 40
Females 53 41 94
Age (y ears)
Median (in te rq u artile
56 47 53
ran g e s)  (44-66) (36-65) (39-65)
Sm okers 27 21 48
D rinkers  34 33 67
Abdominal
symptoms 36 39 75
TABLE 3. TYPES OF NSAID AND SECOND-LINE DRUGS USED
NSAID:
Indomethacin
Naproxen
Fenbufen
Diclofenac
Ketoprofen
Ibuprofen
Piroxicam
Flurbiprofen
Nabumetone
Others
Second-line Drugs:
Sulphasalazine 
Sodium aurothiomalate 
Hydroxychloroquine 
Penicillamine
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4 .3  DISCUSSION
This s tu d y  shows th a t c u ltu re , h istology and  C L O -test have 
com parable se n s itiv ity , specific ity , positive and negative  p red ic tiv e  
values in  d iagnosing  H py lo ri in fection . Such c h a rac te ris tic s  do not 
seem to be influenced b y  trea tm en t w ith NSAID. On th e  o th e r h an d , 
Helico-G and  P yloriset w ere less d iscrim inatory , and  th e  in tak e  of 
NSAID was associated  w ith lower specific ity  and  negative  p red ic tiv e  
values w ith bo th  of th ese  serological te s ts .
D etecting H py lo ri in  g as tr ic  b iopsy  specimens may be  in fluenced  
b y  sam pling e r ro rs  (125). I t  is believed th a t th is  has been
I
minimised b y  s tu d y in g  multiple histological sections made th ro u g h  
each specimen and b y  a ssess in g  additional samples b y  cu ltu re  and  
C LO -test as  well as h isto logy. The minimal d ifferences in  th e  
sen sitiv ity  and  specific ity  betw een th ese  3 methods can be explained 
b y  the  p resen ce  of v e ry  few organism s in  some b iopsies , and  th is  
would be de tec ted  as a ligh t grow th b y  cu ltu re . On th e  o th e r h an d , 
th e  h ig h er num ber of false positives diagnosed by  the  sero logy te s ts  
p robab ly  re flec ts  p rev ious infection w ith H py lo ri (126,127). The 
sen sitiv ity  of Helico-G found in  th is  s tu d y  is comparable to th a t of 
an o th e r re p o rt (120). However, it  was not possible to confirm  th e  
sen sitiv ity  and  specific ity  levels of P y lo rise t, recen tly  re p o rted  (121)
To th e  a u th o r’s know ledge, all H pylori diagnostic  te s ts  have 
been  a ssessed  in  p a tien ts  not tre a te d  w ith NSAID. T h ere  is 
evidence to indicate th a t the  n a tu ra l h is to ry  of pep tic  u lcera tion  can 
be a lte red  b y  such  a g e n ts . F irs tly , a lthough  more th an  30% of 
NSAID ta k e rs  might develop pep tic  damage (42 ,12), many such
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lesions can be completely asymptom atic, as shown by  th is  s tu d y  and 
o th e rs  (81). Secondly, NSAID seem to reduce the prevalence of H 
p y lo ri in fection , as su g g ested  by data  contained in th is  Thesis and 
elsew here (23 ,75 ,83 ,84 , C hapter 7). Such fea tu res  of 
NSAID-induced pep tic  damage might limit the  value of find ing  a 
p o sitiv e  IgG -rela ted  serological te s t in p red ic tin g  u lcer disease in  the 
p re sen c e  o r absence of abdominal complaints (79). This needs to be 
tak en  into consideration  especially when serological te s tin g  is not 
supplem ented w ith endoscopic, cu ltu re , o r histological assessm ents 
(129).
The reason  fo r the  low prevalence of H pylori in the  p resence  of 
NSAID rem ains a  m atter of speculation. It could be due to a  d irec t 
tox ic  action ag ain st th e  organism s, o r ind irec tly  rela ted  to the  
e ffec t of NSAID on th e  g as tric  mucosa. A spirin  and indom ethacin 
w ere found to increase  basal (13) and maximally stim ulated g as tr ic  
ac id  secre tion  (14 ,15). A spirin  (16) and indomethacin (17) w ere also 
show n to inh ib it mucus secre tion . This rise  in g astric  acid and  the 
in te rfe re n c e  w ith the  mucus layer by  NSAID might in tu rn  make it 
d ifficu lt fo r H py lori organism s to su rv ive  u n d e r such  unfavourable 
co n d itio n s.
The median du ra tio n  of NSAID in take in th is  s tu d y  was two 
y e a r s .  Assum ing th a t some patien ts became negative fo r H pylori 
d u r in g  such  p e rio d , th e  behaviour of th e ir  serum  antibody ti tre s  
could not be p red ic ted  as the  p recise  time of th e ir  converstion  was 
no t know n. Recent s tu d ies  have suggested  th a t such ti tre s  might 
fa ll (130) o r rem ain unchanged  (126).
69
In th is  s tu d y , chemical g as tr itis  was only found in p a tien ts  
rece iv in g  NSAID. H pylori IgG antibodies were detected  in p a tien ts  
w ith chemical g as tr itis  (5/11,45%) while the p resence  of H py lori 
organism s was confirmed in only one of these  cases. This 
d isc rep an cy  betw een the  serological and biopsy te s ts  might again  
su p p o rt the  suggestion  th a t the  positive serology re flec ts  p rev ious 
in fection  with H pylori which could have been e rad ica ted , o r a t least 
a lte re d , by  NSAID in take (23 ,75,83,84, C hapter 7).
NSAID rela ted  peptic u lcers or erosions were found in 54% of 
p a tien ts  with chemical g a s tr itis  and 50% of those with H p y lo ri, 
com pared with only 21% of o th er p a tien ts  in the NSAID g roup . This 
is  in  agreem ent with o th er findings in  th is  Thesis su g g estin g  th a t 
th e  p revalence of NSAID-induced peptic damage appears  to be 
in c reased  by  the  p resence of chemical g as tr itis  o r H py lori (23, 
C h ap te r 7).
In  conclusion, cu ltu re , histology and CLO-test have comparable 
sen s itiv ity  and  specificity  th a t do not seem to be influenced b y  
NSAID in tak e . However, IgG antibody serology te s ts  (Helico-G and  
P y lo rise t) ap p ear to be less usefu l than  the above te s ts  involving 
th e  u se  of g as tr ic  biopsy specim ens. Such differences a re  fu r th e r  
em phasised in  p a tien ts  tre a ted  with NSAID. The use  of im proved 
serological te s ts  should still be considered because of th e ir  
non-invasive  n a tu re , low co st, time and labour sav ing  po ten tia l.
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CHAPTER 5
5 EFFECT OF NSAID ON THE SERODIAGNOSIS OF H PYLORI
5.1 SUMMARY
Background: The h o st's  humoral immune resp o n se  to
Helicobacter pylori has been utilized in the diagnosis of active 
infection with these  organism s. Several commercial te s ts  have 
become available, b u t the  assessm ent of th e ir  efficacy has relied  on 
few and unconfirm ed re p o rts , and in  the  absence of NSAID.
Aims: To assess  and compare the  efficacy of th e  following H
pylori serological te s ts  in pa tien ts  tre a ted  o r not tre a te d  w ith 
NSAID: Biolab Malakit, Bio-Rad GAP te s t IgG, Pyloriset L atex , and
Helico-G te s ts .
Methods: Venous blood was te s ted  a t random in  124 p a tie n ts : 64
received NSAID and 60 did no t. H pylori IgG antibodies w ere 
detected  by  Latex agglu tination  (P y lo rise t) , o r b y  ELISA (th e  
rem aining te s ts ) .  Endoscopic g as tr ic  an tra l biopsies w ere also 
obtained for u rease -ac tiv ity , cu ltu re , and histology: detection  of H 
py lo ri by  a t least two of them was considered as a tru e  p o sitiv e , and  
its  absence in all biopsies as a tru e  negative.
R esults: The sen sitiv ity  values in  the p resence (o r absence) of
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NSAID w ere: P y loriset Latex, 59% (60%); Helico-G, 79% (74%); Biolab 
M alakit, 85% (81%); and Bio-Rad GAP T est IgG , 100% (95%). The 
resp ec tiv e  specific ity  values were: 50% (71%), 47% (59%), 50% (65%), 
and  30% (29%).
Conclusion: Bio-Rad GAP te s t  IgG has th e  h ig h est sen sitiv ity
and  th e  lowest specificity  values, reg a rd le ss  of NSAID in tak e . 
However, th e  sen sitiv ity  of the o th e r te s ts  is less th an  th a t of the  
s ta n d a rd  b io p sy -re la ted  te s ts  and th e ir  specific ity  is even lower in 
chronic NSAID u s e rs .
5 .2  INTRODUCTION
It is increasing ly  realised  th a t th e  system ic immune response  to 
H elicobacter (H) pylori infection confers no p ro tec tion  against the  
organism s, and  its  p resence is of d iagnostic  value only (131). 
Several methods have been used to de tec t such  responses includ ing  
agg lu tina tion , complement fixation, and  enzyme linked immunosorbent 
a ssay  (ELISA) (116,119,121,132-135, C h ap te r 4 ) . The low cost and 
convenience of th ese  techniques encouraged  some w orkers to 
recommend th e ir  use  in  the diagnosis and  managment of H pylori 
associated  u lc e rs , w ithout the  need fo r endoscopy (79 ,80). Because 
of th e ir  d iagnostic and  therapeu tic  sign ificance, increasing  num bers 
of commercial serological te s ts  a re  be ing  in tro d u ced . The valid ity  of 
such  te s ts  h a s , how ever, been assessed  b y  few and unconfirm ed 
s tu d ie s , in  th e  absence of NSAID, and  d ire c t comparison betw een 
them has been  lacking. Recent evidence indicates th a t the  
p revalence of NSAID re la ted  u lcers is h ig h e r in  p a tien ts  infected  
w ith H pylori (23,75,129, C hapter 7 ), which emphasizes the need fo r
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accu ra te  diagnosis of th is  infection in  such  p a tie n ts , and  th a t the  
specific ity  of some serological te s ts  can be influenced b y  NSAID (78, 
C h ap te r 4 ) .
The aim of th is  s tu d y  is to evaluate th e  efficacy of fo u r newly 
in tro d u ced  commercial te s ts  (P y loriset L atex, Helico-G, Biolab 
M alakit, and  Bio-Rad GAP T est IgG) in  d iagnosing  H py lo ri in  
p a tien ts  w ith o r w ithout a h is to ry  of chronic NSAID in tak e .
5 .3  PATIENTS AND METHODS
P atien ts w ith ad u lt rheum atoid a r th r i t is  (the  NSAID group) were 
re c ru ite d  from th e  Rheumatology O ut-P atien t Clinic p rov ided  they  
had  taken  th e ir  NSAID fo r a t least fou r w eeks. The re s t  of the 
p a tien ts  w ere rec ru ited  from the  G astroenterology O u t-P a tien t Clinic, 
w here th ey  had p re sen ted  with tra n s ien t or p e rs is te n t abdominal 
com plaints. They w ere excluded if they  had been  tre a te d  with 
s te ro id s , cytotoxic d ru g s , an tib io tics, an ti-u lce r d ru g s ,  o r if  they  
had  a h is to ry  of gastro -duodenal s u rg e ry .
Venous blood, 10ml, was taken  fo r serology te s ts  and  p a tien ts  
w ere endoscoped a t random u sin g  4-6mg midazolam fo r sed atio n , a f te r  
g iv ing  an  inform ed consen t. A to tal of fo u r g as tr ic  a n tra l biopsies 
w ere taken  fo r h isto logy (two specim ens), cu ltu re  (one specim en), 
and  CLO -test (one specim en). U lcers w ere also b iopsied to exclude 
m alignancy.
H py lori was iden tified  b y  cu ltu re  and  histology as  p rev iously  
d escrib ed  (61). The classification of g a s tr itis  was accord ing  to the
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W hitehead system  modified to include the  newly described  en tities  of 
lym phocytic and chemical g a s tr itis  (23,72,123, C hap ter 7 ).
The CLO -test (Delta-W est L td . ,  B entley , W estern A ustralia) was 
ca rried  out b y  p lacing  th e  a n tra l b iopsy specimen into th e  gel pe lle t, 
and  review ing th e  slide fo r th e  positive re d  coloration a t 3 and  24 
ho u rs  (78, C hap ter 4 ) .
The P yloriset Latex (O rion Diagnostica Finland) and the  Helico-G 
(Porton  Cam bridge, M aidenhead, UK) te s ts  were ca rried  out 
accord ing  to th e  m an u fac tu re r’s in s tru c tio n s  and as recen tly  
described  (78, C hap ter 4 ) . The Pyloriset de tec ts  IgG antibodies by  
agg lu tina tion , u s in g  Latex partic le s  coated with ac id -ex trac ted  
an tigen  of H p y lo ri. The Helico-G te s t u ses  ELISA to m easure IgG 
antibodies d irec ted  against H pylori cell m em brane-derived an tig en .
ELISA was also u sed  to de tect IgG antibodies aga inst two more 
p artia lly  p u rified  an tig en s: H pylori u rease  an tig en , by  Biolab Mlakit 
(B iolab, Limal, Belgium ), and  H py lori o u te r  membrane an tig en , by  
Bio-Rad GAP te s t  IgG, (Bio-Rad Chemical Division, Richmond, CA, 
USA). Both te s ts  w ere also carried  out accord ing  to  the  
m an u fac tu re rs’ in s tru c tio n s . The Biolab Malakit te s t  involved 
in cu b atin g  th e  d ilu ted  samples and controls in  microwells p recoated  
w ith H py lo ri an tig en s a t 37°C fo r 45 m inutes, to form an  H pylori 
an tig en -an tib o d y  complex. The unbound components w ere washed 
o ff. An an ti-Ig G , coupled perox idase con jugate , was th en  added 
and  in cu b a ted , th e  unbound conjugate w ashed off, a s u b s tra te  added 
and  also in cu b a ted , and  th e  reaction  was finally  stopped with NaOH. 
th e  abso rbance was read  a t 405nm, w ith the  in ten sity  of th e  g reen
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coloration being  p roportional to th e  amount of anti-H  pylori 
an tibodies in  the sam ple. A sample was considered positive fo r H 
p y lo ri if  its  optical d en s ity  was h ig h er than  the  limit of normal 
v a lu e , specified b y  th e  m anufactu rer. In  Bio-Rad GAP te s t ,  lOOul 
of s ta n d a rd s , controls and  d ilu ted  p a tien t samples were p ipe tted  into 
th e  re lev an t microwells, and  incubated  fo r 60 m inutes a t 25°C. The 
co n ten ts  w ere then  d isca rd ed , the  wells w ashed with the  wash b u ffe r  
solu tion  and  b lo tted  on a p ap er towel. A nti-IgG  enzyme conjugate 
solu tion  was added sifter b lue colour developm ent, and absorbance 
w as read  a t 450nm. A s tan d a rd  cu rv e  was co n stru c ted , and  a 
sample was considered  positive fo r H pylori if  its  an tibody 
concen tra tion  was g re a te r  th an  17 u n its .
A tru e  positive was defined as a  p a tien t who had H pylori 
iden tified  by  a t least two of the  b io p sy -re la ted  te s ts  (h isto logy, 
c u ltu re , and  C L O -test), while a tru e  negative was one who did not 
have  H py lori d iagnosed b y  any  of such  te s t s . P atien ts were 
excluded  when H py lo ri was found b y  only one of the  th ree  
b io p sy -re la ted  te s ts .
S ensitiv ity  was defined  as the  freq u en cy  of a positive te s t  in  all 
su b jec ts  w ith H py lori in fection , and  specificity  was the freq u en cy  of 
a  negative te s t  in  those  w ithout th e  infection .
S tatistical analyses involved th e  C h i-square  (X2) and McNemar’s 
te s t  (124) w ith co rrec tion  fo r multiple com parisons, w here 
ap p ro p ria te . All specim ens ca rried  code num bers, and were assessed  
u n d e r  random ised conditions. The s tu d y  was approved by  th e  local 
E th ics Committee.
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5 .4  RESULTS
Four of 128 p a tie n ts  stud ied  were excluded because H pylori was 
iden tified  in  th e ir  histological specimens only, and  could not be 
confirm ed b y  c u ltu re  o r CLO -test. The rem aining 124 pa tien ts  
e n te re d  the  final an a ly s is : 64 took NSAID and 60 did no t.
The dem ographic details of p a tien ts  a re  shown in  Table 8. Both 
g ro u p s  of p a tien ts  w ere comparable in th e ir  age , smoking, and 
d rin k in g  h a b its , b u t p a tien ts  not tre a ted  with NSAID were more 
likely  to have abdominal complaints. The median duration  of NSAID 
in tak e  was 2.5 y e a rs .
Table 9 dem onstrates the  prevalence of H p y lo ri, as detected  by 
th e  various te s ts ,  in  pa tien ts  with histological and endoscopic 
abnorm alities. C hronic superficial g a s tr itis  was the  commonest 
histological abnorm ality  reg ard less  of NSAID in take: similar num bers
of p a tien ts  with th is  abnorm ality, who were also positive fo r H 
p y lo ri, w ere iden tified  b y  Helico-G and Biolab Malakit as compared 
w ith  the  s tan d a rd  (o r b iopsy-re la ted ) te s ts .  However, Pyloriset 
Latex identified  th e  lowest num ber and  Bio-Rad GAP te s t diagnosed 
th e  h ig h est num ber of p a tien ts  w ith both  H pylori and chronic 
superfic ia l g a s tr i t is .  Chemical g a s tr itis  was found more commonly in 
p a tie n ts  receiv ing  NSAID: H pylori organism s w ere seen in  only one
of nine p a tie n ts , u s in g  the  s tan d a rd  te s ts ,  b u t th e re  were 5-6 
seropositive  cases w ith  th is  histological e n tity . Also, a to tal of 19 
p a tie n ts  tre a te d  w ith NSAID (29%) were found to have peptic u lce rs , 
com pared w ith seven  (11%) in  the absence of NSAID. Erosions were 
only  found in  p a tien ts  tak in g  NSAID. Almost all u lcers and erosions
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w ere positive fo r H pylori by  the serological te s ts .
The overall efficacy of the  serological te s ts ,  in diagnosing H 
py lo ri in fection , is shown in  Table 10 and Figures 1 and  2.
Helico-G and  Biolab Malakit had a similar efficacy. However, 
B io-Rad GAP te s t had th e  h ighest num ber of tru e  and fa lse  
p o s itiv es , and  as a re su lt ,  the  h ighest sensitiv ity  and the  lowest 
spec ific ity  reg ard less  of NSAID in tak e . The specificity  of P y lo rise t 
L a tex , Helico-G, and Biolab Malakit was lower in the p resence of
NSAID. Pyloriset Latex had the  lowest sensitiv ity  and h ig h est 
spec ific ity  in p a tien ts  not tak ing  NSAID.
It is w orth noting th a t the p revalence of H pylori in p a tien ts  
tre a te d  w ith NSAID was 34/64, 53%, compared with 43/60, 72%
(p< 0 .05 ), in  pa tien ts  not tak ing  NSAID, using  the s tan d ard  te s ts ,  as 
show n in  T ab le  10. The d ifferences did not reach s ta tis tica l
sign ificance when the find ings of the  serological te s ts  were compared
in  th e  p resen ce  or absence of NSAID.
H pylo ri was identified in  the  g as tr ic  biopsies of six  out of 17 
rheum atoid p a tien ts  (35%) receiv ing  long-term  gold injections p lu s  
NSAID, which is only two sub jec ts  less than  the expected p revalence 
in  su ch  subgroup  had they  taken  NSAID only: th is  did not a lte r  th e  
overall s ta tis tica l analyses of the  s tu d y .
TABLE 8
PATIENTS' GENERAL CHARACTERISTICS 
On NSAID Not on NSAID
Number 64 60
Males 18 19
Females 46 41
Age (years) median 55 50
(interquartile range) (43-65) (38-65)
Smokers 25 21
Drinkers 31 34
Abdominal symptoms 25 39
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Legends to F igures 1 and  2
The sen sitiv ity  (F igure 1) and specific ity  (F igure 2) of 
serological te s ts  in  the p resen ce  o r absence of NSAID.
*: p  < 0.05 compared with the  s ta n d a rd  b io psy -re la ted  te s ts .
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5 .5  DISCUSSION
This s tu d y  shows th a t the  sen sitiv ity  and specific ity  of th ree  
commercial serological te s ts  (P y loriset Latex, Helico-G, and Biolab 
M alakit) a re  lower th an  those  of the  s tan d ard  b io p sy -re la ted  te s ts  
(c u ltu re , h istology and  C L O -test). The specificity  values of the  
above serological te s ts  a re  also lower in p a tien ts  rece iv ing  long-term  
NSAID. The sen sitiv ity  of a 4 th  serological te s t ,  Bio-Rad GAP te s t 
IgG , is identical to th a t of the  s tan d a rd  te s ts  b u t it specific ity  is 
s ign ifican tly  lower.
Several fac to rs  have recen tly  been identified as being  capable of 
in fluencing  the  perform ance of H pylori serological t e s t s : these
include p a tie n ts ’ ag e , th e ir  histological fin d in g s , H py lo ri an tig en s, 
a n d , as sug g ested  b y  th is  s tu d y , NSAID in take.
H pylori infection and  seropositiv ity  have been shown to increase 
w ith  age (96,136) although  th e  immunological re sp o n ses , in  g eneral, 
m ight be reduced  in  th e  e lderly  (137). Age is unlikely  to have 
influenced the  find ings o r th e  conclusions of th is  s tu d y , because all 
te s ts  and comparisons w ere ca rried  out on th e  same group of 
p a t ie n ts .
P atien ts w ith certa in  histological abnorm alities might be 
seropositive  fo r  H py lo ri desp ite  th e  failure to iden tify  th e  organism s 
in  th e ir  g as tr ic  b iopsies. This is p a rticu la rly  tru e  fo r cases of 
chemical g a s tr i t is ,  as shown b y  th is  s tu d y  and  b y  o th ers  (135), and 
m ight explain , a t least in  p a r t ,  th e  reduced  specificity  of serology in 
NSAID p a tien ts , who have a h ig h e r prevalence of chemical g as tr itis
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(1 3 ,2 2 ). Similar find ings have also been rep o rted  in patien ts  with 
ch ron ic  a troph ic  g a s tr i t is  (138,139) which su g g ests  th a t they have 
b een  in fected  with H py lo ri a t some point in  th e ir  lives. A trophic 
g a s tr i t is  was found in  th re e  p a tien ts  in th is  s tu d y  and is , th e re fo re , 
u n like ly  to have influenced its  re su lts .
The developm ent of serological assays fo r an tibody  responses to 
H p y lo ri an tigens has been  complicated by  the  fact th a t H py lori 
organism s sh are  an tigens with o ther bacteria l spec ies, such  as 
C am pylobacter jejuni (140,141). A relatively  high  frequency  of 
fa lse -p o sitiv e  and fa lse -n eg a tiv e  re su lts  has been observed  in s tu d ies  
u s in g  whole e x tra c ts  of H py lori as an tigens (87,132,136,140,141). 
More re ce n tly , h ig h er sen sitiv ity  and specificity  values have been 
re p o rte d  when antibodies w ere ra ised  against certa in  components of 
H p y lo ri organism s such  as p artia lly  purified  u rease  enzyme o r high 
m olecular w eight cell-associated  pro te ins (119), and th e  25-kilodalton 
an tig en  of H pylori (142). A nother fac to r th a t needs to be 
con sid e red  is the fa te  of th e  antibody ti tre s  once th e ir  formation has 
b een  tr ig g e re d  b y  one o r more of H pylori an tig en s . It has been 
su g g es ted  th a t a considerable num ber of healthy  people p reviously  
in fec ted  w ith H py lo ri might remain seropositive despite the 
spon taneous elimination of th e  organism s (126). This supports  the  
h y p o th esis  th a t H py lo ri colonisation is a dynamic p rocess w ith an 
a c tiv e  phase  of infection and  subsequen t elimination of the bac teria  
in  a t  leas t a p roportion  of infected people (126). Long-term  
sero logical surveillance s tu d ie s  have also found th a t in  most pa tien ts  
w ithout an y  detectab le organism s, 12 months a f te r  anti-H  pylori 
th e ra p y , bo th  specific IgA and  specific IgG an tibody  values were 
low er b u t had  not y e t re tu rn e d  to the normal ran g e  (130). These
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o b se rv a tio n s , like chemical g a s tr it is , might also help u n d ers tan d  the 
low specificity  of the  serological te s ts  in th is  s tu d y  especially in 
p a tie n ts  tre a ted  with NSAID, who have a low prevalence of H py lori.
V ery few stu d ies  have been published  on the evaluation of the  
serological te s ts  described  in th is  C h ap te r. D espite being  d irected  
a g a in s t re latively  specific components of H py lori, th e ir  sensitiv ity  
exclud ing  th a t of Bio-Rad GAP T e st, and  th e ir  specificity  values a re  
low er than  some of the  recen tly  published  da ta . The findings with 
re sp e c t to P y loriset Latex a re  similar to those of an o th er rep o rt 
(143), b u t lower th an  the  values described  by  ano ther s tu d y  (121), 
fo r  unexplained  reaso n s . The sen sitiv ity  and specificity  of Helico-G 
in  th is  s tu d y  a re  also comparable to those of ano ther (120), b u t it is 
w orth  noting th a t some w orkers (79) had to modify the  
m an u fac tu re r’s in s tru c tio n s  in  o rd e r to improve the  perform ance of 
Helico-G te s t .  Some au th o rs  (119) have repo rted  high sensitiv ity  
an d  specificity  values fo r an ELISA te s t which, like Biolab Malakit, 
d e tec ts  an tibodies ag ain st partia lly  purified  u rease  an tigen . 
H ow ever, th e  same te s t (119) has been  used  by ano ther group of 
w orkers  (139) who found th a t 25 out of 124 patien ts stud ied  (20%) 
w ere seropositive fo r H py lori desp ite  the  absence of th e  organism s 
in  th e ir  g as tr ic  b iopsy  specim ens; 20 of the  25 false positive cases 
had  a trophic  g a s tr itis  (139).
The sen sitiv ity  of Bio-Rad GAP te s t  IgG described in  th is  s tu d y  
is  almost identical to th a t found by  an o th er group (135), b u t the  
low er specificity  could be explained b y  one o r more of the  following: 
th e ir  reliance on histology as a s ta n d a rd , which might be d ifficult to 
in te rp re t  in  th e  p resen ce  of v e ry  few organism s; th e  exclusion from 
th e ir  s tu d y  of p a tien ts  w ith chronic superficial or a trophic  g as tr itis
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in whom H pylori was not identified , thus reducing  the  num ber of 
t ru e  n eg a tiv es ; the  relatively  high num ber of cases of chemical 
g a s tr itis  in th e ir  H pylori negative group without specify ing  w hether 
such  p a tien ts  had been trea ted  with NSAID; and  the  p resen ce  in 
th e ir  H pylori positive g roup , of more p a tien ts  with chronic a tro p h ic  
g a s tr itis  (117 out of 160, 73%), which might have been paralle led  by  
a rise  in  the  num ber of false positive cases (138,139).
The lower specificity  of Pyloriset Latex, Helico-G, and Biolab 
Malakit in NSAID p atien ts  could be explained by  the  p resen ce  of 
chemical g a s tr itis  (23,71,72,135, C hapters 4 ,7 ) and  the  low 
prevalence of H pylori in such p a tien ts , as found by  th is  s tu d y  and  
o th ers  (23 ,83 ,85). The la tte r  could be related  to th e  im pairm ent, by  
NSAID, of th e  g astric  mucus lay er, which is considered as the  
n a tu ra l hab ita t of H pylori organisms (23). However, when th ese  
bac teria  p e rs is t  in the p resence of NSAID, it has been su g g ested  
th a t the  damaging effects of NSAID might become in tensified  (23,129, 
C hap ter 7 ). T herefo re , accurate diagnosis of H pylori in  such  
p a tien ts  is , a t leas t, as im portant as it  is in pa tien ts  not tak in g  
NSAID.
In conclusion, th is  s tu d y  has evaluated the efficacy of fo u r 
commercial serological te s ts  in  comparison with s ta n d a rd  
b io psy -re la ted  te s ts .  Despite having high  sen sitiv ity , Bio-Rad GAP 
T est IgG has been found to have low specificity . Pyloriset L atex , 
Helico-G, and  Biolab Malakit all had relatively  low sen sitiv ity  and  
specific ity , th e  la tte r  being  even lower in the  p resence of NSAID. 
These re su lts  could be related  to the  histological find ings, the  
dynamic n a tu re  of H pylori infection, the  types of the  an tigens
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te s te d , NSAID in take , or due to some w eaknesses in  the  
m anu fac tu re rs’ in s tru c tio n s . These fac to rs  have to be considered  in 
o rd e r  to improve the re liab ility  of serodiagnosis because of the  
po ten tia l advantages of such  methods in  iden tify ing  active H py lo ri 
in fection .
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CHAPTER 6
6. PREDICTION OF NSAID-RELATED PEPTIC ULCERS USING THE 
HEALTH ASSESSMENT QUESTIONNAIRE
6.1 SUMMARY
B ackground: P atien ts  with d isab ling  m anifestations of a r th r i t is
m ight be a t a g re a te r  r isk  of developing N SA ID-related pep tic  
u lc e r s , as th e ir  advanced  disease might req u ire  more ag g ress iv e  
th e ra p y .
Aims: To assess  th e  possib lity  of a re lationsh ip  betw een the
deg ree  of physical d isability  in  a r th r it ic  p a tien ts  and  non-stero ida l 
p ep tic  u lceration.
Methods: Patien ts w ere endoscoped immediately a f te r  perform ing
th e ir  a r th r itic  functional assessm en ts . The Health A ssessm ent 
Q uestionnaire was used  and  p a tien ts  w ere classified  into th re e  main 
g ro u p s: I, scoring  0-1; I I , 1 .1 -2 ; and  III , 2 .1 -3 .
R esults: U lcers, found in  36 out of 89 p a tien ts  stud ied  (36/89,
40%), were d is trib u ted  as follows: 15/22 (68%) in  g roup III compared 
w ith 9/28 (32%) in  group I (X2=5.2, p< 0 .02), and  12/39 (31%) in 
g roup  II (X2=7.24 ,p<0.01).
87
Conclusion: P atien ts  w ith deb ilita ting  a r th r i t is  ap p ear to have a
h igher p revalence of non -stero ida l pep tic  u lcera tion . This find ing  
might be re lev an t to th e  p ro cess  of se lecting  p a tien ts  fo r 
p rophylactic  an ti-u lc e r  th e rap y .
6.2 INTRODUCTION
The link betw een pep tic  u lc e rs , or th e ir  com plications, and  
non-stero idal anti-inflam m atory d ru g s  (NSAID) has been emphasized 
by  several s tu d ies  in recen t y ea rs  (42,95,144,145). Evidence of 
pep tic  damage can be found in  more than  30% of p a tien ts  receiv ing  
NSAID (42 ,128). The p red isp o sin g  fac to rs  fo r N SA ID -related pep tic  
u lcer a re  not fu lly  und ersto o d , and  it is not known w hether the  
likelihood of developing such  u lcers  is influenced b y  th e  d eg ree  of 
physical d isab ility  in  a r th r it ic  p a tie n ts . The Health A ssessm ent 
Q uestionnaire (H .A .Q ) has been widely accepted  as a u sefu l tool fo r 
m easuring th e  functional outcome of a r th r i t is  (146-148). Using 
H A Q and  endoscopy, th is  s tu d y  te s ted  the  possib ility  th a t th e  
prevalence of pep tic  u lcers  varies  amongst d iffe ren t functional 
groups of a r th r i t ic  p a tien ts  being  tre a te d  with NSAID.
6.3 PATIENTS AND METHODS
Patien ts  w ith o s teo a rth ritis  o r  rheum atoid a r th r i t i s , diagnosed 
accord ing  to th e  c rite ria  of th e  American Rheumatism A ssociation 
(149) were re c ru ite d  p rov ided  th ey  were 18 y ea rs  o r o v e r, and  took 
NSAID fo r a minimum of 4 w eeks. Second-line d ru g s  w ere allowed if 
th ey  were s ta r te d  a t least 6 m onths before th e  s tu d y . P a tien ts  w ere
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excluded  if th ey  had p rev ious g a s tr ic  su rg e ry  o r if they  took u lcer 
healing  d ru g s , s te ro id s  o r cytotoxic a g en ts .
The degree of physical d isab ility  was assessed  u sin g  H A Q 
(146-148) (F igure 3) which in tu rn  in v estig a ted  p a tie n ts ’ ab ility  to 
d re ss  them selves, r is e , e a t, w alk, m aintain th e ir  hygeine, reach , 
g r ip ,  perform  o th e r ac tiv ities  (sh o p p in g , g e ttin g  in and  out of a 
c a r ,  vacuum ing and light g a rd e n in g ), and  th e ir  need to use  aids or 
su p p o rtiv e  dev ices. P a tien ts  w ere classified  into 3 main functional 
g ro u p s: group 1, capable of perform ing  the  above fuctions with some 
o r no difficu lty  (sco rin g  0 -1 ); g roup  II, find ing  much d ifficu lty  
(sco rin g  1 .1 -2 ); and  group  III , in  need  of severa l devices o r unable 
to  c a rry  out the  above functions (sco rin g  2 .1 -3 ) . P a tien ts ’jo in ts ’ 
pain  was evaluated  on a 4 -po in t scale: none, mild, moderate and 
s e v e re .
Informed consent was obtained and  endoscopy was carried  out 
w ith in  2 hours  of perform ing th e  functional assessm ent. The 
endoscopist was not aw are of th e  functional sco res . At endoscopy, 
sedation  was achieved u s in g  4-8mg midazolam in trav en o u sly . 
Biopsies were tak en  from th e  u lce r edge and base to exclude 
m alignancy, and  from th e  g a s tr ic  an trum  to check fo r H elicobacter 
(H) pylori b y  histology and  bacterio logy , as prev iously  described  
(61 ). An u lcer was defined as  a three-d im ensional in te rru p tio n  in 
th e  mucosa m easuring a t least 3mm in  diam eter (41).
S tatistical te s ts  included  th e  C h i-sq u are  (X2) te s t ,  the 
M ann-W hitney, m ultivariate and  logistical reg ressio n  an alyses, w here 
a p p ro p ria te .
The s tu d y  was approved  b y  the  local Ethics Committee.
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6 .4  RESULTS
E igh ty -n ine  p a tien ts  were s tu d ie d . They were classified  as 
follows: 28 in  g roup I , 39 in  group II and 22 in group III. T heir 
dem ographic details a re  shown in  Table 11. P atien ts were 
com parable in  th e ir  ag e , w eight, and  serum  albumin levels. Weight 
an d  serum  albumin w ere u sed  as a rough  estim ate of p a tien ts  
n u tritio n a l s ta tu s . T here  were no signiciant d ifferences in  the 
num ber of smokers am ongst the  various g ro u p s. Group I contained 
re la tiv e ly  more males and  alcohol d r in k e rs , while pa tien ts  in group 
III w ere more likely to have abdominal complaints.
The duration  of a r th r i t is  did not d iffe r significantly  am ongst the 
s tu d y  g ro u p s, as shown in Table 12. Group III p a tien ts  tended  to 
have sev ere  joint pain ; they  also had h igher e ry th ro cy te  
sedim entation ra te  (ESR) and  C -reactive p ro te in  (CRP). Similar 
NSAID and second-line ag en ts  were taken  by  comparable num bers of 
p a tie n ts  in  all g roups (T ables 12 and  13). The doses and du ra tion  
of NSAID used  were also sim ilar.
The prevalence of pep tic  u lcers was h ig h er in  group III (Table 
14 ), b u t th e  p revalence of H py lori and the histological find ings 
w ere sim ilar am ongst th e  various g ro u p s.
Peptic u lcers described  in  th is  s tu d y  were found in  the  g astric  
an tru m  and the  f ir s t  p a r t  of the  duodenum . They were d is tr ib u ted  
as  follows 5 g as tric  (4 duodenal) in  group I , 8 (4) in group I I , and 
10 (5) in group III.
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The d ifferences in the prevalence of pep tic  u lcers remained 
sign ifican t even  a f te r  allowing for minor variations in  the 
dem ographic ch a rac te ritic s  of p a tien ts , as te s ted  by  the  m ultivariate 
and  logistical reg re ss io n  analyses.
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FIGURE 3
The nature of the Health Assessment Questionnaire. It is 
specially designed for use in osteoarthritis and rheumatoid 
arthritis, and provides an overall "Disability Index" from 0 (no 
disability) - 3 (complete dependence on others). It may be used to 
estimate the impact of arthritis on daily living. It may also help 
to assess changes in disease activity over several months, or to 
monitor disease progression year by year.
The overall score for the index is the mean of the 8 numbered 
sections taken together. The score for each section is that of the 
worse response to any of the questions in that section. The score 
for each response is: without any difficulty = 0, with some
difficulty = 1, with much difficulty - 2, and unable to do * 3. If 
appliances or devices or help from another person is required for 
activities within a section (indicated at the bottom of each page), 
then that section scores at least 2 (it may score 3 if the patient's 
response was "unable to do").
HEALTH ASSESSMENT QUESTIONNAIRE
N a m e ...................................................................................................................  D a t e ........................................................................................................
W e  a r e  i n t e r e s te d  in  le a rn in g  h o w  y o u r  i l ln e s s  a f te c t s  y o u r  a b ility  to  fu n c tio n  in d a ily  life.
P l e a s e  fe e l  f r e e  to  a d d  a n y  c o m m e n t s  a t  th e  e n d  o f  th is  fo rm .
P L E A S E  T IC K  T H E  O N E  R E S P O N S E  W H IC H  B E S T  D E S C R I B E S  Y O U R  U S U A L  A B IL IT IE S  
O V E R  T H E  P A S T  W E E K :
W ithout ANY W ith SO M E  W ith M UCH U n a b le
difficulty difticulty ditticulty  to  d o
1. D R E S SIN G  AND G R O O M IN G  
A re you  a b le  to:
-  D re s s  yourse lf, including  lying s h o e la c e s
a n d  do in g  b u tto n s?  ................................................ ................................................................................................
-  S h a m p o o  your h a ir?  ................................................................................................................................................
2  RISIN G
A re you  a b le  to:
-  S ta n d  u p  from  a n  a r m le s s  s tra ig h t c h a ir?  ...............................................................................................................................................
-  G e t in a n d  o u t ot b e d ?  ................................................................................................................................................
3. EATING
A re you  a b le  to:
-  C ut your m e a t?  .............................................................................................................................................. .
-  Lift a  full c u p  or g la s s  to  y o u r m o u th ?  ............................................................................................................. ..................................
-  O p e n  a  n ew  c a rto n  of milk (or s o a p  .................................................................................................................
p o w d e r)?
4 WALKING 
Are you  a b le  to:
-  W alk o u td o o rs  o n  flat g ro u n d ?  .................................................................................................................................................
-  C lim b up  five s t e p s ?  ................................................................................................................................................
PL E A S E  TICK ANY AIDS O R  D E V IC E S  THAT YOU USUALLY U S E  F O R  ANY O F  T H E S E  A CTIV ITIES:
................  C a n e  ................  D e v ic es  u s e d  for d re s s in g  (b u tto n  hook , z ip p e r pull, long  h a n d le d
................  W alking fra m e  s h o e  horn , etc .)
  C ru tc h e s  ................  B uilt-up o r sp e c ia l u te n s ils
................  W h e e lc h a ir  ................  S p ec ia l o r bu ilt-up  ch a ir
O th e r  ( s p e c i f y ) ......................................................................................................................................................................................
PL E A SE  TICK ANY C A T E G O R IE S  FO R  W H ICH YOU USUALLY N E E D  H ELP FRO M  A N O T H E R  P E R S O N
................  D re s s in g  a n d  ................  E ating
G ro o m in g
................ R ising  ................  W alking
PLEASE TICK THE ONE RESPONSE WHICH BEST DESCRIBES YOUR USUAL ABILITIES 
OVER THE PAST WEEK
W ithout ANY W ith S O M E  W ith M UCH U n ab le
difficulty difficulty difficulty to  do
5. HYG IENE 
Are you a b le  to:
-  W a sh  a n d  dry  your e n tire  b o d y ? ..............................................................................................................................................................................
-  G e t on  a n d  off th e  to ile t?  .................................................................................................................
6  REACH
A re you a b le  tc:
-  R e a c h  a n d  g e t d o w n  a  51b o b jec t (e g, a  bag
of p o ta to e s )  from  ju s t a b o v e  your h e a d ?  .................................................................................................................
-  B en d  do w n  to  pick u p  clo th ing  from  th e  .................................................................................................................
floor?
7. G R IP
A re you  a b le  to:
- O p e n  c a r  d o o rs 9..............................................................................................................................................................................
-  O p e n  ja rs  w hich  h a v e  b e e n  p rev io u sly
o p e n e d 9 .................................................................................................................
- T u r n  ta p s  o n  a n d  o ft?  .................................................................................................................
8 ACTIV ITIES 
Are you  a b le  to:
-  R un e r ra n d s  a n d  s h o p ?  .................................................................................................................
-  G e t in a n d  o u t of a  c a r ?  .................................................................................................................
-  D o c h o r e s  s u c h  a s  v ac u u m in g , h o u sew o rk
or light g a rd e n in g ?  .................................................................................................................
PL EA SE TICK ANY AIDS O R  D E V IC E S  THAT YOU USUALLY U SE  FO R  ANY O F  T H E S E  ACTIV ITIES 
................  R a ise d  toilet s e a t    B a th  rail
................  B ath  s e a t    L ong h a n d le d  a p p lia n c e s  for re a c h
  J a r  o p e n e r  (for ja rs  O th e r  (specify ) ........................................................................
p rev io u s ly  o p e n e d )
P L E A SE  TICK ANY C A T E G O R IE S  FO R  W H ICH YOU USUALLY N E E D  H ELP FRO M  A N O T H E R  P E R S O N :
H y g ien e
R e a c h
G ripping  a n d  o p e n in g  th in g s 
E rra n d s  a n d  h o u sew o rk
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6 .5  DISCUSSION
This s tu d y  su g g ests  th a t a r th rit ic  pa tien ts  with the  g rea te s t 
d eg ree  of functional d isab ility , as m easured b y  H A Q have the 
h ig h e s t p revalence of p ep tic  u lc e r s . Recent s tud ies  have ind icated  
th a t  NSAID-induced u lce rs  w ere found more freq u en tly  in  sm okers 
(4 2 ), in  p a tien ts  rece iv ing  s tro n g e r  NSAID (150) and  in  those 
in fec ted  w ith H py lo ri (23 ,84 , C hapter 7). Such u lcers  w ere, 
how ever, less fre q u e n t in  p a tien ts  receiving gold th e ra p y  (82, 
Section V I). These observations a re  unlikely to explain th e  find ings 
of th is  s tu d y : p a tien ts  in  the  various functional g roups were
com parable in  th e ir  ag e , sm oking h ab its , NSAID, second-line d ru g s , 
an d  th e  prevalence of H p y lo ri. A nother fac to r th a t has recen tly  
rece iv ed  a tten tio n , because of its  correlation with N SA ID -related 
p e p tic  u lcera tion , is th a t of chemical g as tritis  (23,71, C h ap te r 7 ). 
T h is  has also occured almost equally  in the th ree  functional g ro u p s. 
T he  sim ilarity in p a tie n ts ' w eights and serum albumin levels makes it 
un like ly  fo r the  re su lts  to have been influenced b y  any  sign ifican t 
d eg ree  of m alnourishm ent.
I t  could be a rg u ed  th a t p a tien ts  in  group III had more u lcers  
becau se  th e ir  NSAID in take  m ight have been g re a te r  as a re su lt  of 
th e  h ig h er ac tiv ity  of th e ir  a r th r i t is .  However, it is d ifficu lt to  see 
how th is  would explain  th e  sim ilarity  in  the  p revalence of u lce rs  in 
g ro u p  I and  II, who had d iffe ren t degrees of d isease ac tiv ity  as 
su g g e s te d  b y  th e  ESR and  jo in t pain evaluations. M oreover, no 
s ig n ifican t d ifferences w ere found in the  doses or d u ra tion  of NSAID 
ta k e n  b y  th e  various g ro u p s , as shown in Table 13. A lterna tive ly , 
i t  could be specu lated  th a t th e  poor functional outcome of a r th r i t is
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m ight be associated w ith w eakening of mucosal defences by  s tr e s s ,  
ac id , d is tu rb an ce  in mucosal blood flow o r p rostag land in  p roduction , 
o r  b y  as y e t unknow n mechanism. The re la tive  immobility of group 
III p a tien ts  could also be associated  with poor gu t motility and 
delayed  g as tr ic  em ptying which in tu rn  might increase the  r isk  of 
N SAID-induced u lc e rs . Such speculations will obviously need to be 
v erified  b y  fu r th e r  investiga tions.
In  o rd er to p re v e n t NSAID-related pep tic  u lce rs , p rophylactic  
a n ti-u lc e r  th e rap y  has been suggested  fo r p a tien ts  receiv ing  such  
d ru g s  (41). C oncerns about the  cost and s ide-effec ts  of long-term  
a n ti-u lc e r  ag en ts  have lead to calls fo r ta rg e tin g  p a tien ts  who would 
b en efit most from such  prophylactic  treatm ent (151). I t is believed 
th a t  th is  p rocess m ight be facilita ted  by  the  use  of H A Q: a r th ritic
p a tie n ts  with sev ere  physical d isab ility , as assessed  by  H A Q, have 
a h ig h e r prevalence of pep tic  u lceration .
SECTION IV
NSAID-RELATED HISTOLOGICAL CHANGES IN THE 
UPPER GASTROINTESTINAL TRACT
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INTRODUCTION
V ery little is known about the  effect of NSAID on the  histology 
of th e  u p p e r g as tro -in te stin a l t ra c t .  The im portance of th is issue 
re la te s  to its  potential to clarify  several aspects  of the  pathogenesis 
of NSAID-related damage.
C hap ters included in  Section IV s tu d y  the  histological changes in 
th e  stom ach, duodenum, and oesophagus in  the  p resen ce  or absence 
of NSAID, in pa tien ts  w ith o r w ithout local u lceration .
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CHAPTER 7
7. NSAID AND THE GASTRIC MUCOSA
7.1 SUMMARY
B ackground: The stomach is the  commonest s ite  of both
NSAID-related u lcers and  H pylori infection . I t is not known 
w hether NSAID can cause a specific form of inflammation o r ’’chemical 
g a s tr it is ” , similar to th a t caused by o th e r chemicals such  as bile o r 
alcohol.
Aims: To evaluate the prevalence and significance of chemical
g a s tr it is , in  comparison with g as tr itis  re lated  to Helicobacter pylori 
in p a tien ts  receiv ing  NSAID.
M ethods: Patien ts  with or w ithout a h is to ry  of chronic NSAID
in take were s tu d ied . Endoscopic biopsies were tak en  fo r histology 
and  to te s t fo r H py lori. Chemical g a s tr itis  was defined as th e  
p resence of foveolar hyperp lasia , vasodilatation , oedema, paucity  of 
inflammatory cells, and the presence of muscle f ib re s  in  the  lamina 
p ro p ria .
R esults: 218 p a tien ts  were s tud ied : 174 took NSAID and 44 did
n o t. Chemical g a s tr itis  was found in  46 pa tien ts  (26%) in  the NSAID 
g ro u p , and  3 (7%) in subjects not on these  d ru g s  (p<0.01). H 
py lo ri was detected  in  56 subjects (32%) on
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NSAID compared with 22 (50%) in sub jec ts not tak ing  th ese  ag en ts  
(p<0.02). In the NSAID g ro u p , u lcers  were found in  16 out of 72 
p a tien ts  (16/72, 22%) w ithout H pylori or chemical g a s tr itis  com pared 
with 27/56 (48%) of p a tien ts  with H pylori re la ted  g a s tr itis  (p< 0 .01), 
and  25/46 (54%) of pa tien ts  w ith chemical g a s tr itis  (p<0.001).
Conclusion: NSAID re la ted  pep tic  u lcers  ap p ear to occu r more
commonly in pa tien ts  w ith chemical g a s tr itis  or H py lo ri re la ted  
g a s tr it is . Also, p a tien ts  on NSAID have a g re a te r  p revalence of 
chemical g as tr itis  b u t lower prevalence of H py lori th an  those  not 
tak in g  these  d ru g s .
7.2 INTRODUCTION
The effect of non-stero idal anti-inflam m atory d ru g s  (NSAID) on 
g as tr ic  histology is not fu lly  c lear. Recent s tud ies  (73,74) have 
rep o rted  some histological changes similar to those encoun tered  in  
p a tien ts  with p rev ious g astric  su rg e ry  (72). They consisted  of 
foveolar hyperp lasia , vasodilatation, oedema, lack of inflammatory 
cells, and the p resence  of muscle fib res  in the  lamina p ro p ria . 
T hese fea tu res  were initially  called "re flux  g a s tr it is " , re fe r r in g  to 
th e  effect of bile re flux  on the  post-o p era tiv e  stomach (72). Since 
o th e r chemicals, such  as NSAID, were also th o u g h t to be involved in  
th e  in tac t stom ach, the  term s type C o r "chemical" g a s tr itis  w ere 
proposed  (71). The aim of th is  s tu d y  was to evaluate  th e  
prevalence and significance of chemical g a s tr i t is ,  in  com parison w ith 
g a s tr itis  re la ted  to H elicobacter (H) p y lo ri, in  p a tien ts  tak in g  
NSAID. This could also clarify  the  in teraction  th a t might ex is t
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betw een H pylori and  NSAID in the  g a s tr ic  mucosa.
7.3 PATIENTS AND METHODS
P atien ts  with ad u lt onset rheum atoid a r th r i t is  w ere re c ru ite d  
from the  Rheumatology Clinic p rov ided  th ey  had tak en  NSAID fo r a 
minimum of 4 w eeks, and  excluded if  th ey  had  received  an ti-u lc e r  
th e ra p y , an tib io tics, o r cytotoxic d ru g s . P atien ts  not on NSAID 
w ere also accepted p rov ided  they  had  not taken  th ese  ag en ts  o r any  
of th e  d ru g s  mentioned above fo r a t least a month. S ubjects w ith a 
h is to ry  of p revious g a s tr ic  su rg e ry  w ere ex c lu d ed . All p a tien ts  
w ere asked  about th e ir  alcohol in tak e . This was considered  heavy  if 
th e  sub jec t took 10 o r more u n its  p e r  week.
Informed consent was obtained and  endoscopy perform ed a f te r  
th e  adm inistration of 5-15mg diazepam in travenously . The endoscopic 
find ings were g rad ed  as follows: 0, normal o r minor ery them a; 1, 
1-5 erosions; 2, 6-10 erosions; 3, f ra n k  ulceration  m easuring  a t  least 
5mm in  diam eter.
An average of 3 b iopsy  specim ens were obtained from healthy  
looking mucosa in th e  g as tr ic  an trum  of each su b jec t. T hey  were 
fixed  in  10% form alin/saline and p rocessed  ro u tin e ly . C uts were 
made a t 3 levels in  th e  p ara ffin  wax sections, w hich w ere then  
s ta in ed  with haem atoxylin and  eosin . F u r th e r  sections w ere also 
made and  tre a ted  w ith c resy l violet to help iden tify  H p y lo ri.
The findings in  each se t of b iopsies were g raded  tw ice: f ir s tly , 
acco rd ing  to th e  Whitehead classification of g a s tr itis  (122) modified to
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cover the  newly described  en tity  of lymphocytic g a s tr itis  (123), and 
second ly , according to a system  modified from Dixon e t al. fo r the 
diagnosis of chemical g a s tr itis  (72 ). F eatu res of the  modified 
W hitehead g as tr itis  (F igures 4 ,5 ) included neu trophilic  in filtra tion , 
chronic inflammatory cells, lym phocytic ag g re g a te s , in testinal 
m etaplasia and gland a tro p h y . T h e ir degree was g rad ed  on a four 
po in t scale: 0, ab sen t; 3, sev e re . A similar scale was applied to the 
following fea tu res  of chemical g a s tr itis  (F igure 6 ): (i) th e  degree of 
foveolar hyperp lasia , (ii) th e  d eg ree  of oedema and th e  prominence 
of muscle fib res  in the  lamina p ro p ria , (iii) the  degree of 
vasodilatation  and congestion , (iv) th e  in v erse  of th e  num ber of 
n eu tro p h ils  (absence sco ring  3 ) , and  (v ) the  in v erse  of the  num ber 
of plasma cells (absence again  sco rin g  3 ). P atien ts sco ring  8 or 
more by  the chemical scores w ere considered to have chemical 
g a s tr i t i s .
Two fu r th e r  biopsies w ere taken  from the  g as tr ic  antrum  of each 
su b je c t, and  examined fo r th e  p resen ce  of H pylori b y  bo th  histology 
and  bacterio logy, as p rev iously  describ ed  (61).
S tatistical analyses: C h i-sq u are  (X2) te s t w ith Bonferroni
correc tion  fo r multiple com parisons was u sed . Spearm an’s coefficient 
was also used  to te s t  fo r th e  corre la tion  betw een th e  endoscopic and 
histological sco res . The p a tho log ist, and  bacterio logist were unaw are 
of p a tie n ts ’ d ru g s . Code num bers were u sed  to facilitate  
random ization of b iopsy specim ens.
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FIGURE 4
A ntrum  of stom ach: Chronic superficial g a s tr it is , typ ical of
H elicobacter re la ted  g a s tr it is . It shows foci of active g a s tr itis  w ith 
d egradation  of the  su rface  epithelium . HE X 235.
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FIGURE 5
Antrum of stomach: Lymphocytic gastritis. There is a
pronounced increase in lymphocytes in the surface and foveolar
epithelium. HE X 314

p 106
FIGURE 6
Antrum of stomach: "Chemical" gastritis. Note the elongation of
the foveolae, the virtual absence of inflammatory cells and the 
presence of oedema and muscle fibres in the foveolar compartment. 
The "chemical score" was 10. HE X 170
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7.4 RESULTS
A total of 218 patients were studied: 174 took NSAID, and 44 did 
not. Their characteristics are shown in Table 15. Patients not on 
NSAID included 27 subjects with rheumatoid arthritis, and 17 with 
other musculo-skeletal disorders: 13 with osteoarthritis, and 4 with
ankylosing spondylitis.
The prevalence of chemical gastritis and H pylori, in the 
presence or absence of NSAID, is shown in Figure 7. Subjects 
receiving NSAID were more likely to develop chemical gastritis, but 
less likely to have H pylori than those not on NSAID. Two of the 
three patients with evidence of chemical gastritis, in subjects not on 
NSAID, had a history of heavy alcohol intake. They both had 
rheumatoid arthritis.
Patients with chemical gastritis, H pylori, and those with neither 
of these findings in the NSAID group, tended to have similar 
demographic data, as shown in Table 16. H pylori could not be 
detected in any of the patients with chemical gastritis. Histological 
findings,other than chemical gastritis are presented in Table 17. 
Chronic superficial gastritis was the major finding in all groups.
Patients not on NSAID had a total of 14 ulcers: 5 gastric and 9 
duodenal, all of which were positive for H pylori. No erosions were 
found in this group. There was no significant difference in the 
distribution of ulcers, H pylori or the histological findings between 
rheumatoid patients or those with other musculo-skeletal disorders 
not taking NSAID. The distribution of ulcers in NSAID histological
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subgroups is p resen ted  in F igure 8; th is  shows th a t NSAID re la ted  
peptic u lcers a re  more likely to develop in  th e  p resen ce  of H py lo ri 
o r chemical g a s tr it is . However, the  co rrelation  betw een the  
endoscopic and histological scores was sign ifican t only in  those  w ith 
chemical g a s tr it is , as shown in Table 18. Erosions were found in  11 
NSAID patien ts w ithout H pylori o r chemical g a s tr i t is .  Erosions in 
the  o ther NSAID subgroups a re  shown in  Table 18. A to ta l of 68 
u lcers were diagnosed in the  NSAID g roup : 58 g a s tr ic , and  10
duodenal. Tw enty of 58 NSAID re la ted  g as tr ic  u lce rs  (20/58,34%) 
and 5/10 (50%) duodenal u lcers were positive fo r H py lo ri.
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FIGURE 7
T he prevalence of H pylori and chemical gastritis in  th e  p resen ce  o r
absence of NSAID
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FIGURE 8
The d istribu tion  of NSAID re la ted  ulcers in p a tien ts  w ith chemical 
g a s tr it is , H pylori positive g a s tr itis , and in those w ith n e ith e r of
these  conditions.
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7.5 DISCUSSION
This s tu d y  shows th a t NSAID patien ts  have a h ig h er prevalence 
of chemical g a s tr it is , b u t lower prevalence of H py lo ri th an  sub jec ts 
not on NSAID. The p resence  of chemical g a s tr itis  o r H pylori seems 
to increase  the likelihood of having NSAID re la ted  pep tic  u lcera tion . 
A lso, th e re  is a positive correlation betw een th e  endoscopic and  the  
histological chemical scores in subjects tak in g  NSAID.
Histological ap p earan ces , now considered as consisten t with 
chemical g a s tr itis , were p reviously  rep o rted  in p a tien ts  w ith bile 
re f lu x , following gas tro -duodenal su rg e ry  (72,152). S ubsequent 
s tu d ie s  have, on the o th e r hand , found th a t th e re  was no correlation  
betw een the reflux  of bile and the development of chemical g a s tr itis  
in  th e  in tact stomach (71). This would su g g est th a t bile re flu x  has 
not significantly  influenced the prevalence of chemical g a s tr itis  in 
th is  s tu d y . The au th o r believes th a t he has co rrec ted  fo r the  
possib le effect of bile b y  including in the  analyses p a tien ts  who were 
not tak ing  NSAID.
Features of chemical g as tr itis  were also described  in p a tien ts  
w ith  alcoholic haem orrhagic g as tr itis  (153). In  th is  s tu d y , it is 
in te re s tin g  to find th a t 2 cases of chemical g a s tr i t is ,  in  p a tien ts  not 
on NSAID, had a h is to ry  of heavy alcohol in tak e . The development 
of chemical g a s tr itis  in  th e  NSAID group is unlikely  to have been 
to ta lly  related  to alcohol consumption, as judged  from the  
dem ographic data of p a tien ts  in th is  s tu d y .
The prevalence of chemical g a s tr itis  in th is  s tu d y  is comparable
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to th a t found by an o th e r group (71). The scores re g a rd e d  as being  
a ttrib u tab le  to chemical effect in th is s tu d y  w ere lower th an  those  of 
Sobala et a l. (71), th is  being  ju stified  on th e  basis  of some possib le 
d ifferences in in te rp re ta tio n  betw een the  two c e n tre s . M oreover, 
desp ite  being on th e  lower side , the  chemical sco res in  th is  s tu d y  
s till correlated  positively  with the endoscopic sco res . Had the  s tu d y  
included only those p a tien ts  with high  chemical scores (g re a te r  th an  
8 o r 9 ), the  prevalence of chemical g a s tr itis  would have been  low er, 
b u t the  correlation w ith th e  endoscopic scores would have become 
even more sign ifican t. It could not be accep ted , how ever, th a t 
p a tien ts  with chemical scores of 8 o r 9 should be considered  as 
hav ing  normal g as tr ic  histo logy.
In addition to chemical g a s tr it is , NSAID have sev era l o th e r 
ac tiv ities which can lead to g astric  mucosal damage. These include 
inhibition of p rostag land in  syn th esis  (7 ), in te rfe ren ce  w ith mucosal 
blood flow (154, C hap ter 10), and d isru p tio n  of the  g a s tr ic  mucosal 
b a r r ie r  in a m anner th a t allows back d iffusion of hyd rogen  ion w ith 
i ts  damaging consequences (11 ,12). D espite the  considerable  
in te re s t recently  shown in  some of th e  above mechanisms, p robab ly  
because of th e ir  th e rap u e tic  potential (41), no correlation  was found 
betw een peptic damage and  activ ities of NSAID such  as p ro stag lan d in  
inhibition (5 ,8 ) . This should em phasize the  im portance of 
iden tify ing  chemical g a s tr i t is ,  because of th e  positive correlation  
betw een the  endoscopic and the  histological chemical sc o re s , as 
shown by th is  s tu d y . Chemical g a s tr itis  alone is unlikely  to explain  
all cases of NSAID re la ted  pep tic  u lcera tio n , p robably  due to the  
fac t th a t multiple mechanisms a re  involved in such  cases 
(7 ,11 ,12 ,154).
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A link , p robab ly  causal, has been  th o u g h t to ex is t betw een 
g a s tr itis  and  g as tr ic  u lc e rs , as su g g ested  b y  sev era l p rev ious 
s tu d ies  (155-159). Such a re lationship  has been  ex ten d ed  to include 
cases of g a s tr itis  found in association w ith H py lo ri (158-159). The 
s itua tion  in  p a tien ts  tak in g  NSAID has not been  c lear: it  might have 
been  complicated by  not tak ing  into consideration  th e  p resen ce  of 
chemical g a s tr itis  (160), owing to the  fa ilu re  of W hitehead’s 
classification (122) to cover such  histological e n tity . The find ing  of 
a g re a te r  num ber of NSAID rela ted  g as tr ic  u lce rs  in  p a tien ts  w ith 
chemical g a s tr itis  s tren g th e n s  the b ro ad e r re la tionsh ip  betw een 
g a s tr itis  in  general and  g as tric  u lcers  (155-159). P a tien ts  on NSAID 
b u t w ithout H pylori o r chemical g a s tr i t is ,  had a to ta l of 56 cases of 
g a s tr itis  (56/72, 78%), b u t the least num ber of u lc e rs . This might 
su g g e s t th a t g a s tr itis  b ears  a s tro n g  rela tionsh ip  to N SAID-induced 
g a s tr ic  u lcers  only when it is chemical in  n a tu re , o r if it is 
association w ith H py lo ri.
NSAID p a tien ts  had a smaller p roportion  of cases positive fo r H 
py lo ri th an  those  not on NSAID. The reason  fo r th is  is not c lear. 
I t could be specu lated  th a t NSAID might have a d irec t toxic ac tiv ity  
ag ain st H py lo ri or an  in d irec t effect b y  a lte rin g  the  n a tu ra l h ab ita t 
of these  organism s. NSAID were p rev iously  shown to affect th e  
secre tion  ra te  a n d /o r  the  ch a rac te ris tic s  of th e  mucus lay er in th e  
stom ach. A spirin  (16) and indom ethacin (17) were found  to inh ib it 
mucus secre tio n . It was also su g g ested  th a t a sp irin  could increase  
pepsin-m ediated  p ro teo lysis  of m ucus, decrease  mucus v iscosity  and  
in crease  th e  perm eability  of mucus to hy d ro g en  ion (18). 
Indom ethacin was also found to inh ib it active b icarbonate  secre tion  
b y  the g as tr ic  mucosa (19). The mucus lay e r, commonly accepted  as
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th e  n a tu ra l h ab ita t of H pylori (159), m ight be ren d e red  less 
hospitab le b y  th e  above changes.
In th e  NSAID g ro u p , pa tien ts  positive fo r H py lo ri had a g re a te r  
num ber of u lce rs  th an  those w ithout H py lo ri o r chemical g a s tr it is . 
This might su g g es t a sy n erg is tic  effect betw een NSAID and H py lori 
in  causing  g a s tr ic  dam age. Examples of th is  synerg ism  were 
p rev iously  dem onstrated  with o th er b ac te ria  in th e  in testin e  of 
lab o ra to ry  anim als. I t  was observed  th a t th e  ulcerogenic effect of 
NSAID could be reduced  by  antib iotic trea tm en t (20). G erm -free 
animals were also found to be re s is ta n t to indom ethacin-induced 
in testin a l lesions (21). More recen tly , the  a u th o r has dem onstrated 
th a t the  combination of indom ethacin and  H py lo ri cu ltu re  f iltra te  
reduced  human g a s tr ic  mucosal v iab ility  and  its  PGE2 production  to a 
g re a te r  ex ten t th an  indom ethacin alone, in  v itro  (22). On th e  o th er 
h an d , it is w orth  no ting  th a t ,  of 58 g a s tr ic  u lce rs  iden tified  in  
pa tien ts  tak in g  NSAID in th is  c u rre n t s tu d y , only 20 (37%) were 
positive fo r H py lo ri. This is lower th an  th e  p rev iously  rep o rted  
prevalence of H py lo ri in g astric  u lceration  u n re la ted  to NSAID, 
which generally  v aried  betw een 63% (161) and  77% (112). It is , 
how ever, co n sis ten t w ith o th er find ings in  th is  s tu d y , which su g g est 
th a t NSAID might reduce  the  p revalence of H py lo ri in fection . One 
cannot exclude the  possib ility  th a t a t least some of th e  u lce r p a tien ts  
in  th is s tu d y  might have become negative fo r H py lo ri a t some stage 
d u rin g  th e ir  long term  in take of NSAID, a lthough  th e re  was no 
evidence of th is  in  the  s tu d y .
In conclusion, chemical g a s tr itis  occurs more commonly in 
p a tien ts  rece iv ing  NSAID than  in sub jec ts who do not take  these
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a g e n ts . The im portance of iden tify ing  th is  histological en tity  stems 
from its  positive correlation  with NSAID-related g astric  u lcera tion . 
A lthough H py lori was iso lated  in only 32% of sub jec ts  on NSAID, its  
p resen ce  was associated  w ith a g re a te r  num ber of u lcers th an  in 
NSAID p a tien ts  w ithout H pylori or chemical g a s tr it is . These 
find ings might co n trib u te  to ou r u n d ers tan d in g  of the in te rac tion  
betw een NSAID and H py lo ri
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CHAPTER 8 
8 . NSAID AND THE DUODENAL MUCOSA
8.1 SUMMARY
B ackground: Duodenitis and  g as tr ic  m etaplasia, which is often
colonized b y  Helicobacter py lo ri, a re  increasingly  recognized fo r 
th e ir  im portance in the  pathogenesis of duodenal u lc e rs . The 
s itua tion  is not clear in p a tien ts  receiving non-stero idal 
anti-inflam m atory d ru g s , who have a h igher r isk  of pep tic  
u lce ra tio n .
Aims:: To iden tify  the  duodenal histological abnorm alities in
th e  p resence o r absence of NSAID, H py lo ri, and duodenal 
u lcera tion .
M ethods: Endoscopic duodenal biopsies were taken  from healthy
looking mucosa of 172 p a tien ts  (74 took NSAID, and 98 did n o t) . 
D uodenitis was g raded  accord ing  to the  degree of neutrophilic  and  
plasm a cell in filtra tio n , villus h e ig h t, B ru n n er’s gland p ro lapse , 
an d  g as tric  m etaplasia. The ac tiv ity  of duodenitis was dependen t on 
th e  neutrophilic  in filtra tio n . A global score covering all th e  above 
fac to rs  was co n s tru c ted , and  H pylori in both the stomach and 
duodenum , was a ssessed .
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R esu lts: Duodenitis with v a ry in g  d eg rees of neu troph ilic
in filtra tio n  and  g as tric  metaplasia was found in  20 p a tien ts  (27%) 
tak in g  NSAID, compared with 56 p a tien ts  (57%) not on NSAID (X2 = 
16.24, p<0.001). This degree of duodenitis was also found in  20 out 
of 25 p a tien ts  (80%) with duodenal u lc e rs , re g a rd le ss  of NSAID 
in tak e  (X2 = 15.38, p<0.001). G astric  m etaplasia was iden tified  in  20 
p a tien ts  (27%) on NSAID, and 38 (39%) not on NSAID.
Duodenal H pylori was only seen  in  p a tien ts  w ith g a s tr ic  
m etaplasia (10,50% on NSAID and 34, 89% not on NSAID). H
p y lo ri-positive  g a s tr i t is ,  and the  cominbation of active duodenitis and  
g a s tr ic  m etaplasia were independen t p re d ic to rs  of duodenal 
u lce ra tio n .
Conclusion: Active duodenitis is less common in p a tien ts  tak in g
NSAID, b u t is s tro n g ly  associated w ith g as tr ic  m etaplasia, H py lo ri 
positive g a s tr itis  and duodenal u lcera tio n . These find ings a re  
re lev an t to the  pathogenesis and th e  trea tm en t of duodenal u lcers  in  
p a tien ts  tak in g  NSAID.
8.2 INTRODUCTION
G astritis  and  duodenitis have, fo r  a long time, been  th o u g h t to 
p lay  a role in  the  pathogenesis of pep tic  u lce r d isease (155-159, 
162,163) and such  concept has been  fu r th e r  consolidated by  th e  
recognition  of H elicobacter (H) py lori (158-159). S u b seq u en tly , it  
has been  su g g ested  th a t g as tric  m etaplasia in  the  duodenum  and H 
py lo ri associated  g as tr itis  might be sy n e rg is tic  in the  pathogenesis  of 
duoden itis , w ith the m etaplastic g as tr ic  epithelium  allowing H py lori
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to colonise the  duodenal mucosa, w here it  p ro d u ces  an  acu te  
inflammatory response  (164). The m ajority of s tu d ies  in  th is  field 
have been  carried  out in  p a tien ts  not tak in g  NSAID an d  th e  role of 
duodenitis and  g a s tr ic  m etaplasia in m ediating NSAID - re la ted  
damage h as , th e re fo re , rem ained u n clear. This s tu d y  aimed a t 
s tu d y in g  the  h isto logy of the  duodenal mucosa in  th e  p resen ce  o r 
absence of chronic NSAID in tak e , H pylori and  duodenal u lce rs .
8 .3  PATIENTS AND METHODS:
P a tien ts , aged 18 y ears  or over, w ere re c ru ite d  from th e  
Rheumatology and  G astroentero logy o u t-p a tien t c lin ics, p rov ided  th ey  
had  no p rev ious h is to ry  of g as tric  or duodenal s u rg e ry . NSAID had 
to be taken  fo r a minimum of 4 weeks p rio r  to endoscopy . P atien ts  
w ere excluded if th ey  had taken  u lcer-hea ling  a g e n ts , an tib io tics , o r 
cytotoxic d ru g s  w ithin one week of endoscopy. Inform ed consent 
was ob tained , and  endoscopy perform ed u s in g  3-7mg midazolam 
in trav en o u sly  fo r sedation . At endoscopy, an  av erag e  of two biopsies 
w ere taken  from the  an te rio r and  po ste rio r walls of th e  f i r s t  p a r t  of 
th e  duodenum , and  immediately fixed in  a so lu tion  of 10% 
form al/sa line. The duodenal histology was rep o rte d  as follows: 
Normal, w ith villus to c ry p t ra tio  g re a te r  th an  2 :1 , in  th e  p resen ce  
o r absence of B ru n n e r’s g lands above the  m uscularis m ucosa, b u t 
w ithout any  increase  in  the num bers of inflammatory ce lls. Chronic 
d u o d en itis : in the  p resen ce  of mucosal mononuclear cell in filtra tio n  
and  epithelial damage. Active chronic d u o d en itis : th is  was diagnosed 
w henever intram ucosal neu troph ils  were seen , in  the p re sen ce  or 
absence of g as tr ic  m etaplasia, and especially in  the  back b ro u n d  of 
m ononuclear cell in filtra tio n . The sev erity  of th e  above find ings 
(duoden itis , villus h e ig h t, and B ru n n e r’s gland p ro lapse)
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was g raded  on a 0-3 scale: 0, normal; 1, mild; 2, m oderate; and  3, 
se v e re . The e x te n t of g a s tr ic  m etaplasia was a sse ssed  as follows: 
0, ab sen t; 1, p re se n t b u t consisting  of less th an  5 consecu tive cells; 
2, 5 consecutive cells; and  3, g rea te r  th an  5 consecu tive cells, seen 
in  1-3 sections cu t a t 3 levels in  each biopy (F igu re  9 ).
A global score covering  th e  overall to tals of th e  sco res of all the  
above assessm ents was co n stru c ted : in  the  absence of n eu tro p h ils , 
p a tie n ts  scoring  4 o r less w ere considered norm al; th o se  sco ring  5 or 
more w ere considered  to have chronic duoden itis , in  th e  absence of 
n e u tro p h ils . Chronic active duodenitis was diagnosed  when 
intram ucosal n eu tro p h ils  were seen in  p a tien ts  sco rin g  4 or more.
The p resen ce  o r absence of H pylori in  the  duodenal mucosa was also 
a sse sse d  u sin g  c re sy l violet s ta in , and  b y  cu ltu re  of single duodenal 
b iopsies . D etection of H py lori by  e ith e r h isto logy o r cu ltu re  was 
considered  as ind icative of active infection in  th e  duodenum .
G astric  an tra l b iopsies were also taken  to check fo r th e  p resen ce  of 
H py lo ri b y  h isto logy (2 specim ens) and  cu ltu re  (1 specim en), as 
p rev io u sly  d escribed  (61). G astritis  was classified  acco rd ing  to the  
W hitehead system  modified to cover chemical and  lym phocytic g a s tr itis  
(23, C hap ter 7 ).
S ta tistica l analyses included  the  C h i-square  (X2) t e s t ,  analysis  of 
v arian ce , multiple and  logistic reg ressio n  w here a p p ro p ria te . All 
specim ens carried  code num bers, and the  endoscopist and  patho log ist 
w ere not aware of th e  p a tie n t’s medications.
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FIGURE 9
A section th ro u g h  th e  duodenal m ucosa, show ing inflam m atory 
cell in filtra tio n , and  g a s tr ic  m etaplasia. 
M agnification X 110 (124a) ; X 274 (124b)
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8.4 RESULTS
A total of 172 patients were studied: 74 were on NSAID, and 98 
were not. Their demographic data are shown in Table 19. Patients 
in both groups were comparable in their ages and in their smoking 
and drinking habits. Patients treated with NSAID had more gastric 
but similar number of duodenal ulcers to those not taking NSAID.
The duodenal global histological scores are illustrated in Figure 
10. Patients in the NSAID group had fewer cases of active chronic 
duodenitis. There was no significant difference in the number of 
patients with chronic duodenitis (11 on NSAID and 10 not on 
NSAID).
Patients with active chronic duodenitis are described in Table 
20. The two groups were similar with respect to the number of 
smokers, patients with gastric H pylori, gastric metaplasia, and 
duodenal ulcers. However, grade 3 (heavy) neutrophilic and plasma 
cell infiltration was more prevalent in the absence of NSAID. It is 
also worth noting that patients with active chronic duodenitis in 
both groups had a total of 20 out of 25 duodenal ulcer (80%) 
diagnosed in all patients. (Xa=15.38, p < 0.001, versus patients 
without active duodenitis). Duodenal H pylori was found in only 50% 
of NSAID patients with active duodenitis, and 61% of their 
counterparts not taking NSAID; all cases of duodenal H pylori 
coexisted with gastric metaplasia.
The characteristics of patients with gastric metaplasia are shown 
in Table 21; although there were relatively fewer cases of metaplasia
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in  p a tie n ts  tak ing  NSAID, the  differences w ere not sta tis tica lly  
s ig n ifican t. Also, p a tien ts  not tre a te d  with NSAID were more likely 
to  have heavy neutrophilic  and mononuclear cell in filtra tion . 
H ow ever, th e  two g roups were almost identical in  the  ex ten t of
m etaplasia, the  num ber of sm okers, pa tien ts  w ith g astric  H pylori 
an d  duodenal u lc e r s . Not unlike p a tien ts  w ith active chronic 
d u o d en itis , the  m ajority of duodenal u lcers (16/25, 64%) were also 
found  to have g as tr ic  m etaplasia (X2 = 14.00, p < 0 .001).
The prevalence of active duodenitis and g as tr ic  metaplasia in  the 
p re se n c e  o r absence of th e  various ty p es  of g a s tr itis  is dem onstrated 
in  Table 22. The majority of cases were found in  association with 
H p y lo ri-positive  g a s tr i t is ,  reg a rd less  of NSAID in tak e , a lthough H 
p y lo ri was less common in  p a tien ts  receiv ing  NSAID. Active 
duoden itis  was uncommon in p a tien ts  with normal g as tric  histology:
i ts  p revalence varied  betw een 20% (on NSAID) and  24% (no t on
NSAID). I t is also w orth noting  th a t 24 of 25 duodenal u lcers 
(96%), found in all p a tie n ts , were associated with active an tra l 
g a s tr i t is ,  and  th a t g as tr ic  H pylori was identified  in 23 of duodenal 
u lc e r  p a tien ts  (92%). Logistic reg ressio n  showed th a t g as tric  H
p y lo ri and  the  combination of active duodenitis and  g as tr ic  metaplasia 
w ere independen t p red ic to rs  of duodenal u lcera tion . On the  o th er 
h a n d , only 11 (9 on NSAID) of 16 g as tr ic  u lcers  (69%) had H pylori 
re la te d  g a s tr itis ; the  rem aining 5 g as tr ic  u lce rs  were found in 
association  with chemical g a s tr it is ,  which was found only in pa tien ts  
ta k in g  NSAID.
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The d is trib u tio n  of NSAID, with or w ithout second-line d ru g s  in 
p a tien ts  with active  duodenitis and g as tric  m etaplasia is shown in 
Table 23. The median d u ra tion  of NSAID in take was 3 y e a rs , and  
second-line d ru g s  2 y e a rs . Indom ethacin, naproxen  and diclofenac 
w ere the  most widely u sed  NSAID. P atien ts  tak in g  diclofenac, 
ke to p ro fen  o r nabum etone were less likely to have active duodenitis 
an d  g as tr ic  m etaplasia th a n  o ther NSAID b u t the  d ifferences were 
no t s ta tis tica lly  s ig n ifican t. Also, the  in take of second-line d ru g s  
d id  not seem to influence the  development of active duodenitis and 
g a s tr ic  m etaplasia, a lthough  such histological abnorm alities, a s  well 
as  g a s tr ic  H p y lo ri, w ere less common in p a tien ts  tre a ted  w ith gold 
in jec tio n s .
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FIGURE 10
The duodenal global histological scores in the  p resen ce  o r  absence of 
NSAID. P atien ts  w ith intram ucosal neu troph ils  have ac tiv e  chronic 
duoden itis. The rem ainder (b lack do ts) have inactive chron ic  
inflammation, and th e ir  num bers a re  similar in  the  two s tu d y  g ro u p s .
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TABLE 19
DEMOGRAPHIC AND ENDOSCOPIC DETAILS OF THE STUDY GROUPS
ON NSAID NOT ON NSAID
Number 74 98
Males 24 38
Females 50 60
Age (years), median 57 52
(interquartile range) (48-65) (40-61)
Smokers 27 56
Drinkers 28 44
Abdominal symptoms 43 83
Gastric ulcers 17 2
Duodenal ulcers 11 14
Gastric erosions 7
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TABLE 20
CHARACTERISTICS OF PATIENTS WITH ACTIVE CHRONIC 
DUODENITIS No. (%)
ON NSAID
(N=74)
NOT ON NSAID 
(N=98)
Number 20 (27%) 56 (57%)*
Smokers 12 (60%) 37 (66%)
Gastric H pylori 20 (100%) 43 (77%)
Duodenal H pylori 10 (50%) 34 (61%)
Gastric metaplasia 14 (70%) 34 (61%)
Heavy neutrophilic infiltration 4 (20%) 17 (30%)**
Heavy mononuclear infiltration 2 ( 10%) 12 ( 21%)**
Duodenal ulcers 6 (30%) 14 (25%)
SIGNIFICANT RISE: * : p <0.001 ; ** : p <0.05
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TABLE 21; DETAILS OF PATIENTS WITH GASTRIC METAPLASIA IN THE
DUODENUM NO.(%)
ON NSAID 
(N=74)
NOT ON NSAID 
(N=98)
Number 20 (27%) 38 (39%)
Grade: 1 
3
4 (20%) 
16 (80%)
6 (16%) 
32 (84%)
Smokers 12 (60%) 24 (62%)
Gastric H pylori 14 (70%) 34 (89%)
Duodenal H pylori 10 (50%) 34 (89%)
Active chronic duodenitis 14 (70%) 34 (89%)
Heavy neutrophilic infiltration 4 (20%) 15 (39%)
Heavy mononuclear infiltration 1 ( 5 % )  8 (24%)
Duodenal ulcers 6 (30%) 10 (26%)
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TABLE 23
DETAILS OF NSAID AND SECOND-LINE DRUGS IN PATIENTS WITH 
ACTIVE CHRONIC DUODENITIS AND GASTRIC METAPLASIA
No.
Indomethacin 13
Naproxen 12
Diclofenac 7
Ketoprofen 6
Nabumetone 6
Ibuprofen 5
Others* 24
Sulphasalazine 18
Gold (im) 13
Penicillamine 6
Gastric Active Gastric
H pylori duodenitis metaplasia
6 5 4
6 5 5
2
3 1
5 2 1
2 1 2
10 5 6
14 12 8
5 5 2
2 3 1
*: these included 4 patients or less per each of the following
agents:
azapropazone, fenbufen, flurbiprofen, piroxicam, etodolac, 
tiaprofenic acid, and sulindac
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8.5 DISCUSSION:
This s tu d y  shows th a t active chronic duodenitis  is less common 
in  p a tien ts  tre a te d  with NSAID, and th a t th e  p revalence of g a s tr ic  
m etaplasia in  the  duodenum is not s ign ifican tly  red u ced  by  chronic 
NSAID u se . The s tu d y  also dem onstrates a s tro n g  association 
betw een duodenal u lc e rs , active d u oden itis , g a s tr ic  m etaplasia, and  
H py lo ri re la ted  g a s tr itis  reg a rd less  of NSAID in tak e .
Lesions iden tified  as active chronic duodenitis  in  p a tien ts  
not tak in g  NSAID were more fre q u en tly  diagnosed in  th is  s tu d y  th a n  
th a t rep o rted  by  some w orkers (164), who s tu d ied  th is  abnorm ality  
in  p a tien ts  w ith n on-u lcer d y sp ep sia . This could be explained b y  
th e  p resen ce  of few er u lcers  in  th e ir  s tu d y , th e  in te rc e n tre  
varia tio n , and  th e  n a tu re  of th e  sco rin g  system  of th e  c u rre n t 
s tu d y . Such d ifferences should n o t, how ever, influence th e  a u th o r’s 
in te rp re ta tio n  of the  findings and  his su b seq u en t conclusions w ith 
re sp ec t to th e  effect of NSAID on duodenal h isto logy , because of two 
main reaso n s . F irs tly , the same global score was applied  to b iopsies 
tak en  from all p a tie n ts , reg a rd le ss  of NSAID in tak e , u n d e r  b linded 
conditions. Secondly, and allowing fo r  th e  possib ility  th a t the  global 
score had detected  minor in creases  in  th e  mucosal n eu tro p h ils  (mild 
duodenitis) in  some cases, th e  num ber of p a tien ts  w ith heavy  
neu troph ilic  in filtra tion  (severe  duoden itis) was still g re a te r  in  th e  
absence of NSAID.
G astric m etaplasia tended  to occur less f req u en tly  in  NSAID 
p a tie n ts , b u t the  d ifferences did not reach  s ta tis tica l s ignificance.
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T his to g e th e r w ith its  close association with active duoden itis  is in  
agreem ent with th e  find ings of two recen t s tu d ies  (165,166). High 
ac id ity  of the  duodenal con ten ts has for a long time been  found to 
be associated  w ith g a s tr ic  m etaplasia, bo th  in man (164,165,167,168) 
and  in  the  labo ra to ry  animals (159). NSAID are  also known fo r th e ir  
capacity  to stim ulate g as tr ic  acid secretion  (13-15 ,26), w hich, a t 
least in  th eo ry , should increase  the  prevalence of g a s tr ic  m etaplasia. 
The la tte r  has not been  observed  in th is  s tu d y  o r in  o th e rs  
(165,166) and could be re la ted  to th e  possible in te rac tio n  betw een 
NSAID and H p y lo ri. I t has recen tly  been p roposed  th a t the  
inflam m atory in ju ry  to th e  duodenal mucosa by  H py lo ri may stim ulate 
th e  developm ent of fu r th e r  g as tr ic  metaplasia (166). However, the  
p revalence of H py lo ri might be lower in chronic NSAID u s e rs ,  and  
th is  in  tu rn  might explain  th e  lower th an  expected  p revalence  of 
g a s tr ic  m etaplasia in  th e  p resen ce  of NSAID. A lte rn a tiv e ly , g a s tr ic  
acid might not be elevated  when NSAID are  tak en  on long term  
b a s is , 3 y ears  in  th is  s tu d y .
A ctive chronic duodenitis  was also less common in  p a tie n ts  tak in g  
NSAID. The reaso n  fo r th is  is not clear b u t it could be explained 
b y  th e  low prevalence of H pylori in NSAID p a tie n ts , d iscu ssed  
above, and  b y  the  tendency  of NSAID re la ted  damage to be maximal 
in  th e  g as tr ic  an trum  (42,82, C hapter 7 ). A lthough no specific 
histological p ic tu re  could be dem onstrated  in the  duodenal mucosa of 
NSAID p a tie n ts , the  re la tiv e  lack of heavy neu troph ilic  and  plasma 
cell in filtra tio n  in th e  duodenum is rem iniscent of some a sp ec ts  of 
chemical g a s tr itis  (23,71, C hap ter 7 ). In th e  absence of 
gastroduodenal s u rg e ry , the la tte r  is mostly found in  chronic NSAID 
u s e rs ,  as shown in th is  s tu d y  and o thers  (23,71, C h ap te r 7 ).
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Patien ts with active duodenitis had comparable p roportions of 
cases with g astric  H py lo ri, regard less  of NSAID in take , and  d esp ite  
th e  d ifferences in the  overall prevalence of H pylori in the  p resen ce  
o r absence of NSAID. This emphasizes the  role of H pylori in  th e  
pathogenesis  of active duodenitis (166). It is w orth no ting  th a t in  
th e  p resence  of g as tr ic  metaplasia H pylori was almost as re liab ly  
iso lated  from the duodenum as from the stomach and th is  re flec ts  th e  
n a tu ra l h is to ry  of th is  infection, being dependent on the  p resen ce  of 
g a s tr ic  type  epithelium . Since gastric  metaplasia was found in  th e  
duodenum of only a limited num ber of p a tien ts , duodenal H py lo ri 
could not be taken  as the  only evidence of active infection w ith 
th e se  organism s.
P atien ts receiv ing  NSAID had 11 duodenal u lcers (11/74, 15%) 
compared with 14/98 (14%) in those not on NSAID. Similar num bers 
of duodenal u lcers (25-30%) were also seen in  p a tien ts  w ith active 
duodenitis a n d /o r  g as tric  m etaplasia, reg ard less  of NSAID in tak e . 
However, the  majority of patien ts  with duodenal u lc e rs , in  th e  
p resen ce  o r absence of NSAID, were found to have active duodenitis 
(80%) and g as tric  m etaplasia (64%). The s tro n g  association betw een 
su ch  histological and  endoscopic en tities is in agreem ent w ith th e  
suggestion  th a t duodenitis and duodenal u lceration  might re p re se n t 
d iffe ren t poin ts in  a disease spectrum  with a common u n d erly in g  
pathogenesis  (162-166). There was also a s tro n g  association betw een 
ac tive  duodenitis and  H pylori positive g a s tr i t is , which in  tu rn  
h igh ligh ts  the  potential benefits of erad icating  H pylori in minimising 
duodenal damage in  NSAID p a tien ts . The same would app ly  to 
g a s tr ic  u lce rs , 8 of which (8/14, 57%) were positive fo r H py lo ri 
(23 ).
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The re la tive  ra r ity  of active duodenitis in the NSAID g roup  might 
exp lain , a t least in p a r t ,  why duodenal u lcers occur less 
commonly than  g astric  u lcers in  such  pa tien ts  (42 ,82 ). On the  
o th e r h an d , duodenal u lcers were still observed  in  com parable 
p roportions in the  p resence or absence of NSAID, which could be 
due to o th e r mechanisms of NSAID toxicity  such as su p p ress io n  of 
mucosal p ro stag lan d in s.
The prevalence of gastric  H py lo ri, active duodenitis and  g a s tr ic  
m etaplasia was similar in pa tien ts  tak ing  the  various NSAID w ith th e  
exception of diclofenac and ketoprofen . The p revalence of such  
find ings tended  to be lower in p a tien ts  tre a ted  w ith gold injections 
th an  in those receiv ing  sulphasalazine and NSAID (C h ap te r 12). A 
firm  statem ent could no t, how ever, be made because of th e  re la tiv e ly  
small num bers of pa tien ts  tak ing  the  individual NSAID w ith  o r 
w ithout second-line d ru g s  in th is  s tu d y .
In conclusion, despite  the  re la tive  lack of active duoden itis  in  
NSAID p a tie n ts , a s tro n g  association ex ists  between duodenal u lc e rs , 
ac tive  duoden itis, g as tric  m etaplasia and H pylori positive  g a s tr it is  
reg a rd le ss  of NSAID in take . This might be re lev an t to th e  
u n d e rs tan d in g  of the  pathogenesis and the  treatm ent of duodenal 
u lce rs  in chronic NSAID u se rs .
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CHAPTER 9 
9 NSAID AND THE OESOPHAGUS
9.1 SUMMARY
B ackground: D espite th e ir  s tro n g  association with g as tric  and
duodenal u lc e rs , the  effect of non-stero idal anti-inflam m atory d ru g s  
(NSAID) on the  oesophagus rem ains u n clear. Conflicting re su lts
have  been  obtained from stud ies  conducted on laboratory  animals o r 
small num bers of human vo lun teers.
Aims: To iden tify  the  endoscopic and histological abnorm alities
of th e  oesophageal mucosa, in the p resence o r absence of chronic 
NSAID th e ra p y .
P atien ts  and Methods: S even-hundred  and  fifty-tw o p a tien ts
w ere endoscoped; 596 took NSAID and 156 did n o t. All p a tien ts  not 
in  th e  NSAID group had abdominal complaints compared with 187 on 
NSAID. Histological s tu d ies  were perform ed on normal looking
m ucosa of 98 p a tien ts  (53 on NSAID and 45 not on NSAID).
R e su lts : The overall p revalence of endoscopic oesophagitis in
NSAID p a tien ts  was 46/596 (8%). However, in symptomatic p a tie n ts , 
endoscopic oesophagitis was found in  46/187 (25%) tak ing  NSAID, 
com pared w ith 19/156 (12%) not on NSAID (X2=9.8, p<0.001).
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At h isto logy , fo u r patients(7% ) in the  NSAID group (n=53) had 
pap illa ry  elongation and two (4%) had basal cell h y p e rp la s ia , 
com pared w ith 13 (29%) and e igh t (18%) resp ec tiv e ly , in  p a tie n ts  not 
tak in g  NSAID (n=45).
Conclusions: Endoscopic oesophagitis is more commonly found in  
chronic NSAID u se rs  w ith abdominal com plaints. H ow ever, the 
re la tiv e  lack of pap illary  elongation and basal cell h y p erp lasia  might 
su g g e s t th a t histological oesophagitis is not e ssen tia l fo r  the 
developm ent of N SA ID -related u lcers  or erosions. A lterna tive  
mechanisms of NSAID tox icity  should also be considered .
9 .2  INTRODUCTION
The oesophageal mucosa can be adverse ly  affected  b y  a v a rie ty  
of ag en ts  such  as g as tr ic  ac id , pep sin , and bile sa lts  (170-179). 
O esophageal in ju ry  has also been  ascribed  to many of th e  commonly 
u sed  m edications, in g ested  in th erap eu tic  doses (180-183). 
N on-stero idal anti-inflam m atory d ru g s  (NSAID) a re  am ongst the  most 
commonly p re sc rib e d  ag en ts  (94 ,95), and th e ir  u se  has been  
associa ted  w ith g as tr ic  and  duodenal u lcers  in  about 30% of p a tien ts  
(42 ,82 ,128). However, th e  effect of NSAID on the  oesophageal 
mucosa is not c lear. T here have been some re p o r ts ,  m ostly of 
ind iv idual cases, of oesophagitis and s tr ic tu re  form ation in  p a tien ts  
tak in g  NSAID (180-188), b u t some au th o rs  believe th a t the 
oesophagus is re la tive ly  unaffected  by  trad itional NSAID th e ra p y  
(189), and  the  experim ental data  of o thers  su g g est th a t NSAID might 
even  be p ro tec tiv e  to the oesophagus in certa in  circum stances such
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as irrad ia tio n  and  acid -induced  oesophagitis (190-195).
The aim of th is  s tu d y  was to iden tify  th e  endoscopic and  
histological abnorm alities of th e  oesophageal mucosa in  the  p resen ce  
o r absence of long term  trea tm en t w ith NSAID.
9.3 PATIENTS AND METHODS:
P a tie n ts , aged 18 y ea rs  or o v er, were re c ru ite d  from th e  
Rheumatology and  G astroentero logy U nits. NSAID had  to be  tak en  
fo r a t leas t fo u r weeks befo re  endoscopy. Second-line d ru g s , and  
im m unosuppressants such  as  s te ro id s , aza th io p rin e , m etho trexate  
e t c . ,  w ere allowed p rov ided  th ey  w ere taken  to g e th e r  w ith NSAID. 
P atien ts  w ith various a rth ro p a th ie s  were accep ted , includ ing  
rheum atoid a r th r i t is ,  o s te o a rth r itis , ankylosing  sp o n d y litis , 
polymyalgia rheum atica, and  system ic lupus ery th em ato su s. Abdominal 
complaints had  to be p re se n t to ju s tify  endoscopy in p a tien ts  not 
tak in g  NSAID. Subjects w ere excluded if th ey  had  a h is to ry  of 
u p p e r g a s tro in te s tin a l s u rg e ry ,  C rohn’s d isease , m alignancy, 
irra d ia tio n , o r recen t a n ti-u lc e r  th e rap y .
Inform ed consent was obtained and p a tien ts  w ere endoscoped 
a f te r  th e  in trav en o u s adm inistration  of diazepam o r midazolam fo r 
sedation . Endoscopic oesophagitis was divided into two main g ro u p s: 
mucosal ery them a and oedema with o r w ithout erosions (G roup I ) ,  
and  chronic conditions (G roup II) including  isolated deep u lcera tio n , 
s tr ic tu re s ,  and  B a r re tt 's  oesophagus. This m odification of the  
Savary  and  Miller g rad in g  system  (196) was in tended  to im prove the  
rep ro d u c ib ility  of m easurem ents in a large cohort s tu d y , especially  
because of the  d ifficu lty  in d is tin g u ish in g  betw een G rades II and  III
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of Savary  and  Miller (196). The p resen ce  of o th e r mucosal 
abnorm alities of th e  stomach and duodenum  was also re co rd ed . 
P atien ts  w ith th e  above oesophageal lesions and  those w ith g a s tr ic  
u lce rs  had ro u tin e  biopsies taken  fo r h isto logy. Special fungal 
s ta in s  were u sed  w henever Candida albicans was su sp ec ted . 
B a r re t t’s oesophagus was defined as g as tr ic  mucosa ex ten d in g  more 
th an  3cm above th e  endoscopic gastro -oesophageal junction .
Histological s tu d y : The last 100 p a tien ts  to be s tu d ied , who also
had normal looking oesophagus, reg a rd le ss  of NSAID in tak e , had  an  
average  of two biopsies taken  from the  lower th ird  of th e ir  
oesophagus abou t 5cm from the  card ia  fo r h isto logy . The following 
histological fe a tu re s  of the  oesophageal mucosa (F igu res 11,12) w ere 
a sse ssed : pap illa ry  elongation, basal cell h y p erp las ia , and
inflammatory cell in filtra tio n  (197). The mucosal papillae were 
considered  elongated  if th ey  m easured g re a te r  th an  60% of th e  
d istance betw een the  basal cell layer and  the  luminal su rfac e . Basal 
cell h yperp lasia  was defined as a condition in  which th e  basal cells 
w ere g re a te r  th an  two layers in  th ick n ess . Inflam m atory cell 
in filtra tio n  was considered  heavy if a t least five cells were seen  p e r  
microscopic fie ld  of th e  whole b iopsy specim en. S tain ing  fo r Candida 
albicans was perform ed in  all of th e  oesophageal b iopsies. G astric  
an tra l b iopsies w ere also taken  to check fo r H elicobacter py lo ri b y  
bo th  histo logy (two specim ens) and  cu ltu re  (one specimen) as 
p rev iously  d escrib ed  (61).
S tatistica l a n a ly se s : These included the  C h i-sq u are  (X2) te s t
and  the  analysis  of v ariance , and th e  95% confidence in te rv a ls  fo r 
th e  estim ated re la tiv e  r is k ,  w here ap p ro p ria te . The endoscop ist, 
h isto log ist, and  bacterio log ist were not aw are of th e  details of 
p a tie n ts ’ m edications. The s tu d y  was approved  by  th e  local Ethics 
Committee.
FIGURE 11 
Normal oesophageal mucosa (X247)
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FIGURE 12
Some featu res of reflux  oesophagitis: basal
cell hyperplasia, and inflammatory cell infiltration .
The papillary size is a t the upper limit of normal. (X395)
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9.4 RESULTS:
Endoscopic study : A total of 752 patients underw ent endoscopy:
596 took NSAID and 156 did not. Their details are shown in Table 
24. Both groups were comparable in sex d istribution , age, smoking, 
and drinking habits. Because of the nature of the inclusion criteria  
abdominal complaints were less prevalent in patients taking NSAID, 
b u t th is group still had more ulcers and erosions affecting the 
stomach and duodenum. In the NSAID group, patien ts with or 
w ithout abdominal complaints had similar demographic details, but 
gastric  and duodenal lesions were commoner in the symptomatic 
g roup . The numbers of patients with oesophagitis and the details of 
the oesophageal lesions are illustrated  in Figure 13. The overall 
prevalence of endoscopic oesophagitis was 46/596 (8%, NSAID
presen t) and 19/156 (12%, NSAID absen t). However, when abdominal 
complaints were taken into consideration, since all non-NSAID 
patien ts had to have such complaints to justify  endoscopy, the ir
symptomatic counterparts in the NSAID group (acting as case 
controls)had a higher prevalence of oesophagitis (46/187,25%,
p<0.001). Intense erythema without erosions was found in 12 NSAID 
patien ts and 5 others not on NSAID. There were no significant 
differences in the prevalence of s tric tu res  or B a rre ttTs oesophagus, 
b u t oesophagitis with or without erosions or deep ulcers was 
commoner in NSAID patients with abdominal complaints. All 
oesophageal lesions described in this study  affected the lower th ird  
of oesophagus. O ther characteristics of patients with oesophagitis 
are  shown in Table 25. It is worth noting tha t all patien ts with
oesophagitis, regardless of NSAID intake, had upper abdominal
complaints: dysphagia was p resen t in a total of seven p a tien ts , four 
of whom were found to have s tr ic tu re s . The re s t of patien ts with 
oesophagitis complained of epigastric pain, heartbu rn  and nausea 
with or without vomiting.
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Rheumatoid a r th r i t is  was the commonest diagnosis am ongst 
various p a tien ts  tak in g  NSAID (Table 26). A lthough oesophagitis 
was found in fo u r of 27 p a tien ts  (15%) with system ic lupus 
ery them atosus, and  35/499 (7%) with rheum atoid a r th r i t i s ,  the
d ifferences betw een the  two g roups did not reach  s ta tis tica l 
s ign ificance .
D rugs taken  b y  p a tien ts  in the NSAID s tu d y  g roups a re  detailed  
in Tables 27 and 28. Indom ethacin, naproxen , and  diclofenac were 
th e  commonest NSAID u se d . The median du ra tion  of NSAID th e ra p y  
was th re e  y ea rs  in  all g ro u p s. Also, p a tien ts  tre a te d  w ith 
predniso lone had a similar prevalence of oesophagitis to those  tre a te d  
w ith gold in jections, su lphasalazine, or penicillam ine. However, 
oesophagitis was found in  22 out of 206 p a tien ts  (11%) tre a te d  with 
second-line d ru g s  or im m unosuppressants p lus NSAID, com pared with 
24/390, 6% of those tak in g  NSAID only (x 2 =5.4, p<0.02; E R :1 .8 ; 95% 
C l: 1 -3 .3 ) . Oesophageal lesions in  gold tre a ted  p a tien ts  consisted  of 
erythem a (5 cases) and  erosions (3 cases) b u t no u lc e rs ; erosions 
w ere also found in  all p a tien ts  w ith oesophagitis who received  
o th e r d isease m odifying d ru g s . O esophagitis was not seen in  any  of 
the  p a tien ts  rece iv ing  hydroxychloroquine: such  p a tien ts  had a 
median age of 34 y e a rs , compared with 58 years  in p a tien ts  tre a te d  
w ith o th e r a g en ts , and  took NSAID fo r a median period  of one y e a r .
Histological s tu d y : One h u n d red  p a tien ts  w ith endoscopically
normal looking oesophagus were s tu d ied ; two were excluded because 
of recen t use  of H 2-recep to r an tag o n ists . Of the  rem aining 98, 53 
p a tien ts  took NSAID and 45 did no t. T heir ch a rac te ris tic s  a re  
shown in Table 29. T here  were no significant d ifferences betw een 
the two groups with re sp e c t to age , smoking and d rin k in g  h ab its . 
However, p a tien ts  not tak in g  NSAID had few er g as tr ic  u lcers  b u t a 
g re a te r  num ber of p a tien ts  with duodenal u lcers a n d /o r  H elicobacter
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p y lo ri.
The prevalence of the  main histological abnorm alities, in  th e  
p resen ce  o r absence of NSAID, is illu s tra te d  in  F igure  14. P ap illary  
elongation and  basa l cell h y p erp lasia  w ere less common in  p a tien ts  
tre a te d  w ith NSAID b u t the  d ifferences were not h ig h ly  sign ifican t 
as judged  b y  the  confidence in te rv a ls . Also, th e  e x te n t and  deg ree  
of inflammatory cell in filtra tio n  was not influenced b y  NSAID in tak e . 
All 13 p a tien ts  w ith pap illa ry  elongation not tak in g  NSAID, and th re e  
out of fo u r p a tien ts  w ith th is  abnorm ality  in  th e  NSAID g ro u p , w ere 
heavy sm okers. Heavy smoking was also p re se n t in  six  ou t of e ig h t 
p a tien ts  w ith basal cell hyperp lasia  not tre a te d  w ith NSAID, and one 
of two of th e ir  c o u n te rp a rts  in  th e  NSAID g ro u p .
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TABLE 24
Details of all Patients in the Endoscopic Study. NSIAD patients are 
classified according to the presence (group I) or absence (group II) of
abdominal complaints 
On NSAID
I
Not on NSAID
Number 
Male 
Females 
Age, Median
187
62
125
56
II
409
96
313
58
(interquartile range) (43-62) (49-67)
Smokers 88 142
Drinkers 68 92
Total
596
158
438
57
(43-65)
230
160
156
61
95
51
(47-62)
70
71
Indication for endoscopy:
Abdominal complaints 187 - 187 156
Anaemia 46 85 131 -
Weight loss 9 12 21 -
Gastric ulcers 37 46
Duodenal ulcers 33 21
Gastric/duodenal erosions 40 55
83
54
95
.6
16
4
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TABLE 25
Characteristics of Patients with Oesophagitis
Number 
Males 
Females 
Age,median
(interquartile range)
Smokers
Drinkers
Abdominal symptoms
On NSAID
46
15
31
56
(47-65)
10
9
46
Not on NSAID 
19 
6 
13 
52
(36-72)
7
9
19
Co-existing peptic ulcers
Gastric
Duodenal
Oesophageal Candidiasis 3 2
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TABLE 26
The Basic Diagnosis in Patients Taking NSAID
Diagnosis All NSAID
patients
(n=596)
Patients with Patients in the 
oesophagitis histology study
(n=46) (n=53)
Rheumatoid
arthritis 499
Osteoarthritis 29
Systemic lupus 
erythematosus 27
Ankylosing
spondylitis 17
Polymyalgia 
rheumatica 8
Psoriatic
arthropathy 7
Reactive arthritis 4
Gout 4
Henoch-Schonlein 1
35
1
44
9
purpura
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TABLE 27 
Types of NSAID Used
Drugs All NSAID
patients
(n=596)
Patients with Patients in the 
oesophagitis histology study
(n=46) (n=53)
Indomethacin
Naproxen
Diclofenac
Flurbiprofen
Ketoprofen
Ibuprofen
Piroxicara
Others*
146
120
110
70
50
36
24
40
11
12
9
1
1
8
1
3
10
8
6
2
5
2
4
16
* 3-6 Patients per one of the following:
Fenpufen, etodolac, azapropazone, naubmetone, sulindac, 
tiaprofenic acid, tenoxicam, and tolmetin
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Table 28
Details of Second-Line and Immunosuppressive Drugs Taken by NSAID
Patients
Drugs All NSAID Patients with Patients in the
patients oesophagitis histology study
(n=596) (n=46) (n=53)
Gold injections 67
Sulphasalazine 34
Hydroxychloroquine 27
Penicillamine 24
Prednisolone 33
Azathioprine 11
Methotrexate 3
Cyclophosphamide 4
Cyclosporin 3
11
10
4
4
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Table 29
Characteristics of Patients in the Histological Study
On NSAID Not on NSAID
Number 53 45
Males 13 19
Females 40 26
Age,median 58 52
(interquartile ranges) (49-65) (45-63)
Smokers 26 31
Drinkers 16 18
Gastric ulcers 8 2
Duodenal ulcers 5 10
Gastric Helicobacter pylori 31 36
153
Endoscopic 
com plaints,
♦
* *
***
FIGURE 13
oesophageal lesions in p a tien ts  with abdominal 
in  the p resence  or absence of NSAID:
p<0.001 (estim ated re la tive  r is k , E .R .,  2.35;
95% confidence in te rv a ls , C .I . :  1 .31 ,4 .212) 
p<0.01 (ER: 2.42; C .I . :  1 .25 ,4 .67) In tense
erythem a w ithout erosions was found in  12 
NSAID u se rs  and  5 n o n -u se rs . This d id  not 
affect th e  overall levels of s ta tis tica l 
significance 
p<0.02 (ER, C . I . , unm easurab le) .
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FIGURE 14
Oesophageal histological find ings in  the  p resen ce  or absence of 
NSAID:
* p<0.01 ( E R : 0 .2 0 1 ;C . I .  : 0 . 06,0 .671)
** p<0.02 ( E R : 0 . 1 8 ; C . I . : 0 .036,0 .897)
The p -values should  be in te rp re te d  with caution because  of th e  
wide range of th e  95% confidence in te rv a ls  and  th e  sim ilarity  in 
the estim ated re la tiv e  r is k . The overall view is th a t the  two 
s tu d y  groups a re  comparable in  th e ir  histological fin d in g s .
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9.5 DISCUSSION:
This s tu d y  shows th a t the p revalence of endoscopic oesophagitis , 
w ith or w ithout u lce rs  or erosions, is h ig h er in NSAID p a tien ts  with 
u p p e r abdominal complaints th an  in those not tre a te d  w ith such 
a g e n ts . The prevalence of s tr ic tu re s  o r B a r re t t’s oesophagus is 
similar in  bo th  g ro u p s . Histological s tu d ies  in p a tien ts  w ith normal 
looking oesophagus a t endoscopy, show th a t pap illa ry  elongation and 
basal cell h y p erp lasia  a re  relatively  less common in  th e  p resen ce  of 
NSAID, a lthough  the  ex ten t and d eg ree  of inflam m atory cell 
in filtra tio n  a re  sim ilar in the  p resence or absence of NSAID in tak e .
Endoscopic oesophagitis is now a common disease and  accounts 
fo r as many as 19% of new re fe rra ls  fo r endoscopy (198). This is 
almost identical to the  mean prevalence of oesophagitis (18.5%) in  the 
a u th o r 's  symptomatic p a tie n ts , reg a rd less  of NSAID in take (25%, 
NSAID p re se n t;  12%, NSAID ab sen t; mean 18.5%). The overall 
p revalence of oesophagitis in NSAID p a tien ts  was only 8%. The 
p resen ce  of abdominal complaints had to be taken  into consideration  
because all p a tien ts  not tak ing  NSAID were symptomatic and ac ted  as 
case con tro ls . Ideally , asymptomatic su b jec ts  not tre a te d  with 
NSAID should have also been included , b u t eth ical approval was not 
ava ilab le .
In the  few pub lished  s tud ies  on N SA ID -related oesophagitis the 
p revalence of th is  endoscopic abnorm ality had  varied  betw een 15.7% 
(187) to 20% (186) which is comparable to th a t found in symptomatic 
NSIAD p a tien ts  in th is  s tu d y . Also, two out of fou r p a tien ts  with 
oesophageal s tr ic tu re s ,  in th is  s tu d y , had taken  NSAID compared 
with 31% found b y  ano ther group (199). These find ings do not 
su p p o rt the idea th a t benign  s tr ic tu re s  a re  commoner in p a tien ts
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tre a ted  with NSAID, a lthough  a firm statem ent cannot be made 
because of the small num ber of s tr ic tu re s  involved.
U pper abdominal complaints were p re se n t in all p a tien ts  w ith 
oesophagitis. These could be due to the  oesophageal lesion itse lf , 
the  co -ex isting  p ep tic  u lcera tion , or b o th . However, symptoms a re  
not a consis ten t fe a tu re  of N SA ID -related g as tric  or duodenal u lc e rs , 
as found by  th is  s tu d y  and  o th ers  (81 ,82).
O esophagitis a ffected  th e  lower th ird  of oesophagus of all NSAID 
p a tie n ts , confirm ing the  find ings of o th e r stud ies  in  th is  field  (137,
188). This is unlike many cases of oesophagitis re la ted  to o th e r 
ty p es  of d ru g s , which affect the middle th ird  of oesophagus
(181,183). The reason  fo r th is  is not c lear, b u t it could be re la ted  
to the  method of d iagnosis: barium  stu d ies  might not be ideal fo r
id en tify in g  erythem a and small u lcers  or erosions. It is in te re s tin g  
to find  th a t oesophageal lesions were also seen in the lower th ird  of 
oesophagus, as a re su lt of medications not containing NSAID, when 
endoscopy was u sed  (182). Endoscopy w as, th e re fo re , considered  as 
the  most reliable method of d iagnosing d ru g  re la ted  oesophagitis
(180, 182, 200).
In p a tien ts  w ith normal oesophagus a t endoscopy, the  histological 
assessm en ts have shown th a t pap illary  elongation a n d /o r  basa l cell 
h y p erp lasia  a re  uncommon in  the  p resen ce  of a h is to ry  of chronic
NSAID in tak e . Such fea tu re s  a re  recognised  as being  the
histological consequences of gastro -oesophageal re flux  in man (197), 
and  th e ir  re la tive  r a r i ty  in the  p resen ce  of NSAID ra ises  two possib ilitie s . 
F irs tly , NSAID might have a beneficial effect in p rev en tin g  or
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minimising re flu x  oesophagitis, a t least a t the  histological level. 
This has been su g g ested  by  the find ings of s tu d ies  conducted  in 
c a ts , in  which experim ental oesophagitis was defined  as 
polym orphonuclear in filtra tio n  an d , in some cases, denudation  of the  
epithelium  (190). This is  unlikely  to be the case in th is  s tu d y , 
since the ex ten t and  degree  of inflammatory in filtra tio n  w ere the 
same in  the p resen ce  or absence of NSAID. Also, the  d u ra tio n  of 
experim ental oesophagitis might not have been long enough t to allow 
fo r the  evolution of h y p ertro p h ic  a n d /o r  h y p erp lastic  changes in  the  
oesophageal mucosa.
Secondly, it could be specu lated  th a t histological oesophagitis is 
not essen tia l fo r the  developm ent of N SA ID -related u lc e rs  or 
erosions. O ther mechanisms of NSAID damage should th e re fo re  be 
considered , includ ing  th e ir  in te rac tio n  with p ro s tag lan d in s , and  th e ir  
d irec t toxic e ffects  especially  when tab le ts  get lodged in  the  
oesophagus. P rostag land ins a re  known fo r th e ir  h y p e rtro p h ic  
ac tiv ity  in the  g as tro in tes tin a l mucosa (201), a lthough  th is  has not 
been  dem onstrated  in the  oesophagus. The ab ility  of NSAID to 
inh ib it mucosal p ro stag lan d in s  might account fo r th e  lower p rev a len ce  
of pap illary  elongation and  basal cell hyp erp lasia  in  p a tien ts  
receiv ing  NSAID. C ertain  p ro stag lan d in s  (Ex, E2, and  A) can  also 
decrease  the  basal lower oesophageal sp h in c te r  p re s s u re  in  man 
(202) and  th e ir  inh ibition by  NSAID could theo re tica lly  red u ce  
gastro -oesophageal re flu x  with its  histological consequences. 
However, NSAID have o th e r im portant p ro p ertie s  th a t may co n trib u te  
to th e ir  damaging effects on the oesophageal mucosa. T hese ag en ts  
a re  rela tive ly  acidic molecules, and  are  lipid soluble a t low pH. 
When the pH of the
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lower oesophagus is below 4, a t the  time of gastro -oesophagea l 
re flu x , NSAID may e n te r  the  oesophageal mucosal ce lls, causing  
d irec t toxic effects  (183). T h ird ly , the  possib ility  of some sam pling 
e r ro rs  should not be ru led  out g iven the  occasional d ifficu lties in  
in te rp re tin g  oesophageal b iopsies.
Patien ts  not tak in g  NSAID had  a h ig h er p revalence of H p y lo ri, 
duodenal u lc e rs , pap illa ry  elongation, and basal cell h y p erp las ia  of 
th e  oesophageal mucosa. While th e  associations betw een duodenal 
u lce rs  and H pylori o r oesophagitis a re  w ell-recognised , a d ire c t link 
betw een H pylori and  endoscopic o r histological oesophagitis has not 
been  p ro v en .
The histological s tu d y  also showed a s tro n g  association betw een 
smoking and bo th  pap illa ry  elongation and basal cell h y p erp las ia . 
This could be explained by  th e  recognised in h ib ito ry  effec t of 
smoking on the  lower oesophageal sp h in c te r , which as a r e s u lt ,  
increases gastro -oesophageal re flu x  (203).
The possible effect of an ti-rheum ato id  second-line d ru g s  on the  
oesophagus has not been  s tu d ied  befo re . P atien ts tak in g  these  
ag en ts  or im m unosuppressive th e ra p y  p lus NSAID had a h ig h er 
p revalence of oesophagitis than  those tre a ted  with NSAID only , in 
th is  s tu d y . A lthough a d irec t toxic effect cannot be e n tire ly  ru led  
o u t, p a tien ts  re q u irin g  second-line d ru g s  or im m unosuppressants 
ten d  to be old, and  to have more agg ress iv e  u n d erly in g  d isease . 
O lder sub jec ts  a re  a t g re a te r  r isk  of d ru g -in d u ced  oesophageal 
in ju ry  because of the d iso rd ered  con traction  of the lower oesophageal 
sp h in c te r  (204). This might explain the  absence of oesophagitis  in 
rheum atoid p a tien ts  rece iv ing  hydroxychloroquine as th ey  were 
y o unger than  those tre a te d  with o th e r second-line d ru g s . In
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ad d itio n , the  num ber of cases of Candidal oesophagitis , known to 
a ffec t immunocompromised sub jec ts  (181), was not h igh  in  p a tien ts  
rece iv in g  im m unosuppressants in th is  s tu d y , p robab ly  because of the  
small num ber of p a tien ts  who took such  ag en ts . The inclusion in 
th is  s tu d y  of a v arie ty  of a r th r it ic  d iseases is also unlikely  to have 
a ffec ted  th e  fin d in g s , as none of such  diseases has been shown to 
a ffec t the  oesophagus.
In  conclusion, endoscopic oesophagitis with u lcers  o r erosions is 
commoner in  NSAID p a tien ts  w ith abdominal com plaints. The re la tive  
r a r i ty  of pap illary  elongation and  basal cell h yperp lasia  in  NSAID 
p a tie n ts  might su g g est th a t u lcers  and erosions a re  not dependen t on 
histological oesophagitis fo r th e ir  developm ent, and  h ig h lig h ts  the  
im portance of a lte rn a tiv e  mechanisms such  as d irec t mucosal tox ic ity .
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SECTION V 
NSAID AND MUCOSAL BLOOD FLOW
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CHAPTER 10
10 GASTRIC AND DUODENAL MUCOSAL BLOOD FLOW IN PATIENTS 
RECEIVING NSAID; INFLUENCE OF AGE, SMOKING, ULCERATION, 
AND H PYLORI
10.1 SUMMARY
Background: Studies conducted in experim ental animals have
suggested  th a t g astric  mucosal blood flow is red u ced  b y  acu te  
exposure to NSAID. The possible in teraction  with o th e r  fa c to rs , 
re leven t to the pathogenesis of peptic u lce rs , has not been  s tu d ie d .
Aims: To assess  the  possible influence, on mucosal blood flow,
of chronic NSAID in take , age , smoking, u lceration , and  H p y lo ri.
Methods: Using lase r Doppler flowmetry, g as tr ic  and  duodenal
mucosal blood flow was m easured in 70 p a tien ts  who had  tak en  NSAID 
fo r longer than  4 w eeks, and stud ied  the co rre la tion  with 
demographic fac to rs , u lceration , and  Helicobacter p y lo ri. Blood flow 
was also measured in 17 o th er sub jec ts not tak in g  an y  d ru g s . 
M easurements were taken  from healthy  looking mucosa in  th e  g as tr ic  
antrum  and f ir s t  p a r t  of duodenum.
R esults: Both g astric  and duodenal blood flow values were
significantly  lower in pa tien ts  tak ing  NSAID than  in  those  who did 
n o t. In  the NSAID group the  median duodenal mucosal blood flow 
was 150 perfusion  u n its  in  smokers (n=29) compared w ith 175 in 
non-sm okers (p=0.024), 123 un its  in  p a tien ts  with duodenal u lcers
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(n=12) compared with 160 in those w ithout duodenal u lce rs  
(p=0.020), 135 un its  in  p a tien ts  with H pylori (n=30) compared with 
168 in p a tien ts  w ithout H pylori (p=0.033), and  118 in  sm okers 
infected  with H pylori compared with 175 u n its  in  non-sm okers not 
infected  with H pylori (F=13.4, p=0.0005). T here  was no corre la tion  
w ith age . G astric  blood flow was not sign ifican tly  influenced b y  an y  
of the  above variab les.
Conclusion: These re su lts  su g g est th a t chronic NSAID in take  is
associated w ith reduced blood flow in bo th  th e  stom ach and  
duodenum. However, am ongst NSAID p a tien ts  duodenal, b u t not 
g a s tr ic , mucosal blood flow is reduced  in  sm okers, and  in  those  w ith 
duodenal u lcers and Helicobacter py lo ri. M ultivariate analysis  
showed th a t only the sim ultaneous p resence  of smoking and  H py lo ri 
had an independent su p p ressiv e  effec t, and  when com bined, lower 
blood flow values are  o b serv ed , which might su g g es t a sy n e rg is tic  
relationship  between these  two fac to rs .
10.2 INTRODUCTION
Mucosal blood flow is believed to p lay an  im portant role in  
m aintaining the in teg rity  of the  g as tr ic  mucosa. Mucosal ischaemia 
has been found to be the  main cause of g as tr ic  lesions in  p a tien ts  
w ith thermal o r head in ju ry  (205). In te rfe ren ce  w ith blood flow b y  
s tr e s s ,  vascu lar occlusion, o r n on -stero idal a n ti inflammatory d ru g s  
(NSAID) is also thought to cause g a s tr ic  u lceration  in  animals (206). 
The situation is not clear in  p a tien ts  on long term  NSAID who might 
have o ther fac to rs  th a t can , a t least in  th e o ry , influence g a s tr ic  
mucosal blood supp ly . Also, v e ry  little  is known about duodenal 
blood flow in such  p a tien ts . The main aim of th is  s tu d y  was to
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m easure g as tr ic  and duodenal mucosal blood flow in p a tien ts
receiv ing  NSAID, and to see if th is  could be influenced b y  age ,
smoking, u lcera tion , o r (H) py lori. A small num ber of p a tien ts  not 
tak ing  NSAID were also included in o rd e r  to s tu d y  th e  overall effect 
of NSAID on th e  g as tric  and duodenal mucosal blood flow.
10.3 PATIENTS AND METHODS:
P atien ts w ith o steo a rth ritis  or rheum atoid a r th r i t is  were included 
if th ey  had tak en  NSAID fo r a minimum of 4 w eeks. They were
excluded if  th ey  had a h is to ry  of p rev ious g a s tr ic  su rg e ry  o r if they
took an ti-u lce r th e ra p y , hypotensive a g e n ts , o r an ti-ang ina l d ru g s . 
They were also excluded if they  had  o th e r system ic d iseases su ch  as 
d iabetes m ellitus. Similar c rite ria  were also applied to an o th er g roup  
of su b jec ts , not on NSAID, who acted  as co n tro ls , and  w ere being  
investiga ted  fo r u p p e r abdominal com plaints. Inform ed consent was 
obtained and endoscopy was perform ed a f te r  an  overn igh t fa s t . 
Midazolam, 4-10 mg in travenously , was u sed  fo r sedation .
Blood flow was m easured w ith a la se r Doppler flowmeter 
(210,211) (Periflix  PF3, Perim ed, Sweden) which was reg u la rly  
calib rated  u s in g  a s tan d a rd  suspension  of la tex  partic les  to en su re  
constan t sen sitiv ity . The fib re-o p tic  p robe  (Model PF309) was 
in troduced  th ro u g h  the  b iopsy channel of th e  endoscope, and  its  tip  
applied to healthy-looking  mucosa in  th e  g a s tr ic  an trum , w ithin 5cm 
of the  pyloric canal, and the  f i r s t  p a r t  of the  duodenum . The 
antrum  was chosen because it  is th e  commonest s ite  of N SAID-related 
g as tric  damage (5 ,4 2 ). In  pa tien ts  w ith u lc e rs , the p robe  was 
applied a t least 2cm away from the  u lcer edge. The contact 
p re s su re  betw een th e  probe and tissu e  was th e  minimum n ecessa ry  to
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m aintain optical coupling. In  pilot expirem ents it was found th a t 
v a ry in g  the  con tact p re s su re  w ithin reasonable limits did not have 
an y  co n sis ten t e ffects  on reco rded  flow values, presum ably because 
of th e  considerable d ep th  of p en e tra tio n  of la se r lig h t in  
g a s tro in te s tin a l tissu e  (Johansson e t a l,212).
The flowmeter was operated  u s in g  th e  12 kHz bandw idth  and  3 
sec time co n stan t s e tt in g s , and  th e  o u tp u t, in  a rb i tra ry  p e rfu sio n  
u n its , was reco rd ed  continuously fo r  a minimum period  of one m inute 
a t each location on a ch a rt re c o rd e r . Flow values were calcu lated  as 
th e  mean flowmeter read in g  over th is  period , excluding  any  a r te fa c ts  
associa ted  w ith movement of th e  probe o r p e ris ta ls is . The 
rep ro d u c ib ility  of m easurem ents was assessed  in  pilot s tu d ie s  in  
which reco rd in g s  were rep ea ted  in the  same region of th e  stom ach 
a f te r  a period  of 10-15 m inutes, and  the  coefficient of varia tion  was 
found to be 17%. All reco rd ings w ere analysed w ithout know ledge of 
th e  p a tie n ts ’ clinical details o r endoscopic find ings.
The p resen ce  of H py lori was determ ined by  histo logy and  
bacterio logy , as p rev iously  d escribed  (61), in biopsies tak en  from 
th e  g a s tr ic  an tru m . The h isto log ist and  the  bacterio log ist w ere not 
aw are of the p a tie n ts ’ details o r o th e r re su lts .
S ta tistica l te s ts  included th e  M ann-W hitney, K ruskall-W allis, and  
multiple linear reg ress io n  analysis w ith step-w ise variable elim ination, 
w here ap p ro p ria te .
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10.4 RESULTS
A total of 87 p a tien ts  w ere s tu d ied : 70 took NSAID and 17 did 
n o t. T heir c h a rac te ris tic s  a re  shown in Table 30. Mucosal blood flow 
values in th e  stom ach, 125(90-183) and duodenum , 160(123-190) 
u n its ,  median ( in te rq u a rtile  ra n g e s ) , in  p a tien ts  tak in g  NSAID, were 
lower than  th e ir  co rrespond ing  values, 200(110-350) and  265 
(150-310), in  p a tie n ts  not tak in g  NSAID (p=0.01). In  NSAID p a tien ts  
w ith o s teo a rth r itis , th e  g a s tr ic  mucosal blood flow was 125 (90-160) 
u n its ,  and th e  duodenal blood flow was 148 (110-175), com pared with 
125 (90-185) and  160 (125-200) u n its , re sp ec tiv e ly , in  those with 
rheum atoid a r th r i t i s .  T h ere fo re , th e re  were no sign ifican t 
d ifferences betw een p a tie n ts  w ith o s teo a rth ritis  o r  rheum atoid 
a r th r i t is  w ith re sp e c t to blood flow. In add ition , th e re  was no 
correlation  betw een mucosal blood flow and param eters of a r th r it ic  
d isease ac tiv ity  su ch  as th e  e ry th ro cy te  sedim entation ra te  or 
C -reactive  p ro te in .
H pylori was found in  10 of 15 NSAID p a tien ts  (66%) with g as tr ic  
u lce rs  (all a ffec tin g  the  an trum ) and  7 of 12 p a tien ts  (58%) with 
duodenal u lce rs . Four of 15 g as tr ic  u lcer p a tien ts  (27%) were 
sm okers compared w ith 8 of 12 p a tien ts  (67%) w ith duodenal u lce rs . 
Only 2 p a tien ts  in  th e  con tro l group had u lc e rs , bo th  of which were 
in  the  duodenum.
G astric and  duodenal blood flow of NSAID p a tien ts  in  various age 
g roups are  shown in  Table 31. P atien ts  older th an  60 y ea rs  tended  
to have lower blood flow th an  those younger th an  40 y e a rs . 
However, th is  ten d en cy  did not reach  sta tis tica l significance.
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Smoking, u lcera tion , o r H pylori did not seem to affect gas tric  
blood flow of p a tien ts  tak in g  NSAID in th is  s tu d y  (Table 32). On 
th e  o th e r  h an d , th e  p resence  of these fac to rs  was associated with 
lower blood flow values in  the  duodenal mucosa (Table 35). In the 
NSAID group as a whole, mucosal blood flow was 125 (90-183) un its  
in  th e  stomach compared w ith 160 (123-195) u n its  in  the duodenum 
(p= 0 .00017). To investiga te  which fac to rs  were independently  
associa ted  with reduced  blood flow in the  duodenum , multiple linear 
re g re ss io n  analysis w ith step-w ise variable elimination was 
perform ed. The th ree  fa c to rs , (duodenal u lcera tion , smoking and H 
p y lo ri) were assigned  num erical values of 0 o r 1 according to th e ir  
p re sen ce  or absence, and  th e  p red ic to r variables included in the 
analysis  were the  facto rs them selves and all tw o-and th ree -fac to r 
p ro d u c ts . A square  root transform ation was perform ed on the 
duodenal blood flow values to co rrec t an  upw ard skewing of the 
d is tr ib u tio n . The only variable with a s ta tis tica lly  significant 
rela tionsh ip  with duodenal blood flow was the  p roduct (ie 
sim ultaneous p resence) of smoking and  H pylori: smokers infected
with H pylori had a median (in te rq u artile  range) blood flow of 118 
(85-168) compared with 175 (135-250) u n its  in  th e  re s t  of the  NSAID 
group  (F=13.5, p=0.0005). The independent effect of duodenal
u lcera tion  approached s ta tis tica l significance (F=3.3, p=0.076).
In  th e  small num ber of sub jec ts not tak ing  NSAID, no significant 
d ifferences w ere found in  response  to H py lo ri, pep tic  u lceration , or 
th e  dem ographic details.
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TABLE 30
Characteristics of the Study Groups
On NSAID
Total number 70
Males 23
Females 47
Median Age (years) 54
Smokers 29
Osteoarthritis 14
Rheumatoid arthritis 56
Duration of arthritis median (years) 7
Gastric ulcers 15
Duodenal ulcers 12
H pylori 30
Controls
17
6
11
53
11
2
13
168
TABLE 31
Gastric and Duodenal Blood Flow (Perfusion Units), 
Median (Interquartile Ranges), in NSAID Patients Classified 
According to their age Groups (Years)
Less than 41-60 Greater than 60
40
Sample size 14 46 10
Gastric blood 
flow
155
(115-200)
120
(90-175)
115
(83-153)
Duodenal blood 
flow
158
(135-185)
163
(110-235)
145
(110-175)
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TABLE 35
Gastric Blood Flow (Perfusion Units) in NSAID Group 
(Interquartile Ranges) in the Presence of 
Smoking, Ulcers or H pylori
Present Absent
Sample
Size
Value Sample
Size
Value
Smoking 29 123
(85-185)
41 125
(100-190)
Gastric
Ulceration 15 120
(85-140)
55 125
(90-185)
H pylori 30 125
(85-200)
40 135
(105-178)
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TABLE 33
Duodenal Blood Flow (Perfusion Units) of NSAID Patients 
Median (Interquartile Ranges) in the Presnece of 
Smoking, Ulcers, or H pylori
Present Absent
Sample Value Sample Value
size size
Smoking 29 150* 41 175
(100-175) (135-250)
Duodenal
Ulceration 12 123* 68 160
(93-158) (130-215)
H pylori 30 135* 40 168
(100-175) (140-245)
Significant drop compared with non-smokers or those without duodenal 
ulcers or H pylori:
* p<0.05
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10.5 DISCUSSION:
This s tu d y  shows th a t ,  in  p a tien ts  tre a te d  with NSAID, 
duodenal blood flow is lowest in  smokers and  in  those with duodenal 
u lcers  o r H p y lo ri. G astric  blood flow does not seem to change 
sign ifican tly  in  th e  p resen ce  of any  of th ese  v a ria b le s . Mucosal 
blood flow is g re a te r  in  th e  duodenum than  in  the  stom ach, 
b u t no correlation  could be found betw een mucosal blood flow and 
p a tie n ts ' age o r type  of a r th r i t is .  In  th e  s tu d y  g roup  as a whole, 
th e  in take of NSAID is associated  w ith lower mucosal blood flow in  
bo th  th e  stomach and  duodenum , compared w ith con tro ls.
In addition to changes in  cardiac o u tp u t, th e re  a re  severa l 
o th e r fac to rs  th a t can influence the  g as tr ic  mucosal m icrocirculation. 
V asoconstriction has been observed  to take place in  th e  p resence  of 
v aso p ressin , catecholam ines, angio tensin  II , and  a f te r  the  activation  
of a lp h a-ad ren erg ic  recep to rs  (213-216). V asodilatation has been 
described  with parasym pathetic  stim ulation (215,217), g u t pep tides 
(g a s tr in , sec re tin , g lucagon, e tc) (209,213,217,218), and with most 
local m etabolites such  as histam ine, sero ton in , b rad y k in in , cyclic 
AMP, and  p rostag land ins (213,214,218,219). G astric  blood flow has 
also been found to change in  response  to d ru g  in take: it  was 
reduced  by  NSAID (14) and cimetidine (210) and  increased  (220) or 
unaffected  (221) b y  m isoprostol. A part from NSAID, p a tien ts  in  th is  
s tu d y  were excluded if  th ey  took d ru g s  such  as cimetidine or 
m isoprostol. I t is w orth no ting , how ever, th a t th e  majority of the  
above s tu d ies  (213-221) were carried  out in  lab o ra to ry  anim als, and 
when humans were included (210,211,220), duodenal blood flow and 
th e  effect of various dem ographic fac to rs  o r H py lori w ere not 
in v estig a ted . M easurements made in th e  control g roup  of th is  s tu d y  
confirm the  general su p p ressiv e  effects  of NSAID on blood flow in
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b o th  th e  stom ach and  duodenum . The re la tive ly  small num ber 
s tu d ie d  does no t allow fo r detailed analysis  of the effect of H py lori 
o r  th e  dem ographic variab les in the  absence of NSAID, which lies 
beyond  the scope of th is  s tu d y .
In th is  s tu d y , a lthough  NSAID p a tien ts  older th an  60 y ea rs  
ten d ed  to have lower mucosal blood flow th an  those y o unger th an  40 
y e a r s ,  th is  tendency  was not s ta tis tica lly  sign ifican t. This find ing , 
alone, does no t explain the  h ig h er incidence of NSAID re la ted  pep tic  
u lc e rs  o r th e ir  complications p rev iously  rep o rted  in  elderly  people
(95 ,145). O th er fac to rs  should be considered , including  the  
con tinu ing  in crease  in  NSAID p re sc rib in g  (95), the  possible role of 
d ie t (222), and  th e  effect of the  cohort phenomenon (223).
Patien ts  w ith NSA ID-related g as tr ic  u lcers  in th is  s tu d y , had 
sim ilar g as tr ic  blood flow to those w ith normal g as tr ic  endoscopy. 
T h is is unlike th e  find ing  of a p rev ious s tu d y  (211) in  which the  
p re sen ce  of g a s tr ic  u lceration  was associated  with lower g as tric  blood 
flow. The d ifference may have been re la ted  to the in take  of NSAID: 
p ep tic  u lce rs  in  such  cases can be re la ted  to multiple o th e r 
m echanism s, includ ing  inhibition of bo th  p ro stag land in  sy n th esis  (7) 
an d  mucus secretion  (17), and  d isru p tio n  of th e  g as tr ic  mucosal 
b a r r ie r  (12). A lterna tive ly , in  the  p resen ce  of low levels of g as tr ic  
p e rfu s io n  in  NSAID p a tie n ts , the  method used  in  th is  s tu d y  might 
no t have been  sensitive  enough to d e tec t small d ifferences.
Smokers in  th e  NSAID group had lower duodenal blood flow than  
non-sm okers. This might explain , a t least in  p a r t ,  the  h ig h er 
p revalence  of u lce rs  in  sm okers, rep o rted  in p rev ious s tud ies
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(42,75 ,224). Duodenal blood flow was also lower in  the  p resence of 
H py lo ri, in  th is  s tu d y . The reason for th is is not c lear, bu t it is 
in te re s tin g  to note th a t recen t in v itro  stud ies ca rried  out by  the 
au th o r (22,56) showed th a t H pylori cu ltu re  f iltra te  in tensified  the 
inh ib ito ry  e ffects  of indom ethacin on two potential vasodilato rs: PGE2 
and cyclic AMP (213,214,219). However, m ultivariate analysis showed 
th a t the  effec ts  of smoking and  H pylori infection could be accounted 
fo r by  a reduction  in blood flow only in those exposed to both of 
these  r isk  fa c to rs , which might suggest a sy n erg is tic  relationship 
betw een them .
The p resen ce  of duodenal ulceration in NSAID p a tien ts  was 
associated  w ith lower mciaosal blood flow in the  duodenum . This 
could be re la ted  to the  h igh  prevalence of smoking am ongst duodenal 
u lcer p a tie n ts . However, the  independent association between 
duodenal u lcera tion  and reduced  duodenal blood flow should not be 
ignored  as it  approached s ta tis tica l significance.
In th e  NSAID group as a whole, blood flow was lower in the 
g as tric  an trum  than  in the  duodenum . The significance of such  a 
find ing  is not c lear b u t it could be relevant to u n d ers tan d in g  the 
tendency  of NSAID re la ted  pep tic  damage to affect the  antrum  more 
freq u en tly  th an  th e  duodenum (5 ,4 2 ,C hapter 8) a lthough  it  was not 
possible to dem onstrate a correlation  between g a s tr ic  u lceration  and 
g as tric  mucosal blood flow in  th is  s tu d y .
In conclusion, duodenal blood flow in  pa tien ts  receiv ing  NSAID 
ap p ears  to be lowest in sm okers and in those w ith duodenal u lcers or
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H py lo ri. The s tu d y  could not dem onstrate correlation  with ag e , 
and  g astric  blood flow does not seem to be influenced by  any  of the  
above fa c to rs . These findings might be re lev an t to o u r 
u n d ers tan d in g  of NSAID re la ted  peptic damage. They also illu s tra te  
some d ifferences betw een the  gastric  and th e  duodenal mucosa in  
th e ir  response to various r isk  facto rs in  pep tic  u lcer d isease.
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SECTION VI
NSAID-RELATED ULCERS AND SECOND-LINE DRUGS
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INTRODUCTION
The endoscopic s tudy  in  C hapter 11 inv estig a tes  th e  p revalence 
of pep tic  u lcers  in  pa tien ts  tak ing  NSAID only or w ith second-line 
d ru g s . Its  find ing  of a lower prevalence of such  u lce rs  in p a tien ts  
tak ing  gold injections made it necessary  to inv estig a te  th e  p revalence 
of both  u lcers and H pylori in pa tien ts  tre a ted  w ith gold o r with 
an o th er agen t of similar an ti-rheum atoid  ac tiv ity , su ch  as 
su lphasalazine. This was justified  on the basis of two main reaso n s: 
F irs tly , the  possible in teraction  betw een NSAID and  H py lori 
(C hap ter 2); and secondly, because of the h isto rica l evidence 
su g g estin g  th a t gold compounds might have an  an tib ac teria l ac tiv ity  
(C hap ter 3 ).
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CHAPTER 11
11 ENDOSCOPIC NON-STEROIDAL PEPTIC DAMAGE IN 
RHEUMATOID PATIENTS RECEIVING SECOND-LINE DRUGS
11.1 SUMMARY
B ackground: NSAID a re  commonly u sed  to g e th e r  w ith
second-line d rugs fo r th e  control of rheum atoid a r th r i t i s .  I t  is  not 
c lear w hether an in terac tio n  ex ists  between th ese  a g en ts  w ith re sp e c t 
to pep tic  ulceration.
Aims: To assess  NSAID-related g a s tr ic  an d  duodenal
abnorm alities in pa tien ts  tre a te d  with second-line d ru g s .
Methods: Using endoscopy, the  prevalence of p ep tic  u lcera tio n
was stud ied  in 281 rheum atoid pa tien ts  receiv ing  NSAID alone, o r  in  
combination with second-line ag en ts .
R esults: Ulcers w ere found in  33 out of 96 p a tien ts  who took
NSAID only (33/96,34%), compared with 8/33 (24%) on
hydroxychloroquine, 10/30 (33%) on penicillam ine, 13/46 (28%) on 
su lphasalazine, b u t only 11/76 (14%) on in tram u scu la r gold p lus 
NSAID (X2=7.95, 0.001<p<0.01, p<0.05 using  B onferroni c o rre c tio n ) .
Conclusion: Second-line d ru g s  do not seem to in c rease  th e
prevalence of u lcers re la ted  to NSAID. On th e  c o n tra ry , few er 
u lce rs  were found in p a tien ts  receiv ing  gold th e ra p y , and  th is  m ight 
have therapeu tic  im plications.
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11.2 INTRODUCTION
In rheum atoid a r th r i t is ,  second-line d ru g s  p lay  an  in teg ra l p a r t  
in  the  treatm ent of th is  common and  chronic form of a r th r i t is .  
R ecently , argum ents have been p u t fo r the  ea rly , and  th ere fo re  the  
more w idespread u se  of these  d ru g s , in  an  attem pt to minimize the  
deb ilita ting  complications of rheum atoid d isease (225,226). These 
benefits  a re  often limited b y  the developm ent of g as tro -in te s tin a l side 
e ffec ts , which a re  considered  am ongst the  commonest causes of 
in te rru p tio n  o r even  the  term ination of second-line th e rap y  
(227,228). P revious s tud ies  have en tire ly  re lied  on p a tie n ts ’ 
symptoms in evaluating  the  g as tro -in te s tin a l side effects  of 
second-line d ru g s  (227,228). Since these  ag en ts  a re  tak en  in 
combination with NSAID in the  m ajority of cases, p a tie n ts ' symptoms 
might not reflect th e  tru e  ex ten t of pep tic  dam age, which can be 
asymptomatic in many p a tien ts  (81).
The cum of th is  s tu d y  was to m easure the  p revalence of pep tic  
in ju ry  in pa tien ts  tak in g  NSAID with o r w ithout second-line d ru g s , 
u s in g  endoscopy.
11.3 PATIENTS AND METHODS
P atien ts with ad u lt onset rheum atoid a r th r i t is  were rec ru ited  
provided  they  took NSAID fo r a minimum of one month and  
second-line th e rap y  fo r a t least 6 m onths, w ith th e  dose unchanged  
fo r 3 months o r longer.
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Second-line ag en ts  s tud ied  included in tram uscu lar sodium 
aurothiom alate (g o ld ), hydroxychloroquine, penicillamine and
su lphasa laz ine . P atien ts with p rev ious g as tr ic  su rg e ry  o r those
ta k in g  a n ti-u lce r  th e ra p y , s te ro id s  o r cytotoxic agen ts  w ere
ex c lu d ed .
Inform ed consent was obtained and  endoscopy was perform ed 
a f te r  th e  adm inistration  of 5-15mg diazepam in trav en o u sly . The
endoscopist was not aware of the  details of p a tie n ts ’ d ru g s .
Endoscopic find ings were classified  into normal, erosive ch an g es , 
o r  u lc e rs . An u lcer was defined as a th re e  dimensional punched  out 
lesion of a t least 5mm in  diam eter, and  an erosion was a smaller and  
shallow bidim ensional lesion.
S ta tistica l analysis included C h i-sq u are  (X2) te s t and B onferroni 
co rrec tion  fo r multiple com parisons.
11.4 RESULTS
Two h u n d red  and  e igh ty  one p a tien ts  w ere s tu d ied ; th ey  w ere 
re -g ro u p e d  accord ing  to w hether th ey  took NSAID with o r w ithout 
second-line d ru g s .
The endoscopic find ings a re  shown in  F igure 15. The in take  of 
gold p lus NSAID ap p ears  to be associated  with a significantly  sm aller 
num ber of u lce rs  th a n  in  any  o th e r g ro u p .
The p a tie n ts ’ dem ographic details are  shown in  Table 34. 
Subjects w ere comparable in  th e ir  ages except fo r those receiv ing
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hydroxych lo roqu ine: th ey  tended  to be younger th an  the r e s t .
Female/male ratio  was g re a te r  than  2:1 in all g ro u p s. However, 
th e re  was a g re a te r  p reponderence  of females in  p a tien ts  tak in g  
hydroxychloroquine o r penicillam ine. The smoking and  d rin k in g  
h ab its  w ere similar in  th e  various g ro u p s.
T he ty p es  of NSAID taken  by  various p a tien ts  a re  shown in 
Table 35. Indom ethacin, diclofenac, and naproxen  w ere th e  most 
commonly used  NSAID, being  taken  by  approxim ately similar 
p ro p o rtio n s  of sub jec ts  in  all g ro u p s. The dosage and freq u en cy  of 
NSAID in take were also similar am ongst the various g ro u p s.
The p resence  o r absence of indications fo r endoscopy a re  
dem onstrated  in  Table 36. The sulphasalazine group tended  to have 
a  g re a te r  p roportion  of cases w ith u p p er abdominal com plaints. 
A bout a th ird  of p a tien ts  in o th e r g roups did not have anaemia or 
an y  complaints a t all. These asymptomatic sub jects still had a 
sim ilar p revalence of pep tic  damage to th a t found in o th e r sub jec ts  
in  th e ir  resp ec tiv e  g ro u p s.
P atien ts  w ith u lcers  (75 in  to tal) had a median age of 57 y ears  
and  included 41 sm okers. U lcers w ere found in  the  g as tr ic  antrum  
in  49 cases, compared w ith 18 in  th e  duodenum , 5 in  the  g as tr ic  
b o d y , and  3 in  th e  oesophagus. A similar d istribu tion  of u lcers  was 
found in  various p a tien ts  reg a rd le ss  of th e ir  therapeu tic  ag en ts .
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FIGURE 15
The endoscopic findings in rheumatoid p a tien ts  receiv ing  
no n -stero id a l anti-inflam m atory d ru g s  with or w ithout second-line
d ru g s .
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11.5 DISCUSSION
This endoscopic s tu d y  shows th a t the p revalence of pep tic  u lcers  
is  lower in  p a tien ts  receiv ing  gold p lus NSAID, b u t unchanged  in 
p a tien ts  tak ing  NSAID p lus o th er second-line d ru g s  in  comparison 
w ith th e  in take of NSAID only.
T here  were unequal num bers of p a tien t in  th e  various g ro u p s. 
T his is because p a tien ts  w ere rec ru ited  a t random , p rov ided  they  
sa tisfied  the inclusion and exclusion c r ite ria . In  add ition , p a tien ts  
rece iv ing  hydroxychloroquine tended  to be y o u n g er th an  th e ir  
co u n te rp a rts  in o th e r g ro u p s . This re flec ts  a management policy 
th a t involves g iv ing  hydroxychloroquine to young  ad u lts  with 
rheum atoid a r th r i t is ,  in  p re fe ren ce  to o th e r second-line d ru g s  
(229,230). D espite being  yo u n g er, th ey  s till had  a similar 
prevalence of pep tic  u lcers  to those tak in g  NSAID only. This 
find ing  does not necessarily  d isagree  with th e  epidemiological 
evidence of a h igh  incidence of u lce r complications in  the  elderly
(95,145) as the  assessm ent of such  complications lies beyond the  
scope of th is  s tu d y .
The n a tu re  of th is  s tu d y  makes it  d ifficu lt to a sse ss  p a tie n ts1 
compliance with th e  in take of various d r u g s , especially  if  th ese  
d ru g s  had to be taken  fo r re la tive ly  long periods of time. This is 
f u r th e r  emphasized b y  the  insistance  th a t second-line d ru g s  had to 
be  adm inistered fo r a  minimum of six  months befo re  p a tien ts  could be 
included in  the  s tu d y , as the  disease modifying ac tiv ity  of these  
ag en ts  may take severa l months to m anifest itse lf  (225-233). It 
could be argued  th a t p a tien ts  receiv ing  gold th e ra p y  developed few er 
u lce rs  because th e ir  a r th r i t is  was b e tte r  controlled a n d , as a
186
re su lt took NSAID less f req u e n tly . This is unlikely  to be the  case, 
given the fact th a t  sev era l s tud ies  have dem onstrated th a t the  
an ti-rheum ato id  efficacy of gold is comparable to th a t of 
sulphasalazine (227,228,232).
A lthough it is somewhat difficult to explain  the  lower p revalence 
of pep tic  u lcers  in  association with gold th e ra p y , com parison has 
recen tly  been made w ith b ism uth , which is classified v e ry  close to 
gold in  th e  periodic tab le  of elements (101). The bacteric idal 
ac tiv ity  of gold was 30 times s tro n g er th an  th a t of b ism uth in  H 
py lori cu ltu res  (101). Colloidal bism uth su b c itra te  was also found to 
have a p ro tec tiv e  effec t against a sp irin -in d u ced  g a s tr ic  
m icrobleeding, and  th is  p ro tection  occurred desp ite  su p p ressio n  of 
mucosal p rostag land in  p roduction  by  asp irin  (33). W hether gold has 
a similar p ro tec tiv e  ac tiv ity  remains a m atter of specu lation . 
A lthough, th e  p rec ise  role of H pylori in  m ediating NSAID-induced 
damage is not fu lly  c lea r, it is in te re s tin g  to note th a t the  
combination of indom ethacin and  H pylori cu ltu re  f iltra te  has recen tly  
been  shown to red u ce  g a s tr ic  mucosal viability  and its  p ro stag lan d in  
Ea concentration  to a g re a te r  ex ten t th an  indom ethacin alone, in  
v itro  (22) and  th a t NSAID p atien ts  infected  with H py lo ri have a 
h ig h er p revalence of u lce rs  than  p a tien ts  w ithout su ch  infection 
(C hap ters  2 ,7 ) . The effec t of gold on th e  stomach is  p robab ly  
d iffe ren t from th a t on th e  colonic mucosa w here it may cause colitis 
(108).
Previous s tu d ies  in v estig a tin g  the  possible g a s tro -in te s tin a l 
s id e-e ffec ts  of second-line agen ts  in the  p resen ce  of NSAID have 
largely  relied  on p a tie n ts ’ symptoms (227,233). This endoscopic
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s tu d y  su g g ests  th a t the  in take of hydroxychloroquine, penicillamine 
o r su lphasalazine does not increase  th e  p revalence of peptic u lcers in 
p a tien ts  on NSAID. This is of p a rtic u la r  relevance to p a tien ts  
rece iv ing  su lphasa laz ine : th e ir  ten d en cy  to develop abdominal
complaints does no t necessarily  ind icate  a h ig h er prevalence of peptic 
u lce ra tio n , and  might be due to a cen tra l effect especially in  slow 
ace ty la to rs  (234).
In  conclusion, second-line a g e n ts , o th e r than  gold, do not seem 
to a lte r  th e  p revalence of N SA ID -related peptic  damage. The 
ap p aren tly  beneficial effect of gold might have some therapeu tic  
im plications.
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CHAPTER 12
12 NSAID-RELATED ULCERS AND H PYLORI IN RHEUMATOID 
ARTHRITIS PATIENTS RECEIVING GOLD OR SULPHASALAZINE
12.1 SUMMARY
B ackground: The conflicting rep o rts  on gold and  H pylori could
be re la ted  to th e  use  of serological te s ts  of unproven  value in  NSAID 
p a tie n ts , and  to the  lack of the  app rop ria te  control g ro u p s. More 
im portan tly , th e  endoscopic consequences of the  possible effect of 
gold on H py lori have not been in vestiga ted .
Aims: To assess  the  p revalence of H pylori and pep tic  u lcers in
rheum atoid p a tien ts  being  tre a te d  with gold sodium thiomalate p lus 
NSAID, sulphasalazine p lus NSAID, o r NSAID only.
P atien ts  and  Methods: E ighty-five pa tien ts  receiv ing  treatm ent
fo r a t least six  months were endoscoped and H pylori s tud ied  in  
g as tr ic  a n tra l biopsies by  bo th  cu ltu re  and histo logy. Endoscopic 
abnorm alities were classified into u lcers  (m easuring 5mm in  diam eter 
o r more) and  erosions (sm aller lesions).
R esu lts: H pylori (and u lce rs) were found in 17 (12) of 31
p a tien ts  on NSAID only and  21 (9) of 27 pa tien ts  on sulphasalazine 
p lus NSAID compared with 9 (3) of 27 pa tien ts  receiv ing  gold p lus 
NSAID, p<0.05, analysis of variance.
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Conclusion: P a tien ts  tre a ted  with gold and NSAID had th e
low est prevalence of detectab le H pylori. This could explain  the  
a p p a re n t reduction  in  the  prevalence of peptic u lcers  in th is  g roup  
a n d , if confirm ed in  la rg e r  randomised s tu d ie s , might have 
th e ra p e u tic  im plications.
12.2 INTRODUCTION
N early a c e n tu ry  a f te r  its  descrip tion  b y  Koch (106), th e  
antim icrobial ac tiv ity  of gold sa lts  is being reconsidered  because of 
i ts  po ten tia l use  in  the  treatm ent of H py lori. Recent in  v itro  
s tu d ie s  have su g g ested  th a t bactericidal effect of gold sodium 
thiom alate was 30 times s tro n g e r than  bism uth against H py lori 
cu ltu re s  (101), and  th a t such  effect could be re la ted  to th e  
inh ib ition  of H py lo ri u rease  activ ity  by  gold (102). The au th o r has 
found  th a t rheum atoid a r th r itic  pa tien ts  trea ted  with in tram usuclar 
gold were less likely to have NSAID-related u lcers compared w ith 
p a tie n ts  tre a ted  w ith o th er second-line d ru g s  (82, C hap ter 11). 
H ow ever, H py lo ri s ta tu s  was not known in  C hapter 11, and  
endoscopy was not perform ed in recen t serological s tu d ie s , which 
showed conflicting re su lts  on the  prevalence of H pylori in  p a tien ts  
w ith  gold sa lts  (103,104).
The aim of th is  s tu d y  was to assess  the p revalence of H py lori 
an d  pep tic  u lcers  in  p a tien ts  receiv ing  gold p lus NSAID compared 
w ith  those tre a te d  w ith sulphasalazine plus NSAID, o r NSAID only.
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12.3 PATIENTS AND METHODS
P atien ts  with ad u lt rheum atoid a r th r i t is ,  accord ing  to the  c rite ria  
of th e  American Rheumatism Association (149), were rec ru ited  from 
th e  Rheumatology O ut-P atien t Clinic provided  th ey  had been tak ing  
NSAID only or w ith in tram uscular gold o r sulphasalazine fo r a t least 
six  m onths. Sulphasalazine was chosen as a control ag en t because 
its  second-line ac tiv ity  has been recognised as being  comparable to 
th a t of gold (228,232). P atien ts were excluded if th ey  took u lcer 
healing  d ru g s , an tib io tics, s te ro id s , cytotoxic d ru g s , o r if  th ey  had 
a  h is to ry  of p revious g as tric  su rg e ry . A rth ritic  pain  was assessed  
on a  4 point scale: 0(no p a in ), l(m ild ), 2(m oderate), and  3 (sev ere) 
jo in t pain .
Informed consent was obtained and  endoscopy perform ed u sin g  
midazolam 4-8mg in travenously  fo r sedation . Endoscopic 
abnorm alities were classified into u lcers  (3 dimensional punched out 
lesions m easuring a t least 5mm in diam eter) o r erosions (sm aller 
bidim ensional lesions (8 2 ,C hapter 11). G astric a n tra l biopsies were 
tak en  to check fo r H pylori by  bo th  histology and  cu ltu re , as 
p rev iously  described  (61).
S tatistical analyses involved the analysis of variance or the  
Kruskal-W allis te s t ,  where app ro p ria te . The endoscopist, 
h isto lo g ist, and bacterio logist were not aware of th e  details of 
p a tien ts  medications and  the  s tu d y  was approved b y  th e  local Ethics 
Committee.
12.4 RESULTS
N inety p a tien ts  were s tu d ied , five of whom were excluded
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because of u n ce rta in ty  about recen t antib io tic u se . The rem aining 
85 pa tien ts  en tered  the  final analysis and included 31 on NSAID 
only, 27 on NSAID plus su lphasalazine, and  27 on NSAID p lus 
in tram uscular gold. The duration  of second-line th e rap y  was 2(1-2) 
y ears  fo r sulphasalazine and 2 (1 .5-6) y ea rs  fo r gold , median
(in te rq u artile  ran g e s) .
The prevalence of detectable H py lo ri, u lc e rs , and  erosions is 
dem onstrated in F igure 16. Patien ts in the gold g roup  had th e  
lowest prevalence of both detectable H py lori and  u lc e rs , b u t no 
d ifference could be found in the num ber of erosions am ongst th e  
th ree  s tu d y  g ro u p s . Ulcers diagnosed in  th is  s tu d y  w ere 
d is trib u ted  as follows: 7 g astric  (and 5 duodenal) in p a tien ts  tak in g  
NSAID only, 4(5) in the  sulphasalazine g ro u p , and  only 3 g as tr ic  
u lcers in p a tien ts  receiv ing  gold in jections. The d ifferences in  th e  
prevalence of duodenal u lcers were not s ta tis tica lly  s ign ifican t. All 
g astric  u lcers affected the an trum , and were found to be ben ign  b y  
histology. Erosions were also more likely to affect th e  an trum  th an  
the  duodenum, in  a ra tio  of 2 :1 , in all g ro u p s.
The dem ographic ch arac teris tics  of p a tien ts  a re  shown in  Table 
37. The smoking and  d rink ing  hab its were comparable am ongst th e  
g ro u p s, b u t p a tien ts  tre a ted  with gold tended to be o lder.
The du ra tion  and  ac tiv ity  of rheum atoid a r th r i t is  a re  described  
in  Table 38. The median duration  of a r th r i t is  was g re a te r  th an  
seven  years  in all g ro u p s, w ith a tendency to being  longer in
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p a tien ts  trea ted  with gold. Also, desp ite  minor d ifferences in  th e ir  
va lues, the  param eters of d isease ac tiv ity  m easured in  th is  s tu d y  
su g g est th a t p a tien ts  s tab lised  on the  various long-term  d ru g s  had a 
similar degree of d isease control a t th e  time of endoscopy.
The details of NSAID used  a re  p re sen ted  in  Table 39. No 
significant d ifferences could be found in th e  ty p e , dosage, or 
du ra tion  of NSAID used  b y  pa tien ts  in  the  th re e  s tu d y  g ro u p s . It 
must be em phasised th a t the  du ra tion  of NSAID th e ra p y  shown in 
Table 39 re fe rs  to agen ts  c u rre n tly  being  tak en , and  th a t p a tien ts  
have been  tak ing o th e r NSAID fo r the  du ra tion  of th e ir  a r th r i t is ,  
p re sen ted  in Table 38.
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•s p<0.05 
NSAID only
FIGURE 16
Prevalence of H py lo ri, u lc e rs , and  erosions
(analysis of v a r ia n c e ) , compared with p a tien ts  tak in g  
or with sulphasalazine
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TABLE 37
Demographic Characteristics of the Study Groups
NSAID
only
Number 31
Males 5
Females 26
Age (years) Median 55
(interquartile ranges) (45-60)
Smokers 11
Drinkers 10
Patients with
abdominal complaints 14
NSAID plus
Sulphasalazine Gold
27 27
12 7
15 20
51 60
(40-62) (49-68)
12 8
15 12
9 13
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TABLE 38
Duration and Activity of Rheumatoid Arthritis 
Median (interquartile ranges)
NSAID
only
Duration (years) 7
(4-11)
Joint pain* 1
(2-3)
ESR (mm/hour) 30
(20-54)
CRP (mg/1) 16
(10-27
NSAID plus
Sulphasalazine Gold
7 11
(4-13) (5-15)
2 1
(1-2) (1-2)
27 23
(10-41) (9“52)
21 17
(10-43) (10-39)
* Grades of joint pain - 0: none, 1: mild, 2: moderate, and 3
severe
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Types
Indomethacin
Naproxen
Ketoprofen
Diclofenac
Fenbufen
Piroxicam
Nabumetone
Ibuprofen
Flurbiprofen
Others
Table 39 
Details of NSAID Used 
NSAID NSAID plus
only Sulphasalazine Gold
7 5 7
6 3 4
6 4
2 7 1
3 2 2
3 1 1
1 4
3 1
2 3
3 2 4
Dose*,+ 2(2-3)
Duration (years) + 2(1-4)
3(2-3)
3(2-5)
2(2-3)
2(2-4)
* Dosage scale - 1: minimal, 2: submaximal, and 3: maximal
+ Median (interquartile ranges)
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12.5 DISCUSSION
This s tu d y  suggests  th a t patien ts receiving long-term  NSAID and 
gold in jections have a low prevalence of detectable H p y lo ri, which 
in  tu rn  might explain the  app aren t reduction of th e  p revalence of 
p ep tic  u lcers  in  th is  g roup .
P atien ts  trea ted  with gold tended to be o lder th an  those tre a ted  
w ith sulphasalazine or NSAID only; th is could explain the  re la tive ly  
longer du ra tion  of a r th rit is  in  the  gold g roup . Several s tud ies  have 
shown th a t elderly  pa tien ts  a re  a t a g rea te r  r isk  of having  H pylori 
in fection  (96,136), and developing NSAID related  pep tic  u lcers  o r 
th e ir  complications (95,145). I t is in te re s tin g , th e re fo re , to find  
th a t p a tien ts  receiving gold p lus NSAID still had a lower p revalence 
of H py lo ri and  u lcers desp ite  th e ir  tendency to be o lder.
D espite having fewer u lc e rs , patien ts in th e  gold group had as 
many abdominal complaints as those in the o th er g ro u p s . This 
illu s tra te s  the poor correlation between symptoms and pep tic  u lcers 
in  p a tien ts  trea ted  with NSAID (81,82, C hapter 4 ) . Also, p a tien ts  
in  th e  sulphasalazine group did not have more g astro in testina l 
symptom s, which could be due to the possib ility  th a t th ey  have 
become adap ted  to sulphasalazine by the time th e ir  endoscopy was 
perform ed (234).
The low prevalence of detectable H pylori in chronic gold and  
NSAID u se rs  could be due to a d irect bactericidal effect (101), 
inhibition of H pylori u rease  ac tiv ity  by  gold (102) o r bo th . A nother 
mechanism which has to be considered is the possibility  th a t 
long-term  in take of gold injections might ind irec tly  influence the
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su rv iv a l of H pylori by  its  immunomodulatory ac tiv ity ; 
immunocompetent p a tien ts  a re  more likely to be infected  by  H p y lo ri, 
and  th is  chronic infection may be due to occupation of an  
immunoprivileged s ite , and associated with in te rfe ren ce  w ith the  
h o s t's  cellu lar immune response (109,110). However, it  is d ifficu lt 
to  u n d ers tan d  why such  in te re s tin g  observations should not app ly  to 
p a tien ts  tre a te d  with sulphasalazine, which is known to have 
second-line ac tiv ity  comparable to th a t of gold (228,232). Chronic 
su p p ressio n , r a th e r  than  eradication of H pylori b y  gold could also 
explain the smaller num ber of cases of detectab le organism s in 
biopsies taken  from long term gold u se rs . This implies th a t H pylori 
might re c u r  o r become more easily detectable upon w ithdraw al of 
gold , a lthough such  possibility  has not been stud ied  b efo re . The 
presum ed effect of in tram uscular gold on H pylori in th is  s tu d y  is 
though t to be due to the  d istribu tion  of gold into th e  g as tr ic  
mucosa, g as tr ic  secre tions, or bo th . G astric tissu e  o r juice levels of 
gold are  not known in th is  s tu d y , b u t it  could be specu la ted  th a t 
such  levels might have been h igher if oral gold p rep a ra tio n s  w ere 
u se d , which in tu rn  might be more effective against H p y lo ri. The 
u se  of the  cu rren tly  available oral gold compounds is ,  how ever, 
limited by  th e ir  tendency to cause d iarrhoea, and  by  the  re la tive ly  
lower anti-rheum atoid  efficacy in  comparison with in tram uscu lar gold.
These re su lts  are  in agreem ent with an o th er serological s tu d y  
(104) which also found a low prevalence of H pylori in  rheum atoid 
a r th r it ic  p a tien ts  trea ted  with gold compounds. However, conflic ting 
find ings w ere rep o rted  by  ano ther s tu d y  (103), and  th is  could be 
due to the  methodology of detecting  active H pylori in fection . The 
value of serological te s ts  (103,104) has not been estab lished  in
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p a tien ts  receiv ing  NSAID; such  p a tien ts  might have low prevalence 
of H pylori (2 3 ,7 5 ,8 3 ,8 4 ,C hapter 7) and  th is  in  tu rn  might lower the  
specific ity  of the serological te s ts  (78, C hap ters  4 ,5 ) .  I t is  believed 
th a t th ese  possiblities have been covered by  s tu d y in g  m ultiple b iopsy  
specimens u sing  bo th  cu ltu re  and  histology in  th is  s tu d y .
T here was no significant d ifference in  th e  p revalence of 
endoscopic abnorm alities am ongst th e  s tu d y  g roups when th e  size of 
such  lesions was not taken  into consideration . However, p a tien ts  
tre a te d  with gold had the smallest num ber of u lcers  m easuring  a t 
least 5mm in diam eter. The significance of find ing  superfic ia l 
erosions in  chronic NSAID u se rs  is not ce rta in : th e re  is no
evidence th a t they  p ro g ress  to la rg e r  lesions o r to su g g es t th a t th ey  
may lead to serious complications such  as  p erfo ra tio n . I t  is 
specu lated  th a t the  low prevalence of u lcers  in  the  gold g roup  might 
be re la ted  to the  re la tive  ra r i ty  of detectab le  H py lo ri in  th is  g ro u p . 
This is supported  by  the recen t find ings which su g g est th a t NSAID 
re la ted  mucosal damage and pep tic  u lce rs  a re  more likely to develop 
in  the  p resence of H pylori (23,78, C hapters 2 ,7) .
A nother in te re s tin g  find ing  in  th is  s tu d y  is th e  absence of 
duodenal u lcers in  pa tien ts  tre a ted  with gold. H py lo ri is typ ically  
associated  with duodenal u lceration , and  the  low prevalence of th ese  
organism s in gold tre a ted  p a tien ts  could exp lain , a t least in  p a r t ,  
th e  lack of duodenal u lcers in  such  p a tie n ts . The d ifferences in  th e  
num bers of duodenal u lcers  am ongst the  s tu d y  g roups did n o t, 
how ever, reach  sta tis tica l significance, and it  is w orth  no ting  th a t 
th e  in teraction  betw een NSAID and H py lori is not th e  only 
mechanism by  which NSAID cause mucosal damage (C h ap te rs  1 ,2) .
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In conclusion, patien ts  receiv ing  long term  NSAID p lus gold have 
lower p revalence of detectable H pylori th an  those tre a te d  w ith 
NSAID only or NSAID plus su lphasalazine. This could explain  th e  
sm aller num ber of peptic u lcers  found in the  gold g ro u p , and  might 
have th e rap eu tic  im plications, if  confirmed b y  la rg e r  random ised 
s tu d ie s .
SECTION VII 
CONCLUSIONS, AND REFERENCES
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CONCLUSIONS
This Thesis has ad d ressed  sev era l a sp ec ts  of the  pa thogenesis  of 
NSAID-related pep tic  u lcer d isease , includ ing  the  in te rac tio n  betw een 
NSAID and H p y lo ri, th e  effect of NSAID on the  efficacy of H py lo ri 
d iagnostic te s ts ,  th e  histological fe a tu re s  of N SA ID -related mucosal 
damage, the influence of NSAID and  H py lori on mucosal blood flow, 
and  the  in terac tion  betw een NSAID and an ti-rheum ato id  second-line 
d ru g s . The main conclusions of th ese  s tu d ies  a re  as follows:
DIAGNOSTIC STUDIES
NSAID do not affect the sen sitiv ity  and  specific ity  of the  th re e  
b iopsy -re la ted  te s ts  used  for the  diagnosis of H py lo ri (c u ltu re , 
h isto logy, and C L O -test).
Amongst the fo u r serological te s ts  s tu d ied , Bio-Rad GAP te s t 
IgG has the h ig h est sensitiv ity  b u t th e  lowest spec ific ity , re g a rd le ss  
of NSAID in tak e , compared w ith Bio-lab M alakit, Helico-G, and  
Pyloriset te s ts .  The specificity  of all the  serological te s ts  was also 
lower in  pa tien ts  tak in g  NSAID.
The prevalence of NSAID-related pep tic  u lcers  is h ig h e r in  
p a tien ts  with deb ilita ting  a r th r i t is ,  as assessed  b y  th e  H ealth 
A ssessm ent Q uestionnaire and endoscopy. The use  of th is  
questionnaire  m ight, th e re fo re , help in  th e  p rocess  of se lec ting  
p a tien ts  fo r p rophy lactic  th e rap y  against NSAID-induced p ep tic  
dam age.
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HISTOLOGICAL STUDIES
In th e  absence of g astro -duodenal su rg e ry  and  heavy alcohol 
in tak e , chemical g a s tr itis  is ch a rac te ris tic  of chronic NSAID in tak e .
A lthough H pylori is re la tive ly  less common in th e  p resen ce  of 
NSAID, chemical g a s tr itis  and  H p y lo ri-re la ted  g a s tr itis  a re  
associated  w ith a  h ig h er p revalence of NSA ID -related u lcers  th an  in 
p a tien ts  w ithout e ith e r of th ese  histological abnorm alities.
A s tro n g  association ex is ts  betw een duodenal u lce rs  and  active 
chronic duoden itis, g as tr ic  m etaplasia in the  duodenum , and  H 
p y lo ri-positive  g a s tr i t is , reg a rd le ss  of NSAID in tak e .
Active chronic duodenitis is re la tive ly  ra re  in chronic NSAID 
u s e rs ,  and  th is  might explain  why duodenal u lcers  occur less 
freq u en tly  th an  g as tric  u lce rs  in p a tien ts  tre a ted  with NSAID.
Duodenal u lcers  a re  s till as common in  NSAID p a tien ts  as in  
those not tre a te d  with th ese  d ru g s , which in  tu rn  h igh ligh ts  the  
m ultifactorial n a tu re  of the  pathogenesis of NSAID-related damage.
The p revalence of endoscopic oesophagitis is h ig h er in  NSAID 
p a tien ts  w ith u p p e r abdominal complaints th an  in  th e ir  symptomatic 
c o u n te rp a rts  not receiv ing  NSAID.
Papillary  elongation and  basal cell h y p erp lasia , th e  major 
fe a tu re s  of histological oesophagitis, a re , how ever, less common in  
p a tien ts  tre a te d  w ith NSAID. This su g g ests  th a t histological 
oesophagitis might not be critica l fo r th e  development of
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N SA ID -related oesophageal u lcers  o r erosions, which is comparable to 
o th e r  cases of p ill-re la ted  oesophageal damage.
BLOOD FLOW STUDIES
Both g as tr ic  and  duodenal blood flow values a re  lower in  p a tien ts  
tre a te d  with NSAID th a n  those  not tak in g  these  d ru g s
Duodenal, b u t not g a s tr ic , mucosal blood flow is  lowest in 
ch ron ic  NSAID u s e rs  who smoke, and those with H py lori or 
duodenal u lceration .
Step-w ise lin ear reg ress io n  analysis su g g ests  th a t the  
combination of smoking and  H pylori has an  independen t effect in 
low ering duodenal mucosal blood flow in pa tien t tak ing  NSAID.
Duodenal mucosal b leed flow, in genera l, is h igher th an  th a t of 
th e  g a s tr ic  antrum  in  p a tie n ts  receiv ing  NSAID. Not unlike the  
r a r i ty  of active chronic d u oden itis , these  findings might explain  why 
duodenal u lcers  a re  less common th an  g as tric  an tra l u lce rs  in  NSAID 
p a t ie n ts , and em phasize the  role of o ther mechanisms of 
NSA ID -related damage.
NSAID AND SECOND-LINE DRUGS
NSAID-related u lce rs  occu r less commonly in  p a tien ts  receiv ing  
gold injections than  those  tre a ted  with NSAID only , o r with 
su lphasalazine , penicillam ine, and  hydroxychloroquine.
The prevalence of b o th  H py lo ri and  peptic u lcers is lower in 
p a tie n ts  tre a ted  with gold in jections p lus NSAID compared with those
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tre a te d  with NSAID only or w ith su lphasalazine. These re su lts  might 
influence th e  choice of second-line d ru g s  fo r the  control of 
rheum atoid a r th r i t is  especially in p a tien ts  with a h is to ry  of peptic 
u lce r d isease .
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APPENDIX
Definitions u sed  in  th is  th e s is :
Sm okers:
Subjects c u rre n tly  tak in g  more th an  one c ig a re tte , c ig a r, o r a 
ro ll of tobacco p e r  day .
Alcohol d r in k e rs :
Subjects consum ing more th an  one u n it of alcohol p e r  w eek.
Abdominal com plaints:
N ausea, vom iting, h e a r tb u rn , fla tu lence, ind igestion , d y sp ep sia , 
a n d /o r  abdominal pain .
S en s itiv ity :
The freq u en cy  of a positive te s t  in all sub jec ts  w ith H py lo ri 
in fection . I t is calculated b y  div id ing  the  num ber of t ru e  
positives b y  the  sum of t ru e  positives and  false n eg a tiv es .
Specificity:
The freq u en cy  of a negative te s t  in  those w ithout the  in fection .
It is calculated b y  div id ing  th e  num ber of tru e  negatives b y  th e  
sum of tru e  negatives and  false positives.
The diagnosis of the  v as t m ajority of chronic NSAID u se rs  is 
rheum atoid a r th r i t is ,  un less ind icated  otherw ise in  th is  th e s is .
All s tud ies  included in  th is  th esis  a re  covered b y  eth ical approval 
g ran ted  b y  th e  Ethics Committee of Glasgow Royal In firm ary , as p a r t  
of an  ongoing assessm ent of th e  n a tu ra l h is to ry  and  trea tm en t of 
NSAID re la ted  pep tic  u lcer d isease.
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